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Recent epidemiological data have shown that metabolic disease is known to increase the 
propensity for developing cognitive decline and dementia, particularly Alzheimer’s disease 
(AD). While this interaction is not completely understood, clinical studies suggest that both 
hyper- and hypoinsulinemia are associated with an increased risk for developing AD. Indeed, 
insulin signaling is altered in post-mortem brain tissue from AD patients and insulin and 
treatments known to enhance insulin signaling, can improve cognitive function. Furthermore, 
clinical evidence has shown that AD patients and mouse models of AD often display alterations 
in peripheral metabolism. Since insulin is primarily derived from the periphery it is likely that 
peripheral alterations can lead to alterations in central nervous system (CNS) insulin signaling 
and that these changes contribute to cognitive decline. Recent results from our laboratory have 
shown that in both the APP/PS1 and 3xTg-AD mouse models of AD, peripheral metabolic 
alterations exist at an early age. Specifically, 3xTg-AD mice demonstrate impaired glucose 
tolerance at 1 month of age associated with a decrease in insulin and insulin secretion in response 
to a glucose challenge. This led to the hypothesis that insulin signaling in the CNS would be 
decreased as a result of decreased peripheral insulin and insulin transport into the CNS. Indeed, 
insulin signaling through the PI3K/AKT signaling pathway, but not the MAPK/ERK pathway, 
was decreased in the hippocampus of old, but not young, 3xTg-AD mice. PI3K/AKT signaling 
can affect several downstream molecules including glycogen synthase kinase 3 (GSK3), glucose 
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transporters (GLUTs), and ATP dependent potassium (KATP) channels. We first examined 
GSK3 and pTau and found that both GSK3β and pTau were increased in aged 3xTg-AD mice. 
Next we looked at the translocation of GLUT3 and GLUT4 since both are found in the 
hippocampus and have recently been shown to be insulin sensitive. Our results showed that 
GLUT3 translocation, but not GLUT4, was decreased in the hippocampus of aged 3xTg-AD 
mice. Finally, since KATP channels are found in intracellular organelles as well as in the plasma 
membrane we examined crude plasma membrane and total fractions of KATP channel subunits 
Kir6.1 and Kir6.2 and found that the plasma membrane fraction of Kir6.2 was significantly 
increased. To assess how these changes corresponded with the time course of pathology and 
cognitive deficits we additionally looked at these changes in 6-8 month and 14-16 month 
animals. Interestingly, though peripheral insulin was decreased early on, changes in CNS 
PI3K/AKT insulin signaling did not occur until 18-20 months of age. Changes in GSK3β (but 
not pTau) and GLUT3 were consistent with this time point suggesting that they were potentially 
due to the decrease in PI3K/AKT signaling. Since these changes were not consistent with a 
decrease in peripheral insulin levels it suggests that another factor must be at play. One such 
factor is inflammation. The AD brain is characterized by inflammation and inflammatory 
compounds are known to block insulin signaling.  
KATP channels are not only insulin sensitive but have been shown to play a role in 
cognition, AD and epilepsy. Thus, to follow up the studies on KATP channels we used 
immunohistochemistry (IHC), to examine regional and cell specific changes. To our surprise we 
found that Kir6.2, a subunit typically found primarily in neurons, was present in reactive 
astrocytes. This finding was further examined in human AD tissue and a similar change was 
seen. Astrocytes become reactive during damage or under inflammatory conditions, such as AD, 
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diabetes, traumatic brain injury (TBI), epilepsy and in normal aging. When they become reactive 
both gene expression and functions can change. Since reactive astrocytes and inflammation are a 
common finding among many neuropathological changes we looked at another 
neuropathological condition with several similarities to AD, epilepsy. These studies revealed that 
epileptic mice displayed a similar change in Kir6.2 in reactive astrocytes. Since both conditions 
are characterized by inflammation we next hypothesized that chronic peripheral inflammation 
induced by LPS would be enough to drive this change. These studies revealed that while 1 day of 
LPS treatment was not enough to induce a change in astrogliosis and Kir6.2 expression, three 
days caused a significant increase in Kir6.2 in reactive astrocytes. This suggests that an increase 
in Kir6.2 in reactive astrocytes could contribute to the difference in function in these cells and 
subsequently contribute to altered function in neuropathological disease.  
Taken together, these studies demonstrate an intricate balance between metabolism and 
inflammation in the CNS and further suggest that metabolic alterations could be a common link 
in neuropathological diseases that share similar phenotypic changes, as occurs in AD and 
epilepsy (i.e. cognitive decline, enhanced seizure susceptibility). Developing a better 
understanding of metabolism, inflammation, and cortical function/dysfunction could potentially 
lead to the identification of better treatment options for several neuropathological conditions 
including AD.   
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INTRODUCTION 
CNS Metabolism 
To maintain proper function the CNS has very high-energy demands. Maintenance and 
restoration of ion gradients and uptake and recycling of neurotransmitters are the primary 
processes contributing to this high energetic cost (Attwell & Laughlin 2001; Alle et al. 2009). 
Amazingly, although the brain makes up only about 2% of total body weight, it utilizes around 
20% of total oxygen and 25% of all glucose consumed (Bélanger et al. 2011). Glucose is the 
primary substrate for the CNS and can be fully oxidized within the brain to water and CO2 
(Bélanger et al. 2011). If blood glucose levels are altered severe consequences can occur - 
hypoglycemia can lead to dizziness, confusion, loss of consciousness, or hypoglycemic coma 
while hyperglycemia can cause endothelial cell damage, capillary damage in the retina, kidneys 
and other tissues, stroke, heart attack, peripheral nerve damage, diabetic ketoacidosis, or 
hyperglycemic coma (Tripathi & Srivastava 2006; Bonds et al. 2012). Thus, in order to regulate 
peripheral and CNS glucose, the periphery and the CNS work together through many tightly 
regulated events.  
Since all glucose comes from the periphery [although astrocytes do have glycogen stores 
for times of deprivation (Swanson & Choi 1993)] the first step in CNS metabolism is the 
regulation of peripheral glucose levels. The two primary regulators of peripheral glucose are 
insulin and glucagon (Röder et al. 2016). Insulin is secreted from the β-cells of the pancreas in 
response to glucose. Glucose (an extremely hydrophilic molecule) enters the β-cells through 
facilitated transport via glucose transporter 2 (GLUT2) independent of glucose concentration 
(Röder et al. 2016). In most cells hexokinase (HK) is highly expressed to phosphorylate glucose 
to glucose-6-phosphate to begin ATP production, to initiate glycogen storage and maintain the 
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glucose gradient. In pancreatic β-cells, however, the absence or minimal expression of HK 
results in little glycolytic flux and thus low ATP/ADP when glucose levels are diminished 
(Röder et al. 2016).  At high glucose levels, β-cells phosphorylate glucose via high-affinity 
glucokinase (GK) which explains the observed increase in the ATP/ADP ratio making GK 
activity in β-cells the rate-limiting step for further glucose metabolism (Röder et al. 2016). The 
increase in ATP/ADP ratio increases insulin release via closure of KATP channels, β-cell 
depolarization and insulin release (see below for more information on KATP channels) (Ashcroft 
2005). Once insulin is released, it can bind to its receptors found throughout the body to cause 
cellular glucose uptake, suppress postprandial glucagon secretion, promote glycogenesis, protein 
and fat synthesis and inhibit glycogenolysis and gluconeogenesis (Röder et al. 2016). Insulin has 
also been shown to act in the brain. One of its primary actions is on food intake through the 
hypothalamus and brainstem (Coll et al. 2007), but more recent data suggests it plays many 
different roles that will be discussed in more detail below. Glucagon is released from the α cells 
in response to low glucose levels and causes opposite effects of insulin (Jiang & Zhang 2003). 
Thus, it maintains glucose homeostasis during the fasted state. 
Additional hormones controlling peripheral glucose regulation are the incretins, 
glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). These hormones are 
secreted from the gut in response to nutrients (Hayes et al. 2014). These were discovered due to 
the observation that oral glucose gave a much greater surge of insulin than did intravenous 
glucose. They both increase the secretion of insulin and suppress glucagon and appetite, but 
GLP-1 also regulates the amount of glucose entering the bloodstream by regulating gastric 
emptying and motility (Hayes et al. 2014). It has further been shown to play a role in food 
intake, which is believed to be through actions on the vagal afferents of the gut (Hayes et al. 
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2014). Food intake is also highly regulated by two other peripheral hormones: leptin and ghrelin. 
Leptin is released from adipocytes and correlates with BMI (Crespo et al., 2014). It causes 
satiety through its actions on the proopiomelanocortin (POMC) neurons in the hypothalamus to 
make melanocortins (Crespo et al., 2014). Ghrelin is released from the L-cells of the small 
intestine in response to stomach emptying (Crespo et al., 2014). It has orexigenic effects via 
actions on neuropeptide Y (NPY) and agouti-related protein (AgRp) neurons in the 
hypothalamus (Crespo et al., 2014).   
The next step in regulating CNS glucose concentration is getting glucose across the 
blood-brain barrier (BBB). As glucose is exceptionally hydrophilic, it must rely on a facilitative 
transporter to cross the BBB, except for at circumventricular regions that lack the BBB.  This 
transport is via GLUT1 in its glycosylated form (55 kDa), which is highly expressed by 
endothelial cells (Maher et al. 1994). The concentration of GLUT1 is high on the adluminal side 
compared to the luminal side so that glucose can readily flow into the brain (Cornford et al. 
1994). Glucose entry is further regulated through neurovascular coupling by astrocytes. 
Neurovascular coupling is the increase in cerebral blood flow in response to increased neural 
activity (Phillips et al. 2016). A second form of GLUT1 (45 kDa) differing from the 55-kDa 
form by the degree of glycosylation is expressed by astrocyte cell bodies and processes in the 
cerebral parenchyma, as well as in astrocytic end feet surrounding blood capillaries (Leino et al. 
1997). Because astrocytes have thick large processes called end-feet that enwrap the 
intracerebral blood vessels as well as fine peri-synaptic processes that ensheath most synapses 
they are uniquely positioned for sensing neuronal activity and cerebral blood flow (Bélanger et 
al. 2011). They can act on both vasoconstriction and vasodilation through different signaling 
cascades. Ca2+ transients in astrocytes resulting from metabotropic glutamate receptor (mGluR) 
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activation activate cytosolic phospholipase A2 triggering the formation of arachidonic acid 
which is converted into vasodilating agents such as epoxyeicosatrienoic acids (EETs) (Bélanger 
et al. 2011).  Alternatively, arachidonic acid can diffuse in smooth muscle cells and cause 
vasoconstriction after its conversion to 20-hydroxeicosatraenoic acid (20-HETE) (Bélanger et al. 
2011). 
Once glucose enters the CNS, it can be taken up by cells and used as energy.  Neurons 
primarily take up glucose through the glucose transporter GLUT3. GLUT3 is a high-affinity 
transporter found on the neuronal cell processes (Simpson et al. 2008). Currently, it is believed 
that GLUT3 is found predominantly in neuronal processes (i.e., axons and dendrites) with less 
labeling in the cell body (Simpson et al. 2008). GLUT3 has a very high affinity for glucose (5-
fold higher than GLUT1 and 4) and the highest turnover of all GLUTs ensuring efficient glucose 
transfer into neurons (Simpson et al. 2008). GLUT4 and GLUT8 are also found on neurons, but 
their roles are less well understood (Sankar et al. 2002). IHC data has however shown that they 
are present on neuronal cell bodies and thus may play a role in getting glucose into the cell body 
and both are found in the hippocampus (Sankar et al. 2002), a cortical region known to be 
involved in learning and memory that also exhibits an increased susceptibility to generate 
epileptic activity (Anand & Dhikav 2012). GLUT2, GLUT5, SGLT1, and SGLT2 are all found 
in the brain (Shah et al. 2012). While GLUT2 is known to play a role in glucose sensing in the 
hypothalamus, the roles of these transporters in the brain are not well understood (Thorens 
2012). 
Neurons were primarily believed to be responsible for the high glucose uptake present in 
the CNS due to their high-energy demands. However, it has now been shown that astrocytes 
have a higher glycolytic rate and may contribute the majority of fluorodeoxyglucose (FDG)-
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positron emission tomography (PET) (Pellerin & Magistretti 2004). Although, somewhat 
controversial this increase in glycolysis in astrocytes has been proposed to provide energy to the 
neurons. Referred to as the astrocyte-neuron lactate shuttle (ANLS) hypothesis, this theory 
assumes that astrocytes take up glucose, convert it to lactate and then send the lactate to the 
neurons to be used as an energy substrate (Pellerin & Magistretti 2004). Glucose is taken up by 
astrocytes via the unglycosylated form of GLUT1 (45kDa) (Leino et al. 1997). Once in the cells 
glucose can go through glycolysis to make pyruvate.  Pyruvate can then be converted to lactate 
via lactate dehydrogenase A (LDHA) and sent through monocarboxylic transporters (MCTs) to 
the neurons (Pérez-Escuredo et al. 2016). Once in the neuron lactate dehydrogenase B (LDHB) 
can then convert lactate back to pyruvate as depicted in Figure 1.1 below. The pyruvate can then 
be sent into the mitochondria where it can go through the tricarboxylic acid (TCA) cycle and 
electron transport chain for full oxidation to water and CO2 producing 32-36 ATPs (Fernie et al. 
2004).  
 
 
 
Figure  1.1: Model depicting MCT-mediated lactate exchange between astrocytes and neurons 
in the brain (Figure from Pérez-Escuredo et al., 2016). 
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One potential reason for neurons using lactate as a substrate rather than taking up glucose 
is to conserve glucose for the pentose phosphate pathway (PPP). The PPP makes NADPH which 
converts glutathione from its oxidized form, GSSH, to its reduced form, GSH. (Bélanger et al. 
2011). Glutathione has antioxidant properties by reacting with reactive oxygen species (ROS) 
when in its reduced form, thus maintaining a proper ratio between glycolysis and the PPP is 
essential (Bélanger et al. 2011). The ANLS hypothesis is still a working hypothesis, but it has 
been shown that neurons lack 6 phosphofructose-2-kinase (a rate-limiting enzyme in glycolysis 
that causes conversion of fructose 6-phosphate into fructose 1,6 bisphosphate and ADP) 
suggesting that they may have a lower capacity for glycolysis (Bolaños et al. 2010). It has also 
been shown that neurons may prefer lactate as a substrate to glucose and it was recently 
demonstrated that astrocyte-neuron lactate transport is required for long-term memory formation 
(Suzuki et al. 2011). 
Astrocytes can also regulate CNS metabolism and neuronal signaling through their well-
characterized role in neurotransmitter uptake. This is especially important for glutamate, the 
primary excitatory amino acid in the CNS, as overstimulation of glutamate receptors can result in 
excitotoxicity (Lin et al., 2012).  Glutamate uptake is primarily mediated through the astrocyte-
specific sodium-dependent high-affinity glutamate transporter (GLT-1) and glutamate aspartate 
transporter (GLAST) (EAAT1 and 2 in humans) (Lin et al. 2012). Astrocytes convert glutamate 
to glutamine via glutamine synthetase (GS), an enzyme found primarily in astrocytes (Daikhin & 
Yudkoff 2000).  Glutamine is then transferred back to neurons and converted to glutamate via 
deamination by phosphate-activated glutaminase (Daikhin & Yudkoff 2000). While glutamate is 
synthesized through numerous pathways in astrocytes and neurons, astrocytes are responsible for 
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replenishing glutamate because they are the only cell type containing pyruvate carboxylate, the 
central enzyme in the pathway responsible for the conversion of glucose to glutamate (Daikhin & 
Yudkoff 2000).    
Astrocytes are also the primary glycogen stores in the brain, although there is some 
emerging data that neurons can express the required enzymes (Brown & Ransom 2007a). While 
glycogen is much lower in the CNS than in the periphery, it is still a primary energy store in the 
brain that can be used acutely during glucose deprivation (Brown & Ransom 2007a).  
The brain dependence on glucose puts it at risk for cognitive decline if the supply of 
glucose is interrupted, or if defects in the ability to metabolize glucose occur. Disturbances in the 
cerebral metabolic rate of glucose (CMRglu) have been well defined in AD and other 
neuropathological diseases (e.g. epilepsy) (Peppard et al. 1992; Kennedy et al. 1995; Reiman et 
al. 1996; Ishii et al. 1998; Johnson et al. 2001; Diehl-Schmid et al. 2007). In the context of AD, 
early studies determined that the CMRglu was decreased with several studies showing a 20-25% 
decrease in global CMRglu and decreases in glucose use also correlate with cognitive 
performance, suggesting that such declines are a reliable marker of disease status (Kennedy et al. 
1995; Reiman et al. 1996; Johnson et al. 2001). Subsequent studies using FDG-PET have 
confirmed regional declines in glucose uptake as an early and progressive characteristic of AD 
(Mosconi et al. 2004, 2008). One explanation for reductions in metabolism in AD patients is the 
loss of neurons that occurs as the disease progresses (West et al. 1994). However, glucose 
hypometabolism occurs in at-risk individuals (ApoE4 carriers, patients with presenilin 1 (PS1) 
mutations, and those with a maternal family history of AD) prior to clinical symptoms of 
dementia (Mosconi et al. 2004). Additionally, like human patients the 3xTg-AD mouse and other 
models expressing PS1 and amyloid precursor protein (APP) mutations exhibit decreased 
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glucose metabolism and these alterations occur prior to any neuropathological or behavioral 
changes (Dodart et al. 1999; Nicholson et al. 2010; Macdonald et al. 2014). Additionally, the 
3xTg-AD mouse model does not display cell loss. Thus, decreases in CMRglu are unlikely to be 
primarily the result of cell loss. Interestingly, a decrease in PET signal is also seen in epilepsy 
(interictally) and depression (Sarikaya 2015). 
Overall, this section displays the complexity of CNS metabolism and the importance of 
maintaining a tight regulation between peripheral and CNS metabolism. Additionally, it 
discusses decreased CNS metabolism in neuropathological diseases, primarily AD, although it 
appears to be a common characteristic of numerous neuropathological diseases. Given that the 
primary focus of my dissertation was on AD, the next section will discuss this disease in more 
detail.  
 
Alzheimer’s Disease 
AD is a progressive neuropathological condition characterized by a decline in learning, 
memory and cognitive function to the point of dementia. Dementia is a dramatic loss of 
cognition that can affect intellectual and behavioral functions. AD is the most common form of 
all dementias and can be can be categorized into stages based on the degree of cognitive 
impairment (Reisberg et al. 1984). In the first stages of AD, patients begin to experience very 
mild cognitive impairments, such as forgetting words or an object’s location. As the disease 
progresses into mild cognitive impairment (MCI), more severe deficits begin to be noticed such 
as forgetting names and having trouble in social or work settings. During moderate cognitive 
decline, patients exhibit mood swings, forgetting of one’s own personal history and have trouble 
planning and remembering events. During the later stages of the disease, moderately severe 
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cognitive decline occurs. Patients at this stage begin to forget their address or what day it is and 
can become confused about their location. In the final stage of AD, very severe cognitive decline 
occurs. These patients cannot function on their own and require around the clock assistance. 
They cannot remember their name, lose connection with their surrounding environment, and 
exhibit violent mood swings and changes in sleep patterns. These patients experience an inability 
to control their own bodily functions and lose the ability to take care of themselves physically. 
 Anatomically, AD is characterized by 3 neuro-pathological hallmarks, beta-amyloid (Aβ) 
deposition (plaques/lesions/senile plaques), neurofibrillary tangles (NFTs) (Hardy et al. 1998), 
and synapse and cell loss (Ball 1977). Alois Alzheimer first discovered these hallmarks in 1907 
(Hippius & Neundörfer 2003) and these hallmark characteristics have been the focus of much 
research and the targets for many therapeutic options, although to date there is no effect 
treatment for AD. The first hallmark, beta amyloid plaques come from the improper cleavage of 
APP, a transmembrane protein expressed in many tissues and is concentrated at the synapses 
between neurons. The extracellular portion of APP can be cleaved in two ways. In the first way 
APP is cleaved by alpha secretase to yield soluble APP, which plays roles in growth and 
development. In the second pathway APP is cleaved first by β-secretase (BACE1) followed by γ- 
secretase (Kang et al. 1987; Sambamurti et al. 1992; Xia et al. 1998). This yields two major Aβ 
fragments, Aβ 1-40 and Aβ-42 (Xia et al. 1998). The Aβ 1-42 fragments are believed to be the 
primary one associated with AD pathology (Iwatsubo et al. 1994; El-Agnaf et al. 2000). These 
fragments bind together to form oligomers eventually depositing in the brain as extracellular Aβ 
plaques (Walsh et al. 1997). Aβ plaques have been shown to result in impairments with synaptic 
preservation (Davies et al. 1987), neurotransmitter signaling between neurons (Palop & Mucke 
2010) and neuronal cell death (Hardy & Selkoe 2002). While plaques are a central part of AD 
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and the mechanisms of plaque formation are believed to play a key role in disease development 
and progression, it is controversial whether Aβ plaques play a major role in cognitive decline and 
dementia associated with AD. Indeed many potential treatments have been aimed at treating 
these plaques, such as BACE1 inhibitors and Aβ immunotherapy (Hock et al. 2003). Several 
therapies have shown they can decrease plaque load yet no significant improvement in cognitive 
function is seen (Morris et al. 2014). Alternatively, increasing plaque load doesn’t appear to 
decrease cognition either (Hayashi-Park et al. 2017) suggesting that another factor may be 
responsible for decreased cognitive performance.  
The second hallmark, neurofibrillary tangles, results from the hyperphosphorylation of 
the cytoskeletal protein tau (Grundke-Iqbal et al. 1986; Trojanowski & Lee 1994). Tau is located 
in neuronal axons where it binds to microtubules to facilitate their formation and stabilization 
(Mietelska-Porowska et al. 2014). Neuropathological studies have shown that the earliest sign of 
tau-related pathology is the accumulation of highly phosphorylated tau in neuronal cell bodies 
and elsewhere, and these early pathological observations precede clinical symptoms (Braak and 
Braak 1991). As tau becomes hyperphosphorylated it causes the destabilization of the 
microtubules and impairs axonal transport (Mietelska-Porowska et al. 2014). Studies attempting 
to correlate pathological lesions with symptoms have shown that NFTs more closely relate to the 
severity of cognitive impairment than do plaques (Bennett et al. 2004). In addition, mutations of 
the microtubule-associated protein tau (MAPT) gene, the gene encoding tau, leads to 
frontotemporal dementia making this likely to contribute to cognitive decline (Pittman et al. 
2006). Much like Aβ there is an abundance of research aimed at treating neurofibrillary tangles. 
The primary regulators of tau phosphorylation (though there are several others) have been shown 
to be protein phosphatase 2A (PP2A) and GSK3. GSK3 is, however, the predominant 
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phosphatase and is controlled by insulin signaling (Tojanowski and Lee 1995; Martin et al., 
2008; Wang et al., 2007). Indeed, GSK3 inhibition attenuates tau phosphorylation and 
aggregation in mouse models of AD (Nakashima et al. 2005; Noble et al., 2005; Engel et al., 
2006). In addition, transgenic mice that conditionally overexpress GSK3β in hippocampal and 
cortical neurons show some of the biochemical and cellular aspects found in AD pathology such 
as tau hyperphosphorylation, decreased nuclear β-catenin, neuronal death, reactive gliosis and 
spatial learning deficit (Hernandez et al., 2002, Engel et al., 2006a). Further, these mice display a 
loss of long-term potentiation (LTP) (i.e. the physiological mechanism believed to be involved 
with memory formation) that can be that can be restored with lithium, a GSK3 inhibitor (Hooper 
et al., 2007) 
The final hallmark is the marked loss of synapses and cells. As AD progresses more and 
more synapses are lost until there is eventually severe shrinkage of the entire brain. This loss of 
synapses appears to be the hallmark most closely linked to cognitive impairment (Terry et al. 
1991). Interestingly, recent studies show that the complement pathway, astrocytes, and microglia 
may mediate synaptic loss early in AD. Specifically, inhibition of the complement pathway 
reduces the number of phagocytic microglia, as well as the extent of early synapse loss (Hong et 
al. 2016). Additionally, both murine and human astrocyte conditioned media can increase 
synapse density, reduce Aβs binding, and prevent Aβ-induced synapse loss in cultured 
hippocampal neurons (Diniz et al., 2017). The involvement of complement, microglia, and 
astrocytes in AD has been attributed to neuroinflammation, which is a prominent feature in 
advanced disease progression and will be discussed in more detail later.  
Initial changes in AD are found in the transentorhinal region (temporal lobe). From here 
the destructive process encroaches upon the entorhinal region, the hippocampus, and neocortex. 
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Braak staging characterizes disease propagation into six stages based on the location of tangle-
bearing neurons and the severity of changes. Stages I–II describe transentorhinal clinically silent 
cases, stages III–IV are the limbic stages where early AD emerges and V–VI are the neocortical 
stages where fully developed AD is present (Braak and Braak, 1995). The hippocampus is a 
region of the brain within the limbic temporal lobe that is involved in memory forming, 
organizing, and storing. It is particularly important in forming new explicit/declarative (i.e. 
schemantic and episodic) memories and connecting emotions and senses, such as smell and 
sound, to memories (Scoville & Milner 1957; Rudy & Sutherland 1989; Squire 1992). Memory 
is basically divided into implicit and explicit memory. Implicit memory includes all unconscious 
memory types including the type of memory for skill or task-oriented procedures (i.e., procedural 
memory) (Schacter 1987) while explicit memory entails conscious recall of factual information 
(i.e., declarative memory). Declarative memory is further divided into semantic memory 
(memory of facts or concepts) and episodic memory (memory of particular events or 
experiences) (Tulving, 1983). The hippocampus is a horseshoe shaped bilateral structure that acts 
as a memory indexer by sending memories out to the appropriate part of the cerebral hemisphere 
for long-term storage and then retrieving them when necessary although this function is not as 
well understood as is its role in memory consolidation. Its circuitry consists of a tri-synaptic 
circuit as seen below in Figure 1.2. This tri-synaptic circuit is a relay of synaptic transmission, 
which is made up of three major neuronal groups: granule cells, CA3 pyramidal neurons, and 
CA1 pyramidal cells. The hippocampal relay involves 3 main regions within the hippocampus, 
which are classified according to their cell type and projection fibers. Axons from layer II of the 
entorhinal cortex (EC) give rise to the perforant pathway (PP) that projects through the 
subiculum and terminates both in the dentate gyrus (DG) and CA3 (Steward & Scoville 1976; 
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Schwartz & Coleman 1981). The DG then synapses on pyramidal cell dendrites located in 
stratum lucidum (SL) of CA3 via the granule cell axons, the mossy fibers (Claiborne et al. 1986). 
CA3 principal cells then project to CA1 via Schaffer collaterals (Tamamaki et al. 1984, 1988; 
Ishizuka et al. 1990), which then send output to the subiculum (Van Groen & Wyss 1990). 
Collectively the DG, CA3, and CA1 of the hippocampus compose the trisynaptic loop. 
Interestingly, given the high propensity for synaptic plasticity and activity within this region that 
is believed to contribute to its capacity to underlie learning and memory it is also highly 
susceptible to neuropathological neuronal activity (i.e. hypersynchronicity underlying seizure) 
when stressed or damaged. 
 
 
Figure 1.2: Hippocampal anatomy and circuitry. A) Representation of a mouse hippocampal 
slice demonstrating the cellular anatomical regions. The alveus (ALV), stratum oriens (SO), 
stratum pyramidale (SP), stratum ratiatum (SR), stratum lacunosum moleculare (SLM), granule 
cell layer (GCL) and hilus are shown. B) Cartoon demonstrating the primary regions of the 
hippocampus, the cornus amonus 1 (CA1), cornus amonus 3 (CA3) and DG and the basic 
trisynaptic circuit. C) More detailed diagram of hippocampal circuitry where layers I and II of 
the EC lead to the DG through the PP, which feeds to the CA3 via mossy fibers (MF). The CA3 
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then goes to the CA1 via schafer collaterals (SC) and then to the subiculum (SUB), eventually 
leaving through layers V/VI of the EC.  
 
While the presence of plaques and tangles has greatly helped with disease classification, 
their role in the pathological process of AD remains unclear. Research over the past century, 
however, has revealed many risk factors for developing AD. One of which is genetic 
predisposition. Genetically linked AD makes up a very small percentage (5-10%) of total AD 
cases and these cases are referred to as familial AD (FAD) (Tang & Gershon 2003). These cases 
are different from sporadic or late-onset AD (LOAD), the most common form of AD, in that they 
occur much earlier (around 45 years of age) and are believed to be primarily due to mutations in 
specific genes. These genetic predispositions include alterations in either the APP or PS1 genes 
(Tang & Gershon 2003).  As previously mentioned APP is the protein responsible for forming 
the characteristic Aβ plaques. A mutation on chromosome 21 leads to an abnormal APP protein, 
which has been shown to cause FAD (Goate et al. 1991; Levy et al. 2006). Mutations of the 
PSEN1 gene, encoding PS1, are the most common cause of FAD (Kelleher and Shen, 2015). PS1 
functions as the catalytic subunit of γ-secretase (See above) and mutation on chromosome 14 
leads to mutations in the protein that are associated with FAD (Sherrington et al. 1995; 
Moussaoui et al. 1996). While these mutations underlie only a very small subset of total AD 
cases, studying them has led to the creation of numerous mouse models of AD to help 
understand the disease. In this regard, the hippocampus of rodents and humans are similar in 
both structure and function and thus mice are a commonly used species for studying Alzheimer’s 
disease (Burwell et al. 1995). However, mice do not develop Aβ plaques or neurofibrillary 
tangles normally and thus do not truly develop sporadic AD. Still, due to their similarity in 
structure and function, relatively short life span and the ability to examine them 
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electrophysiologically, anatomically, and via cellular and molecular techniques, they are the 
most commonly used model. Therefore, several mouse models of AD have been created by 
genetically incorporating human transgenes into mouse lines (e.g. APP, PS1 and 
hyperphosphorylated tau). This transgenic approach has led to a plethora of available models 
(over 150 are listed on the Jackson Laboratory web site: www.jax.org). Noteworthy among these 
are the Tg2576 (APPswe, APP Swedish mutation; Hsiao, 1998), APP/PS1 (APP Swedish 
mutation coupled with a mutated version of PS1 - delta E9 deletion) (Jankowsky et al. 2001), 
and 3xTg-AD (Swedish mutation for human APP, mutated human PS1 as well as mutated tau) 
(Oddo et al. 2003) mouse models. The model used in this dissertation research, the 3xTg-AD 
mouse, uses the Thy 1.2 promoter to express the mutated human APP and tau genes which 
causes preferential expression of these genes in the CNS. This mouse with the 2 transgenes (APP 
and tau) was then crossed with a PS1 knock-in mouse. However, there is conflicting data over 
the timing of the development of pathology and cognitive decline in this model. Originally, these 
mice were reported to express extracellular Aβ at 6 months and neurofibrillary tangles by 12 
months (Oddo et al. 2003). In our lab we do not see plaque formation until 14 months of age 
with aggregation of hyperphosphorylated tau and cognitive decline appearing only around 18 
months of age (Cai et al. 2012). This is consistent with recent studies from other labs 
(Mastrangelo & Bowers 2008). The reason for the discrepancy between earlier studies and our 
colony is unknown but may be the result of the use of a different background strain from the 
original studies (C57/C129 vs. C57). Other explanations include loss of phenotype due to a 
progressive loss of transgene copies with successive breeding, differences in the gender of mice 
used in the studies, and differences in housing conditions and diet. 
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Unlike FAD, LOAD does not exhibit specific genetic alterations and not a single 
phenomenon has been shown to be primary underlying cause although several risk factors have 
been discovered. One risk factor for LOAD is having the APOE e4 allele. APOE is a major 
cholesterol carrier that supports lipid transport and injury repair in the brain. The human APOE 
gene exists as three polymorphic alleles—e2, e3 and e4 (Liu et al. 2013). The e3 allele is the 
most common with a worldwide frequency of 77.9% and has no effect on risk for AD. E2 
appears to be protective and actually lowers the risk of AD with a frequency of 8.6%. In contrast, 
the e4 allele increases AD risk and is seen in 13.7% of the normal population and is increased to 
40% in AD patients (Tsai et al. 1994). Ninety one percent of individuals homozygous for the e4 
allele develop AD with a clinical onset of 68 years. In heterozygotes the frequency is decreased 
to 47% and the age of onset increases to 76 years of age. Other risk factors for LOAD are aging 
itself, altered metabolic capacity (Ogawa et al. 1996; Struble et al. 2010), changes in 
neurovascularization (Zlokovic, 2002), changes in cholinergic innervation (Arendt & Bigl 1986; 
German et al. 2003), increased inflammation (Hüll et al. 1996), increased free radical formation 
(Good et al. 1996), and changes in fatty acid/lipid distribution (Söderberg et al. 1992; Tully et al. 
2003). More recently, it has been discovered that diabetes doubles the chance of developing AD 
and thus is believed to be the second leading risk factor for LOAD following only aging itself 
(Yoshitake et al. 1995; Leibson et al. 1997; Ott et al. 1999; Arvanitakis et al. 2004; Yaffe et al. 
2004; Biessels & Reagan 2015a).  
 Despite the discovery of all of these risk factors associated with AD and the development 
of numerous treatments for symptomatic relief (primarily early onset learning and memory 
impairments), these therapeutic options have only been marginally effective and certainly no 
cure has been found. Many drugs have been approved for AD such as Exelon, Aricept and 
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Razadyne; though, each drug only works on a small percentage of patients (Rogers 1998; Rösler 
et al. 1999; Clegg et al. 2001). Because of the difficulty in diagnosing AD and the lack of 
effective medications to date, it is highly important to understand the disease and to further 
understand and identify the underlying mechanisms that may contribute to its pathogenesis. 
Determining risk factors that occur early on in the disease or prior to the detection of disease 
onset could play a major role in the prevention and/or amelioration of its pathogenesis. Although 
many risk factors have been identified, diagnosing AD in the early stages of development has 
been troublesome and a definitive diagnosis is still only possible upon death and autopsy. 
Currently, MRI, CT, and PET scans are being used to determine whether specific types of 
changes can be seen in the brain that precede dementia (Small et al. 2006; Amatsubo et al. 
2010). However, whether these techniques allow for detection of AD at the earliest stages of 
disease progression is unknown making AD prevention and treatment clinically impossible. 
Currently AD is the 6th leading cause of death in the United States and an estimated 5.5 million 
Americans are living with AD (Alzheimer’s Association Fact Sheet, 2017). Further, of the top 10 
leading causes of death, it is the only one that cannot be prevented, cured or even slowed. For 
example while deaths from heart disease can be decreased by 14%, deaths associated with AD 
increased by 89% from 2000 to 2014 (Alzheimer’s Association Fact Sheet, 2017). This trend is 
not expected to change with demographic evidence suggesting that by 2050 there will be over 16 
million Americans with AD due to an increase in the aging population as well as an increase in 
risk factors such as diabetes (Alzheimer’s Association Fact Sheet, 2017). Since diabetes has 
recently been described as a leading risk factor for AD, we focused on metabolic changes in this 
study (additional background will be presented below). The following section will discuss 
diabetes.   
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Diabetes 
 Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from 
defects in insulin secretion, insulin action, or both. Polyuria, polydipsia, weight loss, polyphagia, 
blurred vision, impairment of growth and susceptibility to certain infections are all symptoms of 
diabetes associated hyperglycemia (American Diabetes Association. et al. 2003). Long-term 
complications of diabetes include retinopathy with potential loss of vision; nephropathy leading 
to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; 
and autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular symptoms 
and sexual dysfunction. Patients with diabetes have an increased incidence of atherosclerotic 
cardiovascular, peripheral arterial, and cerebrovascular disease and AD (American Diabetes 
Association, 2003).  
There are two major forms of diabetes mellitus primarily categorized based on their 
etiology: Type I and Type II. Type I diabetes is characterized by insulin deficiency where the 
pancreas does not produce insulin in sufficient amounts to decrease blood glucose levels and thus 
glucose uptake and utilization are decreased. Type I diabetes, also known as insulin-dependent 
diabetes or juvenile-onset diabetes, accounts for only 5–10% of diabetes cases and results from a 
cellular-mediated autoimmune destruction of the β-cells of the pancreas (Melmed, 2016). In this 
form of diabetes, the rate of β-cell destruction is quite variable, being rapid in some and slow in 
others. Immune-mediated diabetes commonly occurs in childhood and adolescence, but it can 
occur at any age. Type I diabetes has strong human leukocyte antigen (HLA) associations in that 
possessing certain alleles for the HLA gene can cause it. Having a family history of Type I 
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diabetes increases the risk further (Aly et al. 2006). Diabetes diagnosed in the first 6 months of 
life has been shown not to be typical autoimmune type 1 diabetes. This so-called neonatal 
diabetes can either be transient or permanent. The most common genetic defect causing transient 
disease is a defect on ZAC/HYAMI imprinting, whereas permanent neonatal diabetes is most 
commonly a defect in the gene encoding the Kir6.2 subunit of the β-cell KATP channel 
(American Diabetes Association 2015).  
Comprising 90-95% of cases, Type II diabetes is the predominant form of diabetes 
mellitus. Also referred to as non–insulin-dependent diabetes or adult-onset diabetes, Type II 
diabetes encompasses individuals who have insulin resistance and usually have relative insulin 
deficiency (Melmed 2016). At least initially, and often throughout their lifetime, these 
individuals do not need insulin treatment to survive. The specific etiologies are not known, but 
autoimmune destruction of β-cells does not occur. Type II diabetes does have both genetic and 
environmental risk factors; although environmental factors appear to play a larger role in disease 
onset. The major risk factors for developing type II diabetes are obesity (Kadowaki et al. 1983; 
Felber et al. 1988), high blood pressure (Wei et al. 2011), unhealthy eating habits (Bazzano et al. 
2005), age, and genetic predisposition (over 20 risk alleles have been discovered) (Billings & 
Florez 2010). 
Most patients with this form of diabetes are obese, and obesity itself can cause some 
degree of insulin resistance (American Diabetes Association 2015). This form of diabetes 
frequently goes undiagnosed for many years because the hyperglycemia develops gradually and 
at earlier stages is often not severe enough for the patient to notice any of the classic symptoms. 
The severity of the metabolic abnormality can progress, regress, or stay the same. In some 
individuals with diabetes, adequate glycemic control can be achieved with weight reduction, 
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exercise, and/or oral glucose-lowering agents (American Diabetes Association, 2015). While 
patients with this form of diabetes may have insulin levels that appear normal or elevated, based 
on their blood glucose, insulin would actually be expected to be even higher if their β-cell 
function was normal. Thus, insulin secretion is defective in these patients and insufficient to 
compensate for their insulin resistance. Insulin resistance may improve with weight reduction 
and/or pharmacological treatment of hyperglycemia but is seldom restored to normal.  
Current statistics reveal that 25.8 million children and adults (8.3% of the population) 
have either Type I or Type II diabetes in the United States (CDC National Diabetes Statistics 
Report, 2014). It is now the seventh leading cause of death in the US and the major cause of 
kidney failure, heart disease, stroke and blindness (CDC National Diabetes Statistics Report, 
2014). In 2007, the cost of all the different types of diabetes together including pre-diabetes and 
gestational diabetes totaled $218 billion in medical and indirect costs (American Diabetes 
Association 2015). 
Alarmingly, diabetes has been recently revealed to be the second leading risk factor for 
developing AD (Leibson et al. 1997) and thus could potentially be correlated with either the 
onset or progression of AD. Interestingly, both type I and type II diabetics have been shown to 
be associated with cognitive impairment as well as having an increased risk of dementia 
especially Alzheimer’s related dementia (Gispen & Biessels 2000). Thus, having low insulin 
levels, insulin receptor (IR) desensitization, or hyperglycemia are linked to cognitive dysfunction 
and could contribute to AD. Since numerous clinical studies have demonstrated a correlation 
between AD and diabetes it is necessary to study this relationship using a more controlled 
experimental system, such as AD mouse models, in order to understand if these conditions have 
a common underlying cause or whether one condition can contribute to the pathogenesis of the 
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other. Thus, in the next part we will describe current data demonstrating a relationship between 
diabetes and AD.  
 
Diabetes and Alzheimer’s disease 
As noted above, evidence suggests that diabetes may be involved with the development 
of dementia including AD-related dementia. Several epidemiological studies have shown that 
diabetes increases the risk for cognitive impairment and AD (Yoshitake et al. 1995; Leibson et 
al. 1997; Ott et al. 1999; Arvanitakis et al. 2004; Yaffe et al. 2004; Biessels & Reagan 2015a) 
and patients with diabetes mellitus have also been shown to exhibit cognitive deficits relating to 
either vascular dementia or Alzheimer’s type dementia. Indeed, a population-based study by 
Leibson et al. (1997) showed that patients with Type II diabetes mellitus had an increased risk 
for all types of dementia and specifically an increased risk for AD. Further, Ott et al. (1999) 
showed, using a population based study with multiple regression analysis, that diabetes mellitus 
and AD are strongly associated. Conversely, lower insulin concentrations (both basal and 
following a glucose challenge) have also been implicated in AD (Peila et al. 2004; Rönnemaa et 
al. 2008) suggesting that both type I and type II diabetes might increase the risk of AD. In 
addition to diabetes being a risk factor for AD, these conditions share many common 
characteristics with AD. One such common occurrence is that both diabetic patients without 
dementia (den Heijer et al. 2003) and AD patients (Matsuzawa 1990) exhibit hippocampal and 
amygdala atrophy in MRI images of. 
Interestingly, besides showing brain shrinkage and cognitive deficits, diabetic patients 
can also show amyloid pathology. APP aggregates are commonly observed in pancreatic islets of 
diabetic patients (Mosselman et al. 1988; Höppener et al. 2000; Höppener & Lips 2006). Using 
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Western blot analysis of human pancreatic tissue from Type II diabetic patients, Aβ and 
hyperphosphorylated tau were detected (Miklossy et al. 2010). This data shows that diabetic and 
AD patients have some common pathology, although apparently different target organs, and 
demonstrate that alterations in amyloid and tau can be present in other organs besides the brain. 
In addition to pancreatic pathology, patients with type II diabetes and the e4 allele have been 
shown to have a higher number of hippocampal neuritic plaques and neurofibrillary tangles in 
the cortex and hippocampus than patients with either risk factor alone (Peila et al. 2002).  
Both AD patients and diabetic patients also exhibit CNS hypometabolism. In relation to 
diabetes, insulin resistance is associated with a pattern of reduced CMRglu in frontal, 
parietotemporal, and cingulate regions in cognitively normal adults that were recently diagnosed 
with either pre-diabetes or type II diabetes (Baker et al. 2011). In AD, reductions in CMR occur 
before neuropsychological or imaging evidence for the disease (Kennedy et al. 1995; Reiman et 
al. 1996; Johnson et al. 2001). Interestingly, a decrease in CMR occurs in other forms of 
dementia as well (Peppard et al. 1992; Ishii et al. 1998; Diehl-Schmid et al. 2007) and aging 
related cognitive decline correlates with decreases in CMR (Mosconi et al. 2008). This pattern of 
hypometabolism has also been observed in patients with MCI and AD, in middle-aged carriers of 
the APOE e4 allele who do not have dementia, and in presymptomatic adults with the AD-
causative PS1 gene (Baker et al. 2011). 
Obesity and the metabolic syndrome are important risk factors for the development of 
type II diabetes (Kadowaki et al. 1983; Felber et al. 1988). There is also evidence to support that 
obesity may be a risk factor for AD. A Swedish study found that AD risk increased by 36% for 
every 1.0 increase in body mass index at the age of 70 years (Gustafson et al. 2003) and that both 
men and women with a midlife BMI >30 have a greater risk of developing AD (Kivipelto et al. 
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2005; Beydoun et al. 2008; Kroner 2009). Further, AD patients have been shown to have a 
significantly larger mean waist circumference, higher mean plasma concentration of triglycerides 
and glucose, and lower mean plasma concentration of high-density lipoprotein cholesterol 
(Razay et al. 2007). 
The level of advanced glycation endproducts (AGEs) is also significantly increased in 
both diabetes (Kikuchi et al. 2003; Yamagishi & Takeuchi 2004) and AD (Smith et al. 1997; 
Münch et al. 1998). AGEs are a heterogeneous group of irreversible products formed by reactive 
derivatives of nonenzymatic glucose–protein condensation reactions, and lipids and nucleic acids 
exposed to reducing sugars (Bierhaus et al. 1998). AGEs accumulate in various cell types and 
are a normal consequence of aging. An increase in the production of AGEs can cause tissue 
damage and an increase in cytokine formation (Lavrovsky, Chatterjee, & Clark 2000; 
Niethammer et al. 2009). The degree of nonenzymatic glycation is determined mainly by the 
glucose concentration and since both AD and diabetes can exhibit hyperglycemic events it is 
likely that production of AGEs is increased as a result of increased glucose levels. However, 
increased oxidative stress can also lead to an increase in production of AGEs and oxidative stress 
is increased in AD and diabetes, thereby providing another mechanism (Nowotny et al. 2015).  
AD patients can also exhibit the key characteristic of diabetes, altered glucose 
homeostasis. Meneilly and Hill (1993) using a cross-sectional study, observed that AD patients 
compared to healthy controls have elevated fasting glucose levels and that during a 
hyperglycemic clamp, steady-state glucose levels were also higher and insulin sensitivity was 
decreased in these patients. This observation has been followed up in several studies using 
mouse models. Unfortunately, the results from these animal model experiments have been highly 
variable. For example, in the 3xTg-AD mouse model Vandal et al. (2014), reported that there 
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was no difference in 6 month old mice but that by 10-14 months there was a significant 
impairment, while Giménez-Llort et al. (2010), suggested that at 6 months there was a 
significant impairment but only in females yet Clark et al. (2015) demonstrated glucose 
intolerance in both males and females at 6 months-the earliest time point they tested. In contrast, 
our recent study examined this further by assessing peripheral glucose tolerance relative to 
progression of AD pathogenesis and cognitive decline and found that glucose tolerance was 
impaired as early as 1-2 months of age (prior to any pathological or cognitive change) and 
continued throughout their lifespan. Similarly, in the APP/PS1 model, results are variable with 
some groups reporting glucose impairment early on (as early as 1-3 months) (Zhang et al. 2012; 
Macklin et al. 2017), others suggesting that it occurs later (Mody et al. 2011; Pedrós et al. 2014; 
Clarke et al. 2015), and other groups reporting that this model does not display impaired glucose 
tolerance under control conditions (Takeda et al. 2009; Jiménez-Palomares et al. 2012). The APP 
model is no exception, with some studies suggesting that they do exhibit a change in glucose 
tolerance (Mattson et al., 1999) and others reporting no change (Takeda et al. 2009; Kohjima et 
al. 2010). While the exact reason for all these discrepancies is unclear several factors are likely 
to contribute including the background strain that the transgenes are expressed on, the gender of 
the mice examined and differences in experimental procedures (e.g., fasting time, housing 
conditions, amount of glucose administered). Despite these inconsistent findings under standard 
dietary conditions, pro-diabetic dietary manipulations (e.g. high fat diet, high sucrose levels in 
water) consistently reveal a preferential compromise in glucose tolerance in AD mouse models 
relative to wild-type controls that were on the same background (Kohjima et al. 2010; Mody et 
al. 2011; Knight et al. 2016; Ruiz et al. 2016).   
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Table 1.1: Variability of peripheral glucose tolerance amongst mouse models. Table published 
in Griffith et al., 2018.  
Reference Genotype Gender Age Fast 
Glucose 
injection 
Glucose tolerance 
Gimenez-
Llort et al., 
2010 
3xTg-AD 
Males 
and 
females 
6 months O/N  NA 
Females showed impaired 
glucose tolerance, Males did 
not 
Vandal et 
al., 2015 
3xTg-AD 
Females-
diestrus  
6, 10 and 
14 months 
6h 1g/kg 
No difference at 6 months but 
impaired at 10 and 14 months 
Clarke et 
al., 2015 
3xTg-AD Males  6 months 12h 2g/kg Impaired glucose tolerance 
Clarke et 
al., 2015 
APP/PS1 
Males 
and 
females 
8-13 
months 
12h 2g/kg Impaired glucose tolerance 
Zhang et 
al., 2012 
APP/PS1 Males 
8-10 
weeks 
14h 2g/kg Impaired glucose tolerance 
Ruiz et al., 
2016 
APP/PS1 Males 
5-6 and 
11-12 
months 
O/N 1-2U/kg Normal glucose tolerance 
Mody et 
al., 2011 
PSEN1 Males 
16-17 and 
20-21 
months 
16h 2g/kg 
Slight glucose intolerance-
only significantly impaired at 
30 minute post-glucose bolus; 
more suscpetible to impaired 
glucose tolerance under high 
fat diet 
Mody et 
al., 2011 
APP/PS1 Males 
16-17 and 
20-21 
months 
16h 2g/kg 
Impaired glucose tolerance, 
more suscpetible to impaired 
glucose tolerance under high 
fat diet 
Macklin et 
al., 2016 
APP/PS1 Males 
2, 4-6, and 
8-9 months 
16h 2g/kg 
Impaired glucose tolerance in 
all age groups 
Takeda et 
al., 2009 
APP/PS1 Males 
2-3 and 
18-10 
months 
16h 2g/kg Normal glucose tolerance 
Takeda et 
al., 2009 
APP23 Males 
30-31 
months 
16h 2g/kg Normal glucose tolerance 
Mattson et 
al., 1999 
APPswe  NA NA  NA  NA  
Impaired glucose tolerance in 
APPswe compared to wild 
type controls 
Pedros et 
al., 2014 
APP/PS1 Males 
3 and 6 
months 
16h 1g/kg 
Impaired glucose tolerance at 
6 months but not at 3 months 
Velazquez 
et al., 2017 
3xTg-AD Females 
10 and 16 
months 
16h 2mg/kg 
Impaired glucose tolerance at 
16 but not 10 months 
Velazquez 
et al., 2017 
Tg2576 
Males 
and 
females 
5 and 9 
months 
16h 2mg/kg 
Impaired glucose tolerance at 
9 but not 5 months 
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Rodriguez-
Rivera et 
al., 2011 
Tg2576 
Males 
and 
females 
5, 9, and 
13 months 
16h 
1.5 
mg/kg 
Impaired glucose tolerance at 
9 and 13 months but not 5 
months 
Kohijima, 
Sun, Chan, 
2010 
Tg2576 Females 16 weeks 6h 1g/kg 
Normal glucose tolerance 
under control conditions, 
more susceptible to glucose 
intolerance under high fat diet 
Knight et 
al., 2016 
APP/PS1 
Males 
and 
females 
4-5 months 5h 1.5g/kg 
Normal gluocose tolerance, 
more susceptible to glucose 
intolerance under high fat diet 
Jimenez-
Palomares 
et al., 2012 
APP/PS1 
Males 
and 
females 
10 and 32 
weeks 
16h 2g/kg Normal glucose tolerance 
 
Further, inducing diabetes in mouse models of AD has also been shown to increase AD-
pathology. For example, Cao et al., (2007) reported that providing APP/PS1 mice water with 
high sucrose concentrations can exacerbate glucose intolerance, amyloid deposition and 
cognitive decline compared to APP/PS1 mice given normal water. In 3xTg-AD mice, studies 
showed that providing a high fat diet (HFD) low in polyunsaturated fats (PUFAs) increased Aβ 
1-40 and 1-42 concentrations and increased the amount of insoluble hyperphosphorylated tau in 
the brain (Julien et al. 2010). Further, in the Tg2476 mouse model, nine-month old female mice 
on a HFD exhibit more pronounced spatial learning deficits compared to these mice on a 
standard (Ho et al. 2004).  
In addition to dietary studies, studies have also shown that crossing AD mouse models 
with mouse models of diabetes can also increase AD-like pathology. For example, crossing 
APP/PS1 mice with the Pdx1+/- model of diabetes led to greater loss of synaptic spine proteins 
and increased tau phosphorylation, plaques, gliosis, and memory deficits (Guo et al. 2016). 
Similarly, APP/PS1 mice crossed with db/db mice displayed more vascular pathology and 
learning impairments than either condition alone, although there was no change in amyloid 
burden (Niedowicz et al. 2014). Further, crossing another AD model, APP32 mice with either 
ob/ob or NSY mouse models of diabetes led to more severe glucose intolerance, increased 
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inflammation, and cognitive dysfunction again with no increase in amyloid beta (Takeda et al. 
2010). Finally, in addition to dietary or genetic experiments, other studies have demonstrated that 
peripheral streptozotocin (STZ; a diabetes inducing agent that destroys pancreatic beta cells) 
injections increase plaques and tangles (Clodfelder-Miller et al. 2006; Planel et al. 2007; 
Plaschke et al. 2010; Wang et al. 2010; Hayashi-Park et al. 2017).  
While there is not a complete mechanistic understanding of how a pro-diabetic 
manipulation affects AD pathogenesis, evidence supports that hyperglycemia favors AB 
production. These studies suggest that: 1) experimentally increasing peripheral glucose levels in 
APP/PS1 mice results in greater interstitial Aβ (Macauley et al. 2015); 2) prolonged elevations 
of glucose levels can increase Aβ production in neuroblastoma cell lines overexpressing APP 
(Yang et al. 2015); and 3) hyperglycemia can induce BACE1 expression/activity (BACE1 is the 
rate limiting enzyme involved in cleaving APP into amyloid peptides) (Chen et al. 2015). 
However, the reason why AD mouse models exhibit altered peripheral glucose tolerance 
is unclear. Regardless of the underlying cause, the most likely contributor to a pre-diabetic 
phenotype in these AD models is a difference in insulin levels or insulin sensitivity. In this 
regard, despite the variability in glucose tolerance testing observed between groups all the 
studies that reported impaired glucose tolerance and looked at insulin levels and insulin tolerance 
consistently reported altered insulin activity. In the 3xTg-AD mouse Vandal et al., (2014) 
reported that in female mice with impaired glucose tolerance, insulin levels were decreased 30 
minutes following a glucose challenge with no change in insulin sensitivity relative to controls. 
Similarly, recent results from our lab suggest that impaired glucose tolerance is impaired much 
earlier in 3xTg-AD mice but that they also exhibit decreased insulin levels. In contrast, in 
APP/PS1 mice several studies have reported that insulin levels are increased in animals 
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displaying impaired glucose tolerance compared to controls and that insulin tolerance is 
decreased suggesting that these mice are insulin resistance (Zhang et al. 2012; Pedrós et al. 
2014; Macklin et al. 2017). Similarly, Knight et al., (2016) reported that HFD induced glucose 
intolerance in APP/PS1 mice also results in impaired insulin sensitivity and higher levels of 
fasting plasma insulin.  
Interestingly, human data suggest that impaired glucose tolerance can occur due to either 
insulin insensitivity or a decrease in insulin levels in AD patients. Specifically, a cross-sectional 
study in AD patients with elevated glucose levels reported that insulin sensitivity was decreased 
(Meneilly et al., 1993). Other studies on the other hand have shown that AD patients can have 
decreased peripheral insulin levels (Peila et al. 2004) or reduced insulin secretion (Rönnemaa et 
al. 2008). Regardless, both of these physiological changes could result in impaired glucose 
tolerance and a decrease in insulin transport into the CNS and subsequently altered CNS insulin 
signaling. Additionally, AD patients that lacked an APOE e4 allele were reported to have lower 
CSF-to-plasma insulin ratios compared to normal individuals, suggesting reduced uptake of 
insulin into the brain from plasma, whereas e4 homozygotes with AD had normal values, 
suggesting that there are metabolic differences among APOE genotypes (Craft et al. 1998). 
Taken together these studies suggest that insulin transport into the CNS may be decreased in 
diabetes and AD and hence we will now discuss insulin transport into the CNS.  
 
Insulin Transport into the CNS 
Though some studies suggest that insulin may be produced in the CNS itself (e.g., insulin 
can be produced in neuronal cells in culture; insulin mRNA seen in certain brain regions) 
(Schechter et al. 1988; Devaskarss et al. 1994), it is generally believed that the primary source of 
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CNS insulin is derived from the periphery. In the periphery insulin is produced and secreted by 
pancreatic beta cells in response to glucose levels and GLP-1, as noted above. When glucose 
levels increase, ATP is subsequently increased intracellularly in β-cells causing KATP channel 
closure, membrane depolarization (see below for more information on KATP channels) and 
insulin secretion. Insulin can then affect peripheral tissues and circumventricular CNS regions 
directly or can cross the BBB via a saturable transport mechanism (Banks 2004). Specifically, 
the endothelial and ependymal cells that comprise the BBB and blood-CSF barrier possess 
insulin-binding sites (Frank & Pardridge 1981; Frank et al. 1985; Corp et al. 1986; Miller et al. 
1994). Those binding sites at the BBB, and most likely those at the blood-CSF barrier, perform 
two distinct functions: 1) some of them act as transporters of insulin across the BBB; and 2) 
others act as classic receptor sites, affecting the function of BBB cells by activating intracellular 
machinery. The insulin transporters appear to be saturated at euglycemic conditions and can be 
affected by a variety of factors including diet, plasma glucose levels, diabetes, and obesity 
(Baura et al. 1993; Woods et al. 2003; Banks 2004). Thus, CNS insulin levels will be to a large 
part dependent on peripheral metabolic profile and transporter function. In this regard, prolonged 
periods of peripheral hyperinsulinemia have been shown to down-regulate insulin transporters at 
the BBB, decreasing the amount of insulin that enters the CNS (Wallum et al., 1987). In addition 
Craft and colleagues (1998), reported a decrease in CNS insulin in AD subjects with peripheral 
hyperinsulinemia presumably due to a down-regulation of insulin transporters at the BBB. 
However, a decrease in peripheral insulin is also likely to result in a decrease in CNS insulin if 
levels fall below that associated with transporter saturation. This could subsequently lead to a 
change in CNS insulin signaling. However, a change in CNS IR sensitivity could also occur if 
CNS insulin levels increase and IRs desensitize as has been suggested to occur experimentally 
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following lipopolysaccharide (LPS) treatment and inflammation (Banks et al. 2012). Thus, 
changes in CNS insulin signaling could occur via several mechanisms. In this regard, several 
studies have reported alterations in CNS insulin signaling in post-mortem brain tissue from 
humans with AD (Steen et al. 2005; Moloney et al. 2010; Bomfim et al. 2012; Talbot et al. 
2012) and in AD mouse models (Bomfim et al. 2012; Chen et al. 2013a; Velazquez et al. 2017). 
Insulin is known to exert many effects on the CNS including a role in normal cognition. Thus, 
altered CNS insulin signaling could play a major role in the pathological process of AD. 
Subsequently, the next section will describe the roles of CNS insulin signaling under normal 
non-pathological conditions. 
 
Insulin Signaling in the CNS: A Role in Learning and Memory 
Insulin is a 51 amino acid polypeptide hormone released from the pancreas in response to 
glucose levels and GLP-1. Insulin is widely known to play many roles in the periphery including 
regulating peripheral tissue metabolism by controlling cellular glucose uptake. In comparison, 
the brain was previously considered to be insulin insensitive. This notion has now been 
challenged due to several discoveries including the localization of IRs throughout the CNS 
(Havrankova 1978), and the capacity for peripheral insulin to cross the BBB via a saturable 
transport mechanism (Banks 2004). IRs are found wide spread throughout the CNS with the 
highest expression being in the cerebellum, olfactory bulb, hippocampus, cortex, amygdala and 
hypothalamus (Havrankova et al. 1979; Unger et al. 1991; Abbott et al. 1999; Zhao & Alkon 
2001). Insulin has now been discovered to play several roles in the CNS including regulating 
neuronal survival, reproduction, feeding behavior, energy balance, glucose and fat metabolism, 
and also a role in learning and memory.  
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Indeed, exogenous treatment with insulin can improve memory in humans and animals. 
For example, peripheral administration of insulin under euglycemic conditions increases 
cognitive function as assessed by verbal memory and selective attention tasks in humans (Kern et 
al. 2001). Further, intranasal insulin delivery can improve performance on spatial working 
memory tasks (Benedict et al. 2004; Krug et al. 2010) and intracebroventricular (ICV) insulin 
administration can enhance memory in rats (Park et al. 2000). Peripheral insulin and glucose 
levels are unaffected by both of these methods of administration suggesting that insulin can exert 
a direct effect on the CNS. Consistent with these findings, training on spatial memory tasks 
increases hippocampal IR expression (Zhao et al. 1999) demonstrating a correlation between 
insulin signaling, plasticity, and cognitive function. Additionally, knocking down IRs in the CNS 
can impair long term potentiation (LTP; the presumed cellular mechanism for cognition) (Grillo 
et al. 2015) and cognitive function (Das et al. 2005). Thus, several lines of evidence support the 
idea that insulin plays a beneficial role in cognition under non-pathological conditions, though a 
complete understanding of how insulin affects memory is as of yet unknown. However, in both 
the CNS and the periphery, insulin exerts its effects by binding to specific receptors at the 
plasma membrane. IRs are tetrameric membrane spanning proteins that consist of two α and two 
β subunits linked together by disulfide bonds. The α subunits are located extracellularly and 
contain the insulin binding site while the β subunits are transmembranous and have tyrosine 
kinase activity. Insulin binding to its receptors activates 2 main pathways: the MAPK/ERK 
pathway and the PI3K/AKT pathway. Both of these pathways have been linked to cognitive 
function.  
The MAPK/ERK pathway is primarily involved with cell growth, proliferation, survival, 
and differentiation but has been suggested to play a role in cognition as well. Briefly when 
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insulin binds to the α subunit of its receptor, tyrosine auto-phosphorylation occurs on the β 
subunit. This leads to the tyrosine phosphorylation of the adapter protein SHC (Src homology 2 
domain-containing). SHC can then recruit the GRB2 (Growth Factor Receptor Bound Protein-2)-
SOS (Son of Sevenless protein) complex to the membrane via the SH2 domain of GRB2 binding 
to the phosphotyrosine on SHC. SOS, a guanine nucleotide exchange factors (GEF) for RAS, can 
then exchange the GDP bound to RAS to GTP. Once RAS binds GTP, it can then recruit the 
serine/threonine kinase RAF to the membrane. When RAF translocates to the membrane, it 
becomes activated and then phosphorylates MEK, and subsequently MAPK/ERK. MAPK 
(mitogen-activated protein kinase) can now regulate cytosolic targets as well as translocate into 
the nucleus and play a role in gene transcription through phosphorylation of different 
transcription factors as shown in Figure 1.3 (Subramaniam & Unsicker 2006; Lee et al. 2016). 
Several studies have supported a role for this pathway in cognitive function. In vivo data from 
animal studies reveal that training on a spatial memory task results in elevated IR levels, 
increased phosphorylation of the p42 subunit of MAPK, increased SHC isoforms in the plasma 
membrane of hippocampal neurons, and prolonged activation of ERK1/2 (Zhao et al. 1999). 
Furthermore, a transgenic mouse line expressing dominant-negative MEK1, the upstream 
activator of MAPK ERK1/2, exhibits impaired spatial learning and fear conditioning (Kelleher et 
al. 2004). Additionally, LTP induction is associated with activation of MAPK in hippocampal 
region CA1 (Thomas & Huganir 2004) and pharmacological blockade of MEK with M3804 
prevents LTP induction (English & Sweatt 1996). Thus, ample data link the MAPK/ERK 
pathway and learning and memory. 
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Figure 1.3: Illustration of the basic components of the MAPK/ERK insulin-signaling pathway. 
Figure published in Griffith et al., 2018. 
 
The other insulin signaling pathway, PI3K/AKT, in turn has been shown to promote neuronal 
growth and survival, energy metabolism, and glucose utilization. The PI3K/AKT signaling 
cascade is displayed in Figure 1.4. Briefly, IR phosphorylation leads to tyrosine phosphorylation 
of insulin receptor substrate-1 (IRS1), which then phosphorylates phosphoinositide 3-kinase 
(PI3K). PI3K causes conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which allows for the recruitment of pleckstrin 
homology (PH) domain containing proteins, such as protein kinase B (PKB) or AKT and 
pyruvate dehydrogenase kinase 1 (PDK1), to the membrane. Once at the membrane PDK1 and 
mammalin target of rapamyocin complex 2 (mTORC2) can phosphorylate AKT at Ser308 and 
473 respectively to cause its activation. AKT can then act upon downstream targets to produce a 
variety of effects including GSK3 phosphorylation, GLUT translocation and gene transcription. 
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As for the PI3K/AKT pathway and cognition, studies have shown that PI3K is necessary for the 
expression of LTP in the dentate gyrus (Kelly & Lynch 2000) and CA1 region of the 
hippocampus (Raymond & Redman 2002; Karpova et al. 2006) and behavioral studies have 
shown that inhibiting PI3K activity results in impaired avoidance, spatial learning (Mizuno et al. 
2003) and consolidation, retrieval, and extinction of fear associated memory (Chen et al. 2005).  
 
Figure 1.4: Insulin signaling through the PI3K/AKT pathway. Figure published in Griffith et al., 
2018. 
 
In addition to the direct effects of insulin on learning and memory through the canonical 
signaling pathways, several potential indirect mechanisms exist. One such way is through its 
relationship with the expression of certain ion channels and neurotransmitter receptors localized 
at neuronal synapses. Specifically, some studies report that insulin can promote the 
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internalization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
from synaptic membranes causing insulin dependent long-term depression (LTD) (Beattie et al. 
2000; Man et al. 2000; Ahmadian et al. 2004; Huang et al. 2004). LTD is a persistent use 
dependent decrease of synaptic efficacy that together with the converse process, LTP, affects 
learning and memory. Indeed, LTD has been considered crucial for information storage in the 
brain and refinement of neuronal circuitry during development. Although the physiological 
consequences of LTD remain an open question, LTD in the mammalian brain is assumed to be a 
synaptic mechanism underlying learning during novel experiences. Other studies report that 
insulin elicits LTP and enhances membrane trafficking of glutamate receptor subunits (Liu et al. 
1995; Chen & Leonard 1996; Skeberdis et al. 2001). Insulin has also been reported to recruit the 
expression of functional post-synaptic gamma-aminobutyric acid (GABA)A receptors in 
hippocampal neurons (Zhao et al. 2004) and a more recent study reported that insulin shifts tonic 
GABAergic currents in the CA1 region of the hippocampus, presumably through recruitment of 
GABAA receptors (Jin et al. 2011). For a more detailed review of insulin-mediated synaptic 
plasticity see Ferrario and Reagan (2017). 
Another way through which insulin may affect learning and memory is through the 
regulation of certain neurotransmitters such as acetylcholine, serotonin, noradrenaline, and 
dopamine which are known to deteriorate in aging and AD (Kodl & Seaquist 2008). These 
neurotransmitters are associated with important roles in cognition and insulin has been shown to 
modulate the CNS levels of acetylcholine, norepinephine and dopamine (Figlewicz et al. 1993; 
Kopf & Baratti 1999).  
Insulin could also exert cognitive effects through peripheral glucose regulation. As 
aforementioned, glucose is the main energy substrate of the adult brain and peripheral 
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hyperglycemia can induce a decrease in glucose transporters at the BBB (Cornford et al. 2000), 
thus, presumably, affecting CNS glucose levels. Interestingly, peripheral glucose levels have 
been shown to correlate with cognition in that acutely increasing peripheral glucose can increase 
cognitive performance in both mice and humans (McNay et al. 2000). Systemic administration 
of d-glucose at doses that produce modest, physiological elevations in blood glucose levels 
enhance memory for aversive, appetitive, spatial, and habituation tasks in rodents (Messier & 
White 1984, 1987; Gold 1986; Messier & Destrade 1988; Kopf & Baratti 1994, 1996; Ragozzino 
et al. 1996). Central glucose injections also enhance aversive and spatial learning and memory 
(Ragozzino et al. 1998; Stefani et al. 1999) and extracellular glucose levels in the hippocampus 
have been shown to decrease during maze testing presumably as a result of increased neural 
glucose utilization (McNay et al. 2000). Conversely, chronic hyperglycemia has been linked to 
cognitive impairment including AD (Alosco & Gunstad 2014). However, studies showing that 
both intranasal insulin and ICV insulin can improve cognition in AD or AD mouse models (Haj-
ali et al.; Watson et al. 2005; Reger et al. 2006, 2008; Benedict et al. 2007; Craft et al. 2012; 
Guo et al. 2017) suggest that insulin also has a direct mechanistic effect on learning and 
memory. It is thus likely that insulin regulates cognitive function at a molecular level in the CNS, 
although it is important to note that insulin’s action in the hypothalamus can also regulate 
peripheral glucose levels and could potentially also affect insulin’s effect on learning and 
memory via an indirect mechanism.  
An additional potential mechanism whereby insulin can affect learning and memory is 
through CNS cellular glucose uptake itself since insulin can affect glucose transporter 
expression/translocation. While glucose transporters were previously believed to be insulin 
insensitive within the CNS several studies have shown that several GLUTs are actually insulin 
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dependent. For instance the insulin sensitive glucose transporter, GLUT4, is present on neurons 
throughout the brain and in the endothelial cells at the BBB and appears to act in a similar 
manner as it does in the periphery (Grillo et al. 2009). Moreover, recent data suggest that the 
translocation of the primary neuronal glucose transporter, GLUT3, is also insulin dependent but, 
it requires simultaneous cellular depolarization for insertion into the membrane (Uemura & 
Greenlee 2006). The transport of glucose into the CNS and into astrocytes may also be insulin 
dependent through actions on GLUT1. Prolonged exposure to insulin results in an increase in 
GLUT1 protein levels (Ciaraldi et al. 1995) and insulin up-regulates GLUT1 mRNA translation 
through a PI3K/AKT dependent manner (Taha et al. 1999). Further, GLUT1 translocation in 
astrocytes has recently been suggested to be dependent on a collaborative effort through insulin 
and IGF1 (Fernandez et al. 2016). Interestingly, both GLUT1 and GLUT3 have been reported to 
be decreased in post-mortem AD tissue as well as in some AD mouse models (Liu et al. 2009), 
although it is unclear whether the change in GLUT1 was endothelial or astrocytic in nature since 
most antibodies do not differentiate between the two forms in western blot studies.  
Insulin could also affect cognition through KATP channels. KATP channels have been 
shown to play a role in memory through the use of KATP channel openers and closers 
(Ghelardini et al. 1998; Stefani et al. 1999; Stefani & Gold 2001). In one such experiment, ICV 
injections of various KATP channel openers impaired inhibitory (passive) avoidance memory 
and this was attenuated by the KATP channel closer glibenclamide (Ghelardini et al., 1998). 
Additional studies have shown that intraseptal injections of glibenclamide, enhanced 
spontaneous alternation performance and antagonize impairments in alternation scores produced 
by KATP channel openers (Stefani et al. 1999; Stefani & Gold 2001). In this regard, several 
studies have shown that insulin can regulate KATP channel activity. In the pancreas exogenous 
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insulin has been shown to hyperpolarize pancreatic β-cells, inhibit their electrical activity and 
abolish their intracellular calcium concentration oscillations through insulin-induced activation 
of KATP channels via a PI3K dependent manner (Khan et al. 2001). As for the CNS, in the 
hypothalamus physiological levels of insulin activate KATP channels on glucose responsive 
neurons in control rats (Spanswick et al. 2000).  
Taken together, there is strong evidence for both direct and indirect actions of insulin on 
cognitive function. Interestingly changes in insulin signaling have been associated with AD. In 
the next section we will discuss clinical and experimental data supporting the notion for altered 
CNS insulin signaling in AD.   
 
CNS Insulin and Alzheimer’s disease 
Clinical studies report that AD patients often exhibit altered peripheral glucose regulation 
and that this is characterized by either hyperinsulinemia and insulin resistance (Meneilly & Hill 
1993; Ott et al. 1996; Kuusisto et al. 1997; Craft et al. 1998; Peila et al. 2004) or 
hypoinsulinemia (Peila et al. 2004; Rönnemaa et al. 2008). In mouse models it has been shown 
that peripheral glucose intolerance is associated with defects in insulin. Taken together, these 
data suggest that CNS insulin signaling is likely altered in AD. In this regard, insulin signaling 
via the PI3K/AKT pathway has been shown to be altered in post-mortem brain tissue from AD 
patients and in AD mouse models (Steen et al. 2005; Jolivalt et al. 2010; Moloney et al. 2010; 
Liu et al. 2011; Bomfim et al. 2012).  
Another factor that could affect CNS insulin signaling is insulin-degrading enzyme 
(IDE). IDE is responsible for the degradation of several short peptides with molecular weights of 
3–10 kDa, including insulin, insulin-like growth factors I and II, amylin, Aβ and several other 
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peptides. Indeed, data suggest IDE is altered in AD brains compared to control brains, although 
some studies report a decrease (Cook et al. 2003) while others report an increase (Frölich et al. 
1998). Aβ has been shown to compete with insulin for IDE binding; however, insulin binds with 
a much higher affinity (Xie et al. 2002). Therefore, when insulin resistance is present in the 
brain, a decrease in Aβ degradation is observed (Ho et al. 2004) due to an increase in the higher 
amount of insulin binding to IDE. Conversely, if there is hypoinsulinemia in the brain, IDE is 
downregulated and Aβ degradation would presumably be decreased. Indeed, regardless of 
whether protein levels are increased or decreased, Aβ degrading activity by IDE has been shown 
to be lower in AD brains than in the controls and thus could contribute to the increased plaque 
loads in AD patients (Pérez, et al. 2000). 
 Along these lines insulin and Aβ have been shown to have many close ties. For one, Aβ 
has been shown in several studies to block insulin signaling. This may occur through an increase 
in serine phosphorylation due to Aβ itself (for more detail see Inflammation and Insulin 
Signaling below) or due to an increase in inflammation and inflammatory mediators (see section 
on inflammation) in response to an increase in Aβ. Additionally, glucose levels, which are 
regulated by insulin, have been shown to play a role in Aβ production. These studies suggest 
that: 1) experimentally increasing peripheral glucose levels acutely in APP/PS1 mice results in 
greater interstitial Aβ (Macauley et al. 2015); 2) prolonged elevations of glucose levels can also 
increase Aβ production in neuroblastoma cell lines overexpressing APP (Yang et al. 2015); 3) 
hyperglycemia can induce BACE1 expression/activity (BACE1 is the rate limiting enzyme 
involved in cleaving APP into amyloid peptides) (Chen et al. 2015) and 4) inducing diabetes in 
the 3xTg-AD mouse model increases the number of plaques (Hayashi-Park et al., 2017).  
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In addition, insulin sensitive KATP channels have been shown to play a role in memory 
through studies showing that KATP channel openers can impair memory while KATP channel 
closers can improve cognitive function (see above section on insulin and memory). Thus, 
changes in CNS insulin in AD could affect KATP channels. Interestingly, chronic treatment of 
the 3xTg-AD mouse model of AD with diazoxide, a KATP channel activator, can reduce plaque 
and tau pathology and somewhat preserve memory relative to vehicle-treated 3xTg-AD controls 
(Liu et al. 2010). Thus, KATP channels may be altered in AD due to changes in insulin signaling 
and could be a potential theurapeutic target. Indeed, recent studies have demonstrated that there 
is a relationship between these channels and Aβ. For instance, the toxic form of Aβ (Aβ1–42) 
can increase the expression of KATP channel subunits in primary neuronal cell culture (Ma et al. 
2009), while the direct administration of the KATP channel blocker glibenclamide into the 
hippocampus of APP/PS1 mice can increase interstitial β-amyloid levels. Additionally, KATP 
channel openers (diazoxide and pinacidil) can block increases in interstitial Aβ which are 
triggered in APP/PS1 mice by a hyperglycemic challenge (Macauley et al. 2015). These studies 
demonstrate that KATP channel expression can be altered in AD potentially due to altered CNS 
insulin signaling and by β-amyloid and that KATP channels can also affect AD 
pathogenesis/phenotype. Additionally, α-endosulfine has the sulfonylurea-like ability to block 
KATP channels and α-endosulfine has been found to be decreased in the frontal cortex and 
cerebellum from patients with AD (Kim & Lubec 2001). Additionally, ketone bodies, which 
have been shown to affect insulin levels and potentially insulin sensitivity improve AD-
pathology/behavior, have also been shown to open KATP channels (Ma et al. 2007). The next 
section will provide a more detailed discussion of these inwardly rectifying potassium channels. 
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KATP channels 
While the role of KATP channels in insulin release is well known, less is known about 
insulin’s regulation of these channels, although it has been demonstrated that insulin can cause 
alterations in channel activity in both the pancreas and the hypothalamus. In addition, KATP 
channels are regulated by ATP levels and thus metabolic alterations will play a major role in 
their function. Thus, metabolic alterations in AD could contribute to changes in KATP channels 
and affect cognitive function. These channels are large heterooctameric complexes composed of 
2 different types of subunits, 4 Kir subunits and 4 sulfonylurea (SUR) subunits. The Kir subunit 
is a traditional channel protein belonging to the inwardly rectifying potassium channel 
superfamily. Two different subtypes exist, Kir6.1 and Kir6.2. The SUR subunit is a member of 
the ATP-binding cassette (ABC) or transport ATPase superfamily with multiple transmembrane 
domains and two nucleotide-binding folds. This is the regulatory subunit that senses and 
responds to the ATP/ADP ratio. There are 3 subtypes of the SUR subunit, SUR1, SUR2A, 
SUR2B (Aguilar-Bryan et al., 1998; Ashcroft and Gribble, 2000).  
These channels couple cellular metabolism to electrical activity through sensing 
nucleotide exchange. Namely the SUR subunit senses increases in the ATP/ADP ratio and causes 
channel opening or closing leading to membrane depolarization. Conversely when ATP/ADP 
ratios are low these channels remain open. Opening of KATP channels shifts the membrane 
potential toward the equilibrium potential for potassium ions, near -80 to -90 mV, thus 
decreasing the likelihood of cellular depolarization (Bryan & Aguilar-Bryan 1999). The 
physiological role for these channels is best understood in the context of pancreatic β-cells where 
they are responsible for insulin release. Specifically, an increase in plasma glucose results in 
glucose uptake by pancreatic β-cells through GLUT2. Glucose metabolism in β-cells 
 42 
 
subsequently increases the ATP/ADP ratio causing KATP channel closure and thus membrane 
depolarization and exocytosis of insulin (Röder et al. 2016). Insulin can then exert its effects on 
the periphery and CNS. Mutations in this channel can result in familial hyperinsulinism or 
persistent hyperinsulinemic hypoglycemia of infancy. The phenotype of this disorder in 
newborns and infants is increased insulin secretion despite profound hypoglycemia due to a loss 
of KATP channel activity that resets the resting membrane potential to a more depolarized value 
within the voltage-window for steady state L-type Ca2+ channel currents and insulin release. 
Congenital hyperinsulinaemia, a genetic disorder characterized by dysregulated insulin secretion, 
is the most common cause of hypoglycaemia in infancy, with more than 50 loss-of-function 
hyperinsulinaemia mutations in KATP genes identified to date (Sharma et al. 2000). Whereas 
loss of KATP activity causes persistent hypersecretion of insulin, gain of function should cause 
the opposite effect, a lack of insulin secretion and diabetes. Indeed, multiple mutations in Kir6.2 
have recently been found to underlie neonatal diabetes mellitus (NDM).  
KATP channels are found in the pancreas, heart, muscle and brain with different 
combinations of the SUR/KIR subunits present amongst these regions. The particular 
combination of subunits can affect channel function and susceptibility to KATP channel openers 
and closers (Seino & Miki 2003). In the brain, as in pancreatic β-cells, the Kir6.2/SUR1 channel 
seems to be the dominant KATP isoform (Zawar et al. 1999; Yamada et al. 2001). CNS 
Kir6.2/SUR1 KATP channels have been detected in many regions such as the hippocampus, 
hypothalamus, the substantia nigra (SNr) and the neocortex. Hypothalamic KATP channels 
participate in central glucose sensing by opening and hyperpolarizing glucose responsive 
neurons in response to insulin (Spanswick et al. 2000) while in the SNr KATP channels have 
been shown to prevent seizure propagation (Yamada & Inagaki 2005). Accumulating evidence 
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also suggests that CNS KATP channels can influence the release of neurotransmitters. For 
example, they may modulate glutamate release from fused nerve terminals of the rat motor 
cortex (Lee et al. 1996), as well as dopamine, acetylcholine (ACh), glutamate and GABA release 
in the striatum (Amoroso et al. 1990; Tanaka et al. 1995; Lee & Boden 1997) and GABA release 
in the SNr (During et al. 1995). In both humans and rodents, the Kir6.2 protein is abundantly 
expressed in neurons of all hippocampal regions including the pyramidal neurons in the CA1 and 
CA3 fields, granule cells in the DG and interneurons in the hilar area (Thomzig et al. 2005; Sun 
et al. 2007). Hippocampal KATP channels are suggested to play a role in neuroprotection. 
Specifically, their activation during cellular stress causes a transient membrane hyperpolarization 
with a consequent reduction of energy demand, thus providing an effective protection to the 
metabolically compromised cell (Yamada & Inagaki 2005). Accordingly, Kir6.2 null mice are 
more prone to neuronal damage after ischemic insult relative to wild-type control littermates 
(Sun et al. 2006). Finally, several in vitro studies suggest a modulation of mossy fibers glutamate 
release by Kir6.2/SUR1 channels and also granule cell excitability which could potentially 
contribute to the DG’s role as a gate that filters the neuronal activity entering the hippocampus 
proper. Additionally, glibenclamide can enhance glutamate release in rat hippocampal slices 
(Ben-Ari 1990) while, the KATP channel opener diazoxide was able to reduce glutamate release 
through the opening of presynaptic KATP Kir6.2/SUR1 channels (Bancila et al. 2004).  
Although less is known about its role, Kir6.1 is also found within the brain. Anatomical 
data suggest that the Kir6.1 subunit in the hippocampus is preferentially found in astrocytes and 
in the inner mitochondrial membrane of neurons, although Kir6.1 has also been detected in the 
plasma membrane of neurons (Zawar et al. 1999; Zhou et al. 1999, 2002; Thomzig et al. 2001). 
In other structures however, (dorsal root ganglia, dorsal vagal neurons, retina) data have 
 44 
 
suggested that Kir6.1 is primarily restricted to glia cells (Zawar et al. 1999; Eaton et al. 2002; 
Skatchkov et al. 2002; Zoga et al. 2010).  
In comparison, Kir6.2 has been suggested to be primarily localized in neurons (Thomzig 
et al. 2005) with the expression of Kir6.2 in glial cells being a subject of controversy. For 
example, using whole-cell patch clamp recordings McKhann et al., (1997) found that astroglial 
cells do not express KATP channels and Dunn-Meynell et al., (1998) reported that while various 
neurons express Kir6.2 mRNA neither astrocytes nor oligodendrocytes express Kir6.2 mRNA. 
However, using patch clamp recordings Zawar et al. (1999) showed that both neurons and glial 
cells in the hippocampus were sensitive to KATP channel openers and inhibitors and Karschin et 
al., (1998) showed that glial cells expressing glial fibrillary acidic protein (GFAP) show a high 
level of mRNA for Kir6.2, using single-cell PCR techniques. Further, Zhou et al. (2002) showed 
moderate to intense expression of Kir6.2 protein in glial cells, concomitant with co-localization 
of Kir6.2 mRNA. Indeed, they reported that some glial cells immunopositive for Kir6.2 were 
simultaneously GFAP immunopositive, suggesting that some astrocytes do contain the Kir6.2 
subunit.  
Thus, insulin can affect hippocampal function not only via its traditional downstream 
targets, MAPK/ERK and PI3K/AKT, but can also by affect KATP channels and thus function. In 
addition to insulin itself, several studies have demonstrated that improving insulin sensitivity 
(through the use of insulin sensitizers or through lifestyle changes) can also affect hippocampal 
function and improve AD phenotype, though the mechanism is unclear. The next section will 
describe some of these manipulations in detail. 
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Improving Insulin Sensitivity 
Interestingly, in addition to insulin itself, several manipulations which improve insulin 
sensitivity have also been shown to improve AD-pathology and or cognition. First, insulin 
sensitizers, such as the thioglitazones (e.g., pioglitazone, rosiglitazone), and biguanides (e.g., 
metformin) can improve cognitive function (Ryan et al., 2006). For example, treatment with 
rosiglitazone for six months resulted in preserved memory function in patients with AD 
compared to placebo-assigned controls (Watson et al. 2005), and long-term treatment with 
pioglitazone has been shown to improve cognitive function and decrease AD pathology in 3xTg 
mice (Searcy et al. 2012). Additionally, 4-month treatment with either pioglitazone or 
rosiglitazone improved spatial learning, enhanced AKT signaling, attenuated tau 
hyperphosphorylation and decreased neuroinflammation in 3xTg-AD mice (Yu et al. 2014). As 
for the biguanide metformin, data has demonstrated that it can improve insulin’s action in the 
CNS by increasing IR expression and tyrosine kinase activity (Gunton et al. 2003; Gupta et al. 
2011). One possible mechanism may be through increasing GLP-1 levels (Maida et al. 2011). 
GLP-1 is an incretin hormone secreted from the L-cells of the lower small intestine that increases 
pancreatic beta cell proliferation, and thus insulin production (Buteau et al., 1999; Fehmann et 
al., 1995). GLP-1 agonists have recently been shown to decrease AD-like symptoms in AD 
mouse models (Perry et al. 2003; McClean et al. 2011; Gengler et al. 2012; Han et al. 2012; 
Hölscher 2016) and clinical trials of these compounds in AD patients are currently in progress 
(Hölscher, 2016). 
In addition to insulin sensitizers, dietary manipulation can also affect insulin sensitivity 
and thus potentially be beneficial in AD. For example, intermittent fasting and caloric restriction, 
which also results in elevated circulating ketones levels, has been reported to ameliorate age-
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related behavioral deficits in 3xTg-AD mice (Kumar et al. 2007). Further, adherence to a 
Mediterranean-type diet, which is high in fiber and monounsaturated fats, has been shown to 
decrease the risk of AD or MCI (Scarmeas et al. 2006) and a ketogenic diet, which is high in fat 
and low in carbohydrates, has been shown to decrease Aβ plaque deposition in AD patients and 
increase cognitive performance (Henderson et al. 2009). Interestingly, both the Mediterranean 
and ketogenic diets have been shown to resolve Type II diabetes and improve hyperglycemia 
(Al-Khalifa et al. 2009; Esposito et al. 2010; Solfrizzi & Panza 2014) and decreasing 
inflammation may in part play an important role to the beneficial effects of these diets. Indeed, 
these diets are high in PUFAs and PUFAs have been shown to play an anti-inflammatory role in 
many brain disease models such as brain ischemia–reperfusion, aging, depression and 
Parkinson’s disease (Song et al. 2009; Belayev et al. 2011; Luchtman et al. 2012; Moranis et al. 
2012). One of the major omega-3 PUFAs in the brain, docosahexaenoic acid (DHA), is 
important for brain development and plasticity, and provides support for learning and memory in 
animal models of AD (Hashimoto et al. 2002; Lim et al. 2005) and brain injury (Wu et al. 2004). 
Additionally, it has been shown to reduce oxidative stress and tumor-necrosis factor (TNF) 
expression and to protect hippocampal neurons by increasing AKT phosphorylation and 
decreasing caspase-3 and caspase-9 expression during exposure to high glucose (Lim et al. 
2005). These dietary manipulations are in general designed to reproduce some of the effects of 
fasting and consequently shift the energy source from glucose to ketones, thereby decreasing the 
generation of ROS and AGEs. Interestingly, a shift in metabolic profile from primarily glucose 
consumption to increased ketone utilization has recently been reported to be associated with 
preserved cognitive function in an animal model of extended lifespan, while an animal model of 
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AD that develops cognitive impairment was shown to have decreased ketone levels (Griffith et 
al. 2017).   
In addition to diet, exercise can also reduce insulin resistance and has been shown to be 
beneficial for AD patients and mouse models of AD. Indeed, physical activity of any type was 
protective against the development of cognitive impairment in AD, with subjects who exerted the 
highest activity showing a 60% decrease in AD incidence (Laurin et al. 2001). Further, long-
term exercise resulted in a decrease in extracellular amyloid-plaques and an enhanced rate of 
spatial learning and memory in the TgCRND8 mouse model of AD (Adlard et al. 2005).  
Taken together, these studies suggest that a decrease in insulin signaling/sensitivity and insulin 
sensitive targets may play a role in cognitive decline in AD. Additionally, improving insulin 
signaling/sensitivity can improve cognition and decrease AD-related pathologies in AD. While 
the etiology of decreased insulin sensitivity and signaling in AD is not well understood, one 
potential mechanism is through inflammation since inflammation has been shown to block 
insulin signaling. Thus, the next few sections will begin to describe inflammation, the cellular 
player primarily involved with neuroinflammation and then the interaction between 
inflammation and insulin signaling in AD.  
 
Inflammation 
Inflammation is part of the body’s primary defense mechanism against multiple threats 
(Ryan & Majno 1977; Lavie & Milani 2004). When a tissue is injured the process of 
inflammation starts automatically and is accompanied by erythema, edema, hyperalgesia, and 
pain. The major cells involved in peripheral inflammatory responses include mast cells, 
neutrophils, eosinophils, macrophages, lymphocytes, endothelial cells, and platelets (Ryan and 
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Majno, 1977). At the time of tissue injury several inflammatory mediators, either cell derived or 
plasma derived, are released and work together by binding specific receptors, activating cells, 
recruiting cells to sites of injury, and stimulating release of additional soluble mediators (Jain et 
al. 2015).  
Cell-derived mediators include, histamine, serotonin, prostaglandins, leukotrienes, and cytokines. 
Cytokines are produced by a broad range of cells and include the interferons, interleukins (IL), 
lymphokines, chemokines, colony-stimulating factors, growth factors and TNF (Jain et al., 
2015). TNF and IL-1 are primary inflammatory cytokines which participate in acute and chronic 
inflammatory reactions as well as repair and resolution. Transforming growth factor-β (TGF-β), 
IL-4, IL-10, and IL-13 are anti-inflammatory cytokines that inhibit chemokine production 
(Holmes 2013). Cytokines such as TNF, IL-1β and IL-6 can be directly cytotoxic, when 
chronically produced at high concentrations (Jeohn et al. 1998). Thus, both beneficial and 
detrimental compounds are elevated with inflammation making our understanding of the specific 
pathways somewhat limited at this time.   
Inflammation can be divided into two categories, acute and chronic. Acute inflammation 
is the initial response of the immune system against pathogens and tissue injury. Acute 
inflammation persists for a short duration from a few hours to days. Chronic inflammation is 
prolonged inflammation lasting several months to years. Chronic inflammation may arise due to 
persistent infections or can arise due to autoimmunity in chronic inflammatory diseases such as 
rheumatoid arthritis, inflammatory bowel disease and psoriasis (Jain et al., 2015). Additionally, 
chronic inflammation has been shown to be related to certain diseases like AD, atherosclerosis, 
metabolic syndrome, type 2 diabetes, epilepsy and some forms of cancer (Jain et al., 2015). 
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Much like the story with insulin, the CNS was previously believed to be an 
immunologically privileged site due to the BBB’s ability to prevent many peripheral molecules, 
including antibodies, from entering the CNS and because of the absence of macrophages and 
lymphocytes within the CNS. This notion was first challenged by the observation that acute 
systemic infection leads to centrally derived symptoms such as lack of appetite, depression, 
somnolence; decreased social interaction; decreased concentration and fever (Dantzer 2001; 
Holmes 2013). While a thorough understanding of peripheral inflammatory mediate d effects on 
the CNS is unknown, it is known that the brain can express an inflammatory response. This is 
primarily regulated through glial cells, especially astrocytes and microglia. Under pro-
inflammatory conditions these cells undergo activation and, in a similar process as that of 
peripheral immune cells, these glial cells increase production of inflammatory cytokines. 
Therefore, the next section will discuss astrocytes and microglia and their proposed roles in 
neuroinflammation.  
 
The Primary Regulators of Neuroinflammation: Microglia and Astrocytes 
While the primary focus of the current study is astrocytes and no work was done to look 
at microglia, it is impossible to describe CNS inflammation without their mention. Microglia are 
the resident macrophage cells and they act as the main immune cell within the CNS (Kreutzberg 
1996a). They are found throughout the brain and spinal cord where they occupy large non-
overlapping regions (Kreutzberg 1996b) making up 10-15% of cells found in the CNS (Lawson 
et al. 1992). Microglia are key in maintaining overall brain integrity by their actions which 
include, scavenging plaques, damaged or unnecessary neurons and synapses, infectious agents 
(Gehrmann et al. 1995) and synapse remodeling (Hong et al. 2016). Since these processes must 
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be efficient to prevent potentially fatal damage, microglia are extremely sensitive to even small 
pathological changes in the CNS (Dissing-Olesen et al. 2007). In this sense, resting microglia 
rapidly transform from a resting to an activated state in response to a wide range of injuries. 
Microglial activation is characterized by proliferation, recruitment to the site of injury, 
morphological, immunophenotypical and functional changes. Activated microglia can play 
neurotoxic roles by producing pro-inflammatory cytokines, nitric oxide (NO), and ROS (Chao et 
al. 1992a; Hunot et al. 1996; Cassarino et al. 1997; Liu et al. 1998; Kim et al. 2000; McGuire et 
al. 2001; Koutsilieri et al. 2002). Activated microglia may also play neuroprotective roles by 
producing neurotrophic components such as IL-10, TGF-β, plasminogen, nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor 
(GDNF) (Nagata et al. 1993; Suzumura et al. 1993; Elkabes et al. 1996; Miwa et al. 1997; 
Batchelor et al. 1999; Sawada 1999; Nakajima & Kohsaka 2001). Other cytokines produced by 
activated microglia include TNF, IL-1β, and IL-6, which can produce either neurotoxic or 
neuroprotective effects (Barger et al. 1995; Liu et al. 1998; Fisher et al. 2001; Mason et al. 2001; 
McGuire et al. 2001; Bolin et al. 2002; Arai et al. 2004). In response to injury microglia respond 
more quickly than astrocytes. Thus it has been suggested that astrocyte reactivity may occur due 
to their activation by substances released from microglia. However, astrocytes and microglia 
function cooperatively (Martin et al. 1994) and astrocytic reaction may lead to the production of 
growth factors that could further promote microglial growth and activation (Lee et al. 1994) or 
could modulate the cytotoxic activity of microglia. 
Astrocytes on the other hand are the most abundant cell type within the CNS and they 
play many roles in organizing and maintaining brain structure and function (Maragakis & 
Rothstein 2006; Sofroniew & Vinters 2010). They consist of a diverse population of cells whose 
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morphology and function can differ based on their location, subtype and developmental stage. 
Astrocytes can be divided into two main classes based on their morphology and distribution. 
This includes fibrous astrocytes which have many glial filaments and are located mainly in white 
matter and protoplasmic astrocytes that have fewer glial filaments and are found mainly in gray 
matter (Sun & Jakobs 2012). Fibrous astrocytes tend to have regular contours and extend 
cylindrical branching processes while protoplasmic astrocytes have irregular contours and extend 
sheet-like processes that appear to fill most of the space between the other elements within the 
neuropil (Sun & Jakobs 2012). These cells are ideally suited to sense and respond to changes in 
their local surroundings and thus can provide neuroprotection through a variety of mechanisms. 
Particularly, these cells participate in regulating neurometabolism (Tsacopoulos & Magistretti 
1996), ionic and osmotic homeostasis, energy storage (Brown and Ransom, 2007; Cataldo and 
Broadwell, 1986; Magistretti, 1999), synaptic remodeling (Stevens 2008; Perea et al. 2009), 
gliotransmitter release (Araque et al. 2014), blood flow and BBB integrity (Abbott et al. 2006) 
and can also help defend against oxidative stress (Bélanger et al. 2011).  
Astrocytes respond to CNS insults such as infection, trauma and neurodegenerative 
disease by undergoing reactive astrogliosis (Sofroniew 2009; Sofroniew & Vinters 2010). 
Reactive astrogliosis is characterized by cellular hypertrophy, proliferation, process extension, 
and upregulation of GFAP, vimentin, nestin, heparan sulfate proteoglycans, chondroitin sulfate 
proteoglycans, and growth factors (Eng & Ghirnikar 1994; Norenberg & Bender 1994; Gómez-
Pinilla et al. 1995; McKeon et al. 1999; Leadbeater et al. 2006). Astrogliosis is a heterogenous 
process that can range from astrocytic hypertrophy to more severe changes entailing both 
hypertrophy and proliferation (i.e., scar formation) (Sofroniew & Vinters 2010; Pekny et al. 
2014). Diverse changes in gene expression, dependent on the severity or specific trigger, are also 
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seen during astrogliosis (Zamanian et al. 2012a). For example, there are major differences in the 
transcriptome profiles of reactive astrocytes isolated from in vivo tissue after stroke or peripheral 
LPS injections (Zamanian et al. 2012a) or hyperammonemia (Lichter-Konecki 2008) or in 
normal aging (i.e., young vs. old) (Orre et al. 2014a). In addition, related studies demonstrate 
major differences in the transcriptome profiles in astrocytes in cell cultures after stimulation with 
different mediators of reactive astrogliosis such as LPS, IL1β, TNF, INFγ or TGFβ individually 
or in combination (Meeuwsen et al. 2003; John et al. 2005; Hamby et al. 2012).Thus, depending 
on the degree of astrogliosis different astrocytic functions may be affected. Additionally, whether 
astrogliosis is beneficial or detrimental is a major topic of debate. For example, formation of 
glial scar tissue can be beneficial due to encapsulating infections and areas of tissue necrosis, 
restoring BBB integrity, or excluding non-neural cells from the CNS (Eddleston & Mucke 1993), 
but can also be detrimental by precluding remyelination and decreasing axonal regeneration 
(Silver & Miller 2004; Pekny & Nilsson 2005; Nair et al. 2008). Thus, while activated astrocytes 
may provide neuroprotection via the release of neurotrophic factors they also participate in 
inflammatory reactions by expressing pro-inflammatory molecules, such as cytokines and 
chemokines (Farina et al. 2007) that may participate in some neurodegenerative changes. 
Reactive astrocytes are found in numerous disease states and dysfunction of astrocytes has been 
recently suggested as a potential source of pathology in diseases such as AD, amyotrophic lateral 
sclerosis, depression, Huntington’s disease, ischemia/stroke, epilepsy, and Parkinson’s disease 
(Sofroniew & Vinters 2010; Pekny et al. 2014). Although significant progress in understanding 
the function of astrocytes has been made over the last few decades, the cellular and functional 
responses of astrocytes to injury during the progression of AD and other neuropathological 
conditions, such as epilepsy, are not completely understood.  
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Figure 1.5: Representation of normal astrocytes versus reactive astrocytes in post-mortem AD 
tissue (top) and tissue from old 3xTg-AD mice (bottom).  
 
Up to this point we have covered a brief explanation of inflammation and the primary 
cells involved with neuroinflammation, the microglia and astrocytes. Inflammatory markers have 
been shown to interfere with insulin signaling and contribute to insulin resistance. Thus, the next 
section will focus on the relationship between insulin signaling and inflammation.  
 
Inflammation and Insulin Signaling 
A closely linked relationship between regulation of metabolic and immune responses 
would likely be an advantageous characteristic since energy could be reallocated during an acute 
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inflammatory response to help with tissue repair. Thus the ability for inflammatory responses to 
block anabolic signaling pathways such as the insulin/insulin-like growth factor (IGF) pathway 
could hold many benefits and ample evidence exists to support the idea that inflammatory 
cytokines can regulate insulin signaling. However, in situations of chronic inflammation this 
relationship could turn detrimental. Indeed, obesity, insulin resistance, and type 2 diabetes are all 
linked with chronic inflammation and various inflammatory mediators and cytokines are 
overexpressed in mouse models of obesity and humans, including TNF, JNK, IKK and protein 
kinase C (PKC). All of these proteins can inhibit insulin action by serine phosphorylation of IRS-
1. Serine/threonine phosphorylation of IRS-1 impairs the protein's ability to recruit and activate 
downstream SH-2 containing signaling molecules and thereby disrupts the ability of the IRS 
protein to interact with the IR. 
Overproduction of TNF is a key feature of the pathophysiology of metabolic disorders. 
TNF is overexpressed in adipose tissue of obese individuals (Hotamisligil et al. 1995), and it has 
been demonstrated that elevated TNF levels cause peripheral insulin resistance. In type 2 
diabetes, elevated TNF levels have been shown to trigger serine phosphorylation of IRS-1 by 
stress kinases (Kanety et al. 1995; Hotamisligil et al. 1996; Rui et al. 2001). Additionally, 
blockade of TNF in obese mouse models results in improved insulin sensitivity and glucose 
homeostasis (Hotamisligil et al. 1993; Samad et al. 1999). 
A number of MAPKs are also activated when exposed to an inflammatory environment. 
The MAPKs are composed of a family of related serine/threonine protein kinases, such as JNK, 
ERK, and p38 MAPK. These kinases can be activated in response to cellular stimuli such as 
stress, inflammatory cytokines, and G protein coupled receptor agonists (Son et al. 2011). 
Additionally, there is a striking increase in JNK activity in adipose and liver tissues as well as in 
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the hypothalamus in obesity (Sun et al. 2012; Makki et al. 2013). JNK is activated upon 
exposure to cytokines such as TNF, as well as by free fatty acids and internal cues such as 
endoplasmic reticulum stress (Hotamisligil & Erbay 2008). Experimental activation of JNK in 
the liver can generate insulin resistance and mice with a genetic JNK1-deficiency are protected 
from obesity-induced JNK activation, IRS-1 serine phosphorylation, and, consequently, insulin 
resistance, fatty liver disease and diabetes (Solinas and Beccatini 2017). In addition, blocking 
JNK activity in models of obesity and diabetes has been shown to improve systemic glucose 
homeostasis and insulin sensitivity (Hirosumi et al. 2002; Hotamisligil & Erbay 2008).  
NF-κB is a transcription factor that plays a major role in mediating immune and 
inflammatory responses. The NF-κB pathway is activated by phosphorylation of the inhibitory 
subunit, IκB, by an active serine kinase, IKK which has also been shown to exert a negative 
effect on insulin signaling (Israël 2010). Mice that are heterozygous for a null mutation in IKK-
beta are partly protected from obesity-induced insulin resistance, and inhibition of IKK-beta by 
administration of high-dose salicylates improves insulin action in experimental models of 
diabetes and in humans (Yuan et al. 2001; Hundal et al. 2002). Similarly to JNK, experimental 
activation of this kinase in the liver seems to be sufficient to generate systemic insulin resistance 
(Cai et al. 2005). Interestingly, myeloid-specific deletion of IKK-β results in partial protection 
against obesity- or lipopolysaccharide-induced insulin resistance, providing clear evidence that 
IKK-β activity in myeloid cells can participate in the regulation of systemic metabolic 
homeostasis (Arkan et al. 2005). 
PKC is also important in the interaction between the inflammatory and metabolic 
pathways, and in particular has been implicated as a kinase downstream of lipid signaling. Fatty 
acid metabolites such as diacylglycerol can activate PKC-σ in muscles or PKC-Δ in the liver and 
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inhibit insulin action (Samuel et al. 2010). Mice deficient in PKC-σ are protected against fatty-
acid-induced insulin resistance, confirming the contribution of this kinase to metabolic regulation 
in vivo (Kim et al. 2004). At the mechanistic level, PKC-σ is known to activate IKK and might 
contribute to insulin resistance through this pathway (Trushin et al. 2003).  
Another way inflammation may inhibit insulin signaling is through ROS. ROS are 
essential for host defense and are produced by phagocytes in response to microbial and 
inflammatory stimuli, either within the mitochondria or through a process termed ‘oxidative 
burst’, which is mediated by the NADPH oxidase complex (Noubade et al. 2014). However, 
ROS levels need to be tightly controlled since ROS formation causes damage to tissues, DNA 
strand breaks and alterations in glucose uptake (Katz 2016). Additionally ROS can impair insulin 
signaling through a variety of different mechanisms including, IRS-1 serine/threonine 
phosphorylation, cellular redistribution of insulin signaling components, decreasing GLUT4 
gene transcription, or altering mitochondrial activity (Bloch-Damti & Bashan 2005; Morino et al. 
2006). Serine/threonine kinases involved in insulin signaling can also be directly activated by 
ROS. Among these are PKC, AKT, mTOR, and GSK3, all of which can act synergistically to 
desensitize the insulin signal by phosphorylating IR or IRSs on select serine/threonine residues 
(Rains & Jain 2011). 
Hence, there is numerous data to support that inflammation can interfere with insulin 
signaling within the periphery. While the data presented here were primarily based on 
experimental data examining peripheral insulin sensitivity/signaling, it is likely that these 
processes are also occurring within the CNS since several inflammatory compounds can cross 
the BBB and similar signaling pathways are found within the CNS. As previously mentioned, 
CNS insulin signaling has been shown to be disrupted by inflammatory events and so it is likely 
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that this association may contribute to AD since AD is associated with peripheral inflammation 
as well as neuroinflammation. Therefore, the following section will describe the role of 
inflammation in AD.  
 
 
Figure 1.6: Links between inflammation and insulin signaling. Insulin signaling through both 
MAPK/ERK and PI3K/AKT can activate several inflammatory mediators that in turn cause 
serine phosphorylation of IRS1 and inhibit insulin signaling. Additional inflammatory markers 
can also act on these pathways and independently to cause serine phosphorylation of IR and 
IRS1.  
 
 
 
Inflammation in Alzheimer’s Disease 
Both in the brain and in peripheral tissues, unchecked or chronic inflammation becomes 
deleterious, leading to progressive tissue damage. This process is believed to play a critical role 
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in the pathogenesis of metabolic and neuropathological diseases, including type 2 diabetes and 
AD. Indeed, several studies have revealed that markers of inflammation including gliosis and 
levels IL-1α, IL-1β, IL-6, TNF, granulocyte-macrophage colony-stimulating factor (GMSF), 
IFN-α, and the receptor for CSF-1 are all increased in AD (Lee & Landreth 2010; Perry et al. 
2010; Wyss-Coray & Rogers 2012; Aguzzi et al. 2013; Ferreira et al. 2014) Additionally, blood 
concentrations of TNF, IL-6, and IL-1β have also been shown to be increased in AD patients 
(Swardfager et al. 2010) and  TNF levels are elevated in AD cerebrospinal fluid and AD brain 
microvessels (Grammas & Ovase 2001; Tobinick 2007), as well as in the brain of transgenic 
mouse models of AD (Jin et al. 2008; Ruan et al. 2009). In addition, lots of epidemiological 
studies have demonstrated that, in patients treated with NSAIDs, the incidence of dementia and 
age-related cognitive decline was lower (Imbimbo et al. 2010). Additionally, pre-treatment with 
NSAIDs has been shown to produce an in vivo decrease of inflammatory markers (Teeling et al. 
2010) and cyclo-oxygenase-2 (target of NSAIDs) is also reduced in the cerebrospinal fluid of 
end-stage AD patients (Cole & Frautschy 2010).  
While the reason for this association between inflammation and AD is unclear one 
possibility is a relationship between inflammatory mediators, Aβ, and insulin signaling. It has 
been shown that inflammatory cytokines such as IL-1β, IL-6, TNF or TGF-β can augment APP 
expression and Aβ formation (Lee et al. 2008). It was also reported that cytokines are able to 
transcriptionally upregulate β-secretase mRNA, protein and enzymatic activity (Goldgaber et al. 
1989). Further, combinations of cytokines such as TNF or IL-1β with interferon-γ (IFN-γ), can 
also stimulate the production of Aβ peptides (Blasko et al. 1999) and inflammatory cytokines 
decrease the secretion of the neuroprotective APPsα (Blasko et al., 1999). Both IL-1 and TNF 
immunoreactivity have been found on activated microglia surrounding senile plaques in 
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Alzheimer's disease and inducing the amyloidogenic pathway and treating mice with intracortical 
LPS can induce inflammation and increases amyloidogenesis (Deng et al. 2014).  
 Taken together, several studies suggest that inflammation is a critical factor in AD 
pathogenesis and may do this not only by inducing amyloidogenesis but also by impairing CNS 
insulin-signaling which as we have previously noted is highly related with AD pathogenesis. 
Inflammation is a commonality between many neurological diseases and thus, it is plausible that 
similar changes can occur in several neuropathological conditions. One such condition is 
epilepsy. Epilepsy shares many common features with AD and emerging data suggest they may 
be frequent comorbidities. Therefore, the next part will briefly cover epilepsy followed by a 
section on the commonalities between epilepsy and AD.  
 
Epilepsy 
Epilepsy is a common and devastating neurological disorder, affecting more than 70 
million people worldwide (Ngugi et al. 2011). The lifetime risk of developing epilepsy is 3.9%, 
with males having a slightly higher risk (Hesdorffer et al. 2011). However, because many 
persons (particularly children) become seizure free, at any given time epilepsy affects less than 
1% of the U.S. population, with a disproportionate impact on infants and older adults (Russ et al. 
2012). Total annual health care costs associated with epilepsy are an estimated $15.5 billion 
(England et al. 2012).  
A seizure is a transient event characterized by abnormal hypersynchronous neuronal 
activity in the brain, while epilepsy is a neurological condition that entails an enduring 
predisposition to generate spontaneous recurrent seizures that is often associated with 
neurobiological, cognitive, psychological, and social consequences (Fisher et al. 2014a). A 
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person is considered to have epilepsy if they meet any of the following conditions: at least two 
unprovoked (or reflex) seizures occurring greater than 24 hours apart, one unprovoked (or reflex) 
seizure and an increased probability of further seizures, two unprovoked seizures occurring over 
10 years or diagnosis of an epilepsy syndrome. Epilepsy is considered to be resolved in 
individuals diagnosed with an age-dependent epilepsy syndrome, if they are past the applicable 
age or if they have remained seizure-free for the last 10 years, with no seizure medicines taken 
for the last 5 years. About half of the people who have one seizure without a clear cause will 
have another one, usually within 6 months. People who have had two seizures, have about an 
80% chance of having more seizures. Often, more seizures don’t occur until weeks or months 
after the initial injury or infection (Fisher et al. 2014b). 
Epilepsy patients have recurrent unprovoked seizures, that can be either focal or 
generalized in nature (Löscher & Potschka 2002; Mohanraj & Brodie 2013). Seizures are 
typically characterized as generalized (tonic-clonic) when they involve both hemispheres or 
multiple structures or focal if they are limited to one hemisphere. Focal seizure may be discretely 
localized but can also be more widely distributed yet do not spread throughout the whole brain. 
As a first line of treatment, antiseizure drugs (ASDs) (or a combination of them) are routinely 
tried to assess whether they can control seizure occurrence. Unfortunately, about one-third of 
epilepsy patients suffer from uncontrolled seizures despite pharmacotherapy (Kwan & Brodie 
2001) and are thus considered “refractory,” “drug-resistant,” or “intractable” (Tang et al. 2017). 
Amongst such refractory epilepsies are several pediatric epilepeptic syndromes (e.g. Dravet’s 
syndrome) as well as temporal lobe epilepsy (TLE) which entail the limbic region including the 
hippocampus (Tang et al. 2017). In TLE, the hippocampus displays extensive cell loss, synaptic 
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reorganization (e.g. mossy fiber sprouting), astrogliosis, neuroinflammation, and typically is the 
site of seizure onset (Curia et al. 2014).  
Refractory epilepsy in general is associated with increased morbidity and mortality, 
serious psychosocial consequences, cognitive problems, and a reduced quality of life. Despite the 
introduction of many new ASDs since 1990s, there has been little improvement in the prognosis 
of common refractor epilepsies (TLE) and childhood epilepsy syndromes (Harden 2007). This is 
not surprising given the lack of compelling evidence supporting the superiority of new ASDs 
over older ones, as well as the small placebo-corrected efficacy of adjunctive treatment with 
modern ASDs. Additionally, most studies screening and developing new ASDs were primarily 
done on seizures generated in control animals versus seizures occurring in animal models of 
refractory epilepsy (Vezzani 2009). This oversight has led to the creation of numerous models of 
epilepsy including the pilocarpine-induced epilepsy mouse (or rat) model of TLE, which was 
used for our studies. TLE and AD exhibit numerous common characteristics and interestingly, 
some of the first descriptions of amyloid plaques by Alois Alzheimer were actually made on 
human epileptic tissue. Thus, the next section will discuss the relationship between these two 
neuropathologies.  
 
Epilepsy and Alzheimer’s disease 
Both epilepsy and AD are relatively common neurological disorders whose incidence and 
prevalence increases with age (Hirtz et al. 2007; Alzheimer’s Association 2011). Clinical and 
epidemiological evidence suggests that an interaction exists between these two disorders. First 
off, patients with AD have an increased risk of developing seizures and epilepsy, and thus AD 
may be an important cause of epilepsy in the elderly (Pandis & Scarmeas 2012). Further, animal 
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model studies have shown that epilepsy can accelerate AD pathogenesis in the 3xTg-AD model 
(Yan et al. 2012a).  
Neurodegenerative conditions, including but not limited to AD, are the presumed 
etiology for ∼6% of all incident and ∼4% of all prevalent cases of epilepsy. In comparison, in 
patients older than 65, neurodegenerative conditions accounted for approximately 10% of all 
presumed causes of new-onset epilepsy (Friedman et al. 2012a). However, generalized 
convulsive seizures are rather infrequent in AD. Nonetheless, up to 21% of patients with 
sporadic AD are estimated to have at least 1 unprovoked clinically identifiable seizure (Palop & 
Mucke 2009) and the risk for unprovoked seizures markedly increases in patients with early-
onset AD, reaching 3-, 20-, and 87-fold higher concordant with dementia onset at age 70-79, 60-
69, or 50-59 years, respectively (Amatniek et al. 2006). Notably, more than 30 mutations in PS1 
are associated with epilepsy (Larner & Doran 2006), and 56% of patients with early-onset AD 
with APP duplications have seizures (Cabrejo et al. 2006). Further around 83% of pedigrees with 
early onset of AD-related dementia (<40 years of age) show frank seizures or epilepsy (Snider et 
al. 2005). In addition, most cases of Down syndrome have an extra copy of the APP gene and 
develop early-onset AD; notably, 84% of those cases also have recurrent seizures (Lai & 
Williams 1989). The APOE4 allele, which is a risk factor for developing sporadic AD, 
predisposes nondemented carriers for the development of epilepsy (epileptogenesis) (Friedman et 
al. 2012b). Additionally, it is likely that spontaneous epileptic seizures are frequently not 
diagnosed in AD patients since the hippocampus, the bilateral structure involved with focal TLE 
seizures, is situated deep within the temporal lobes and thus it is unlikely that hippocampal 
activity can be picked up via surface EEG recordings. Indeed, a recent study using intranasal 
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readings suggested that the incidence/prevalence of epileptic seizures in AD patients is likely to 
be way higher (Lam et al. 2017). 
In addition to these clinical data transgenic mice expressing human APP in neurons 
indicate that high levels of Aβ are sufficient to elicit epileptiform activity and seizures, even at 
early stages of the disease process and in the absence of overt neuronal loss (Palop et al. 2007). 
Notably, experimental manipulations that prevent seizure activity in human APP mice also 
prevented cognitive deficits in these models (Roberson et al. 2007). There is also evidence from 
some animal models of AD that deposition of Aβ can lead to hippocampal hyperexcitability and 
seizures in certain cases (Reyes-Marin & Nuñez 2017). AD models have also been shown to 
have increased susceptibility to chemoconvulsants and prolonged video-EEG in a subset of 
mutant mice found frequent epileptiform discharges and intermittent nonconvulsive seizures 
(Palop et al. 2007; Minkeviciene et al. 2009).  
These two neuropathological conditions also share many common characteristics. Both 
AD and TLE exhibit pathological changes in mesial temporal structures including the CA1, 
subiculum, entorhinal cortex, and DG. Studies using models of TLE suggest that cell loss and 
reorganization of neuronal circuitry within these hippocampal regions leads to pathological 
hyperexcitability with hippocampal sclerosis found in 60% of patients undergoing surgical 
treatment for refractory TLE (Zarow et al. 2008). Prominent cell loss and gliosis in CA1 is also 
seen in patients with AD and other forms of dementia (Price et al. 2001). Further, GS, an enzyme 
preferentially found in astrocytes that is involved with glutamate-glutamine cycling, is decreased 
in both conditions (Robinson 2001; van der Hel et al. 2005; Eid et al. 2008). Both conditions are 
also associated with CNS hypometabolism as assessed by FDG-PET scanning. Indeed, temporal 
hypometabolism is present in 80% of patients with pathologically proven hippocampal sclerosis 
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during interictal periods and is seen in nearly all AD patients (Spencer 1994; Kennedy et al. 
1995; Mosconi et al. 2004). 
Additionally both conditions are characterized by neuroinflammation and while the role 
of neuroinflammation in CNS disease pathogenesis is widely investigated, the exact cause and 
effect relationship is unclear. Elevated serum inflammatory mediators have been found in 
cerebral ischemia, multiple sclerosis, Parkinson's disease, AD, epilepsy and TBI (Perry 2004; 
Perry et al. 2010; Aalbers et al. 2014; Corps et al. 2015; Hemmer et al. 2015; Mallucci et al. 
2015) and a growing body of evidence now implicates a link between inflammation and certain 
epilepsy syndromes. In general, the epileptic brain displays a chronic inflammatory state as is 
seen in AD and also exhibits increased BBB permeability; both of these changes can lead to 
enhanced neuronal excitability (Vezzani et al. 2010). Specifically, in patients with febrile 
seizures and antibody mediated autoimmune encephalitis (e.g., NMDA-receptor encephalitis) the 
immune system is activated (Dubé et al. 2005; Dalmau et al. 2008), and a pro-inflammatory 
profile has also been found in patients with TLE and focal cortical dysplasia (Henshall et al. 
2000; Ravizza et al. 2006; van Gassen et al. 2008; Kan et al. 2012; Tan et al. 2015; van Vliet et 
al. 2015). Indeed, neuroinflammation has even been proposed to contribute to seizure generation 
and hippocampal reorganization in TLE (Vezzani et al. 2015). Further, immunomodulating 
therapy with systemic corticosteroids and adrenocorticotropic hormones has proven successful in 
treating specific pediatric epilepsy syndromes, supporting the involvement of the immune system 
in epilepsy (Gupta & Appleton 2005; Hancock & Cross 2013; van den Munckhof et al. 2015). 
 While acute alterations in glycemic control has been linked with seizure activity the role 
of insulin signaling in epilepsy has not been as thoroughly as it has been in AD. However, one 
potential common player in AD and in epilepsy is the insulin sensitive KATP channel. As 
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previously mentioned these channels may play a role in AD since: 1) diazoxide can improve AD 
pathology (Liu et al. 2010); 2) modulation of KATP channels can affect Aβ production 
(Macauley et al. 2015); and 3) the ketogenic diet can improve AD and ketone bodies can 
modulate KATP channels (Yellen 2008; Li et al. 2017). Interestingly, the ketogenic diet has also 
proven to be a useful therapeutic in several forms of epilepsy and has been suggested to work 
through these KATP channels demonstrating a relationship between epilepsy and these channels. 
Further, a novel pediatric epileptic phenotype type (developmental delay-epilepsy-neonatal 
diabetes syndrome-DENDS) has recently been described whereby mutation in KATP channels 
underlie their seizures and developmental delay (Shimomura & Maejima 2017). Further, in TLE 
the gating function of the DG is compromised and KATP channels have been suggested to 
contribute to the normal gating function of the DG (Tanner et al. 2011). Thus, in the next section 
we will present a more detailed discussion of the potential correlation between epilepsy and 
KATP channels 
 
KATP Channels and Epilepsy 
As noted above KATP channels have been proposed to underlie the epileptic syndrome 
of DENDS and potentially contribute to DG gating of activity entering they hippocampus 
(Tanner et al. 2011; Shimomura & Maejima 2017). Several other studies have further provided a 
potential link of KATP channels in epilepsy. For example, cultured tuberous sclerosis complex 
type 1(Tsc1)-deficient astrocytes exhibited reduced Kir currents and decreased expression of the 
specific Kir channel protein subunits, Kir2.1 and Kir6.1. (Jansen et al. 2005). Expression of these 
Kir subunits was also noted to be reduced in astrocytes from the neocortex of Tsc1GFAP 
conditional knockout mice. KATP channels within the SNr have also been suggested to prevent 
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seizure propagation (Yamada & Inagaki 2005) and ketone bodies (β-hydroxybutyrate or 
acetoacetate) can reduce the spontaneous firing rate of neurons in slices from rat or mouse 
substantia nigra pars reticulate which is critical in controlling seizure generalization (Ma et al. 
2007). In contrast to decreases in KATP channels, transgenic mice overexpressing the SUR1 
subunit display a reduced sensitivity to kainic-acid (a commonly used chemoconvulsant) induced 
seizure (Hernandez-Sanchez et al. 2001). While the work on KATP channels in the context of 
epilepsy is relatively small at this point in time, the available data demonstrates the importance 
of following up on these initial observations.  
Taken together the data presented in this dissertation so far establishes several links 
between metabolism (i.e. insulin signaling and KATP channels) and inflammation and 
demonstrates the importance of these concepts in neuropathological disease. Since both AD and 
epilepsy are severe neurological disorders with numerous common alterations including 
inflammation, in the following section we will discuss a commonly used experimental 
manipulation known to induce peripheral and neuroinflammation-acute and chronic LPS 
treatment.  
 
Inducing Inflammation: Lipopolysaccharide Systemic inflammation has been largely studied 
through peripheral administration of LPS. Bacterial lipopolysaccharides are the major outer 
surface membrane components present in almost all Gram-negative bacteria which act as 
extremely strong stimulator of innate immunity (Alexander & Rietschel 2001). Peripheral 
administration of LPS has been shown to give rise to a number of sickness-related behavioral 
symptoms in rodents including fever, loss of appetite and decreased activity (Holmes 2013). LPS 
acts primarily through the production of pro-inflammatory cytokines. It is well established that 
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LPS binds to CD14 receptors and activates toll-like receptor 4 (TLR4) ligands on leukocytes and 
macrophages in the periphery. LPS also induces the secretion of the pro-inflammatory cytokines 
IL-1b; IL-6 and TNF (Lacroix & Rivest 1998). These peripheral cytokines have been shown to 
directly lead to the development of sickness behavior (Kent et al. 1992a; Bluthé et al. 2000; 
Cartmell et al. 2000) and knockout mice without inflammatory cytokine receptors do not display 
similar behavioral changes following LPS administration (Kent et al. 1992b; Bluthé et al. 2000). 
However, several studies have suggested that cytokines are not the only mechanism responsible 
for LPS-induced sickness behavior since mice pretreated with antibodies to IL-1b, IL-6 and TNF 
prior to low levels of systemic LPS show a reduced production of peripheral (but not central) 
pro-inflammatory cytokine production but still exhibit some symptoms of sickness behavior 
(Teeling et al. 2010). Thus, peripheral LPS may also be associated with the activation of other 
molecular cascades, such as the production of chemokines (CXCL8, CCL2 and CCL5), immune 
response receptors (CD14, TLR2), complement proteins (C3, C3A receptor; C5aR), nitric oxide 
synthase, thromboxane, leukotrienes, adhesion molecules, as well as increased catecholamine 
secretion, cyclooxygenase 2 (COX2) activation, and high mobility group box and prostaglandin 
synthesis (Riust et al., 2009; Fitzgerald et al., 2000).  
LPS and pro-inflammatory cytokines are large molecules that cannot easily penetrate the BBB. 
Thus, several alternative mechanisms for how peripheral LPS affects the CNS have been 
proposed. One way in which LPS may act on the CNS is through the stimulation of peripheral 
nerves by cytokines and prostaglandin. This has been demonstrated in rodent models where 
peripheral administration of cytokines or prostaglandins directly activated vagal afferents 
(Dantzer et al., 1999; Blatteis et al., 1998; Romanovsky et al., 2004; Szekely et al., 2000; Ek et 
al., 1998). Additionally, LPS is also thought to induce IL-1b and prostaglandin E2 (PGE2) 
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production in the liver, which can then interact with the vagus nerve (Ek et al., 1998; Gohler et 
al., 1997; Goehler et al., 1999; Lazarus et al., 2002). Another potential mechanism is through 
direct action on CNS sites that lack the BBB such as the circumventricular organs or via acting 
on the vascular cells at the BBB. Indeed, it has been shown that LPS or pro-inflammatory 
cytokines can directly stimulate TNF production from microglial or perivascular macrophages 
Breder et al., 1994; Nakamori et al., 1994; Quan et al., 1999) and it is hypothesized that TNF 
could then activate the pro-inflammatory transcription factor nuclear factor-KB (NF-KB) in 
these areas and subsequently let to the progression of an inflammatory response across the brain 
parenchyma (Nadeau et al., 2000). Alternatively, in vascular endothelial cells and perivascular 
macrophages both LPS and cytokines are thought to activate prostaglandin synthesis through 
increased expression of COX-2 (Matsummura et al., 2004). Specifically LPS or IL-1b can lead 
to an intense production of COX-2 and membrane bound prostaglandin e synthase 1 (mPGES-1) 
with subsequent production of PGE2 in these cells (Breder and Saper, 1996; Cao et al., 1995; 
Elmquist et al., 1997; Ek et al., 2001; Engblom et al., 2002). Interestingly, PGE2 has been 
proposed to be the major inflammatory player in TLE (Vezzani et al. 2015). Furthermore, 
animals lacking COX-2 or mPGES-1 fail to produce a fever response to either systemic LPS or 
IL-1b and the use of specific COX-2 inhibitors blocks the fever response (Zhang et al., 2001; 
Yamagata et al., 2010). Additional factors may include the direct entry of immune cells 
(monocytes and possibly bone marrow derived microglial cells) from the periphery into the 
brain, active transport of pro-inflammatory cytokines across the cerebral vasculature and into the 
brain, or BBB damage allowing for cytokine or LPS entry into the CNS.  Regardless, available 
data suggest that peripheral LPS does result in neuroinflammation and astrogliosis. Given that 
some of the metabolic changes we observed in AD and epilepsy were specific to reactive 
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astrocytes we performed experiments to assess whether simply inducing acute or chronic 
peripheral inflammation with LPS could induce similar changes in KATP channel expresion and 
thereby provide a potential mechanism that could contribute to hippocampal dysfunction across 
several neuropathological diseases. 
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Specific Aims 
 
Hypothesis: Alterations in metabolic proteins are a common characteristic of to 
neuropathological conditions-AD and epilepsy- and peripheral inflammation can 
contribute to the alterations in CNS metabolic properties.  
 
Aim 1: Assess CNS insulin signaling in a mouse model of AD known to exhibit peripheral 
and CNS inflammation & determine how these changes temporally correlate with 
peripheral metabolic dysfunction and AD-like neuropathology. 
3xTg-AD mice exhibit impaired glucose tolerance as early as 1-3 months of age that persists 
throughout their life. Further, this compromise in peripheral glucose tolerance is associated with 
decreased insulin levels and response following a glucose challenge and occurs prior to 
pathology and cognitive decline. Since CNS insulin is primarily supplied by the periphery we 
wanted to examine whether and when the change in peripheral insulin translates into impaired 
CNS insulin signaling, a characteristic seen in human AD brain tissue post-mortem. A change in 
insulin signaling could contribute to AD pathogenesis and cognitive decline. To assess this 
hippocampi were collected from 3xTg-AD and C57/129BL6 wild type mice at 6-8 (pre-
pathology and cognitive decline), 10-12, 14-16 and 18-20 MOA (pathology and cognitive 
decline are present). Western blotting was used to assess PI3K/AKT and MAPK/ERK pathways. 
Downstream targets of the PI3K/AKT pathway were also examined (e.g. GSK3, GLUT3 and 4 
translocation). 
Aim 2: Determine whether the expression of Kir6.2, a downstream target of insulin, is 
altered in AD and epilepsy (epilepsy is another neurodegenerative disease characterized by 
hypometabolism, inflammation, and reactive astrogliosis) using immunoblotting and IHC. 
We chose to examine KATP channels since they link cellular metabolism and physiology 
and both AD and epilepsy are characterized by regional CNS hypometabolism in the 
hippocampus. This hippocampal hypometabolism is implicated in the cognitive decline and 
enhanced seizure susceptibility observed in both neuropathological conditions.   
Brains were collected from 3xTg-AD and C57/129BL6 mice at 20-24 MOA. Half the brain was 
used for western blotting while the other half was used for immunohistochemistry to assess 
Kir6.1 and Kir6.2 in the hippocampus to examine a model of chronic TLE. C57/129BL6 mice 
aged 3-4 months were treated with pilocarpine. Mice treated with pilo were then examined either 
24 hours following status epilepticus to assess astrogliosis and Kir6.2 levels immediately post-
injury or months later following the observation of spontaneous recurrent seizures months 
following the innital pilo-treatment to verify epileptogenesis. Brains were collected from saline 
treated controls and pilocarpine-treated mice with hippocampi examined using 
immunohistochemistry.  
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Aim 3: Determine if chronic vs. acute inflammation by itself can induce astrogliosis and 
altered Kir6.2 expression. 
Since AD and epilepsy were both observed to exhibit altered Kir6.2 expression in reactive 
astrocytes and both neuropathological conditions are characterized by a chronic inflammatory 
state, LPS was used to induce acute and chronic inflammation. Astrogliosis and Kir6.2 
expression/distribution was then examined. Young control mice were given peripheral 
lipopolysaccharide for either 1 day or 3 days to induce acute and chronic inflammation, 
respectively. Immunohistochemistry was used to assess whether peripheral inflammation alone 
was enough to drive astrogliosis and changes in Kir6.2.  
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METHOD 
3xTg-AD mice 
For studies using an AD mouse model, male 3xTg-AD mice and age-matched wild-type 
controls on a 129/C57BL6 background were used. The 3xTg-AD mouse was created using a 
Thy1.2 promoter to express human mutated APP and tau primarily in the CNS. These mice were 
then mated to a PS1 mutant line to create the triple transgenic mutant (Oddo 2003). 3xTg-AD 
mice have been previously characterized by others in the laboratory for AD-characteristics and 
peripheral metabolic changes (Figs. 3.1-3.3). For experiments examining CNS insulin signaling 
western blot was performed using 9 wild type and 3xTg-AD mice aged 6-8 months, 7 wild type 
and 3xTg-AD mice aged 14-16 months and 13 wild type and 3xTg-AD mice aged 18-20 months 
were used. For examing KATP channels (i.e. Kir6.1 and Kir6.2) western blot experiments were 
performed using 12 wild type and 12 AD mice aged 18–26 months. For KATP IHC experiments 
4 wild type and 4 AD mice aged 18-26 months were used. The mice used for insulin signaling 
and KATP western blots were anesthetized with sodium pentobarbital (100 mg/kg, i.p.; Sigma–
Aldrich, St. Louis, MO, USA), the hippocampus was removed from one hemisphere, frozen on 
dry ice and stored at -80ᵒC until use. The other half of the brain was immersion fixed overnight in 
4% paraformaldehyde and then cryoprotected in 30% sucrose for future experiments. For KATP 
IHC experiments mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.; Sigma–
Aldrich, St. Louis, MO, USA) and intracardially perfused with 4% paraformaldehyde. The brain 
was removed, post-fixed overnight, and then cryoprotected in 30% sucrose. All animals were 
housed in the Southern Illinois University Carbondale (SIUC) vivarium on a 12/12hr light dark 
cycle and were provided Purina rodent chow (fat-13.5%, protein-28.5%, and carbohydrates-58%) 
and water ad libitum. All experiments were approved by SIUC’s Institutional Animal Care and 
 73 
 
Use Committee and comply with the guidelines set forth by the National Institutes of Health.  
 
Postmortem Human Brains  
Brain tissue was obtained from the Chinese human brain banking consortium at Xiangya 
School of Medicine and Peking Union Medical College (Yan et al. 2015) (Table 1). Samples 
were selected from clinically diagnosed AD patients and age-matched non-AD subjects. Braak’s 
staging system was used to evaluate neuropathological changes. Tissue with Braak’s scores of 
postmortem neuropathology at or greater than IV from patients that had a clinical history of 
dementia were considered as the AD group. The control group was selected based on tissue 
showing little to no amyloid and/or tau pathology in the cerebrum (limited to Braak’s stages I–
II). Neuropathological characterization of postmortem human brains has been published 
elsewhere (Zhu et al. 2015; Xu et al. 2016). Standardized procedures were used for banking all 
human brains where one side of each brain was saved for future biochemical studies by rapidly 
freezing and storing at −70 °C, and the other side immersion fixed in 10% formalin. For 
anatomical studies a block ∼2 cm in thickness from mid-hippocampal temporal lobe was 
removed from the formalin-fixed hemisphere. This block was then cryoprotected in 30% sucrose 
and cut with a cryostat at 40 μm in the frontal plane into 12 sets of sections consisting of four 
equally distant (12 × 40 μm or ∼500 μm) sections. The sections were then stored in a 
cryoprotectant at −20 °C until histological processing. The experiments using human brain tissue 
were performed in Dr. Yan’s laboratory at Xiangya School of Medicine since this tissue cannot 
leave China.  
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Table 2.1: Human Tissue 
Group Case # Age Sex Cause of death 
Aged 1 75 M Prostate cancer 
2 78 F Lung cancer 
3 79 F Pneumonia 
4 85 M Diabetes mellitus, hypertension 
5 88 M Pneumonia, multisystem failure 
6 94 M Pneumonia 
7 96 F Lung cancer 
8 99 F Cerebral stroke 
AD 1 73 M AD 
2 80 F AD 
3 80 F AD 
4 80 M AD, cerebral stroke 
5 82 F AD, pneumonia 
6 86 M AD, multisystem failure 
7 98 F AD, respiratory failure 
8 100 F AD, hypertension 
 
 
Pilocarpine-treated Mice: 
Twenty-eight male 129/C57BL6 mice aged 2-4 months were used for the experiments 
examining KATP channels in TLE. Mice were injected with methylscopolamine (1–1.2 mg/kg, 
i.p.) followed 15 min later by an intraperitoneal injection of either 290–295 mg/kg pilocarpine in 
0.9% saline or just saline as the control. Animals were then closely monitored for 4–6 h to verify 
that they developed convulsive seizures (i.e., status epilepticus) sufficient to induce 
epileptogenesis and thus spontaneous recurrent seizures 2 months following the initial 
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pilocarpine-treatment (i.e., at least 3 seizures with a seizure score ≥ class III in severity over the 
next 2–3 h) (Shibley & Smith 2002). A 43% mortality rate was observed among pilocarpine-
treated animals. Surviving mice were returned to their home cages and were subsequently 
behaviorally monitored for 8-10 h per week to verify the onset of spontaneous recurrent 
convulsive seizures (i.e., an epileptic phenotype). Four mice that exhibited an initial bout of pilo-
induced seizures (i.e., status epilepticus) sufficient to induce epileptogenesis, and 4 control mice 
were sacrificed 24–48 h later to assess short-term histological alterations for comparison with 
chronically epileptic animals (3 months later; n=4). Saline-treated controls (n=4) and 1 
pilocarpine-treated mouse that did not exhibit an initial bout of seizures sufficient to induce 
epileptogenesis (i.e., 1–2 non-convulsive seizures over 6 h) were also allowed to survive for 
additional examination. At the appropriate time point, either 1 day (post-status) or 3 months 
(epileptic) following pilocarpine administration, mice were anesthetized with sodium 
pentobarbital (100 mg/kg, i.p.; Sigma–Aldrich, St. Louis, MO, USA) and their brains were 
collected. Brains were immersion fixed in 4% paraformaldehyde overnight and then 
cryoprotected in 30% sucrose. Animal use was in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and all procedures were preapproved by the Animal Care and 
Use Committee at SIUC. 
 
Table 2.2: Pilocarpine-treated Mice 
Group Total mice 
3 days post-
treatment 
3 months post-
treatment 
Deaths 
Saline 9 4 4 1 
Pilocarpine 18 5 4 9 
Pilocarpine + no seizures 1 0 1 0 
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LPS Mice 
Twenty 2-3 month old male mice on a 129/C57BL6 background were used for the LPS 
studies (see table below for treatment groups). Mice were given an intraperitoneal injection of 
either 5 mg/kg LPS (L2880; Sigma-Aldrich, St. Louis, MO.) or an equal amount of saline for 1 
or 3 days. Weight was recorded and mice were monitored throughout the day on each day of 
treatment. Following treatment mice were anesthetized with sodium pentobarbital (100 mg/kg, 
i.p.; Sigma–Aldrich, St. Louis, MO, USA) and their brains were collected. One hemisphere was 
immersion fixed in 4% paraformaldehyde overnight and then cryoprotected in 30% sucrose. 
From the other half the hippocampus was collected, flash frozen, and stored at -80 C for 
immunoblots. All animals were housed in the SIUC vivarium on a 12/12hr light dark cycle and 
were provided Purina rodent chow and water ad libitum. All experiments were approved by 
SIUC’s Institutional Animal Care and Use Committee and comply with the guidelines set forth 
by the National Institutes of Health.  
 
Table 2.3: LPS treated mice 
Group Total mice 
1 days post-
treatment 
3 days post-
treatment 
Deaths 
Saline 9 4 4 1 
LPS 11 5 6 0 
 
Immunoblotting 
To examine levels of metabolic proteins (e.g. AKT, pAKT, IRS-1, pIRS-1, Kir6.2) in 
AD, western blotting was used. Crude plasma membrane and total cell fractions were collected 
for Western blots using a modified version of a protocol previously described (Reagan et al. 
2000; Griffith et al. 2016). Briefly, samples were homogenized in 700 μL of cold 
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homogenization buffer (320 mM sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, and 
protease and phosphatase inhibitors) and centrifuged at 800g for 10 min. The supernatant was 
saved where a portion of this (350 μL) was used as the total protein sample and the remainder 
was subsequently centrifuged at 20,000g for 20 min at 4 °C. The resulting pellet, which contains 
the crude plasma membrane fraction, was then re-suspended in 100 μL of PBS containing 
protease and phosphatase inhibitors. To ensure that this separation of crude plasma membrane 
worked appropriately, samples were subjected to western blots to look at GAPDH (a cytoplasmic 
protein that should be nearly absent in the membrane fraction) and Kir6.1 (channel portion of 
KATP channels primarily found in astrocytic membranes, which should be mostly absent from the 
cytosol). Additionally, this method of separation was compared to that of Qproteome cell 
compartment kit (37502; Qiagen, Hilden, Germany). Both methods provided distinct membrane 
fractions with little to no GAPDH seen (Fig. 2.1). Samples were aliquoted and stored at −80 °C 
until use. Protein concentration was determined using a commercially available kit for the 
bicinchoninic acid (BCA) assay (Life Technologies, Grand Island, NY, USA). Samples (50 μg) 
were then loaded onto 7 or 10% SDS–Page gels (depending on protein size) and transferred to 
polyvinylidene fluoride (PDVF) membranes (Millipore, Billerica, MA, USA). Membranes were 
subsequently blocked in Odyssey blocking buffer (Licor, Lincoln, NE, USA) for one hour and 
then probed with primary antibody (Table 2.4) diluted in blocking buffer overnight at 4 °C. 
Following incubation with the primary antibody, membranes were rinsed three times in TBS 
with 0.1% tween 20 and then incubated for 1 h at room temperature with appropriate secondary 
antibodies (Rockland, Limerick, PA). β-actin or Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) were used as loading controls where β-actin was used for normalization in 
experiments not using isolated membrane fractions while GAPDH was used as the control for 
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normalization of total protein levels and to verify successful isolation of the plasma membrane 
fraction in these experiments. Subsequently, crude plasma membrane samples were normalized 
to the corresponding total membrane sample with densitometric quantification of protein bands 
performed using the Odyssey Clx system (Licor, Lincoln, NE). For comparison between 
experimental and control groups, control means were normalized to one and statistical 
significance was tested using a non-paired student’s t-test in which a p-value less than 0.05 was 
considered significant. To determine significance for total and crude plasma membrane samples, 
student’s T-test with Bonferroni’s correction to protect against Type 1 errors was applied (p < 
0.025 for significance) since the same samples were used. 
 
Figure 2.1: Comparison of Plasma Membrane Separation Protocols 
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Table 2.4: Antibodies used for Western Blotting: 
Antibody Source Dilution 
p44/42 MAPK Cell Signaling Technology, Danvers, MA 1:1000 
Phospho-p44/42 MAPK (Thr202/Tyr204) Cell Signaling Technology, Danvers, MA 1:1000 
IRS1 Abcam, Cambridge, MA 1:500 
Phospho-IRS1 (Ser307) Cell Signaling Technology, Danvers, MA 1:1000 
AKT Rockland, Gilbertsville, PA 1:2500 
Phospho-AKT (Ser473) Cell Signaling Technology, Danvers, MA 1:2000 
GSK3α/β Cell Signaling Technology, Danvers, MA 1:1000 
Phospho-GSK3α/β (Ser21/9) Cell Signaling Technology, Danvers, MA 1:1000 
Phospho-Tau (PHF) (Ser202/Thr205) ThermoFisher Scientific, Waltham, MA 1:500 
Phospho-Tau (Ser396) Cell Signaling Technology, Danvers, MA 1:1000 
GLUT3 Alpha Diagnostic, San Antonio, TX 1:2500 
GLUT 4 Dr. Lawrence Reagan 1:500 
Kir6.1 Santa Cruse, Dallas, Texas 1:500 
Kir6.2 Santa Cruse, Dallas, Texas 1:500 
Kir6.2 Alomone Labs, Jerusalem, Israel 1:200 
Kir4.1 Alomone Labs, Jerusalem, Israel 1:200 
β-Actin Sigma-Aldrich, St. Louis, Mo 1:10,000 
GAPDH Genetex, Irvine, CA 1:5000 
 
Immunohistochemistry 
For IHC experiments using mouse brain tissue, coronal sections of the entire brain were 
cut at 30 μm using a freezing microtome. Ten sets of sections were serially collected between 
bregma −1.06 and bregma −3.88 (Franklin & Paxinos 2008) in cell culture wells and stored in 
cryoprotectant (1 L consists of 500mL of .1 M phosphate buffer, pH7.2, 300g sucrose, 10 g 
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polyvinylpyrrolidone, 300 ml ethylene glycol) (Watson, et al.).  
For IHC data using an immunoperoxidase reaction to visualize the antigen, mouse brain 
sections were treated with H2O2 (1%) in phosphate buffered saline (PBS) for 1 hour to quench 
endogenous peroxidase activity, and then were incubated overnight (4 °C) with one of the 
primary antibodies diluted in blocking serum (PBS with 5% normal goat serum and 0.3% Triton 
X-100) or in blocking solution without the primary antibody as a control for non-specific 
staining. As an additional control for Kir6.2, a control antigen to the sequence of the antibody 
was incubated with the antibody at a 1:100 concentration for one hour prior to adding sections. 
The next day, sections were rinsed, reacted with biotinylated goat anti-rabbit IgGs at 1:400 (for 2 
h) followed by the Vectastain elite ABC kit (PK-6101, 1:400; Vector Laboratories, Burlingame, 
CA, USA) for another hour. Immunoreactive product was visualized using 0.003% H2O2 and 
0.05% 3,3'-diaminobenzidine (DAB) (Sigma–Aldrich, St. Louis, MO). Three, 10-min, washes 
with PBS were performed between all incubations. Sections were mounted on slides, allowed to 
air-dry, de-lipidated in a series of ethanol and xylene and then cover-slipped. For all 
immunoperoxidase experiments, sections from one control and one 3xTg-AD animal were batch 
processed and were subsequently examined side by side. 
For immunofluorescence, sections were incubated in blocking solution (PBS with 5% 
normal goat serum and 0.3% Triton X-100) for 1 hour and then incubated overnight with primary 
antibodies (Table 2.5) in blocking serum (4 °C) or without the primary antibody as a control for 
nonspecific staining. The next day, sections were rinsed, reacted with biotinylated goat anti-
rabbit IgGs at 1:400 for 2 h followed by the Vectastain elite ABC kit (PK-6101, 1:400; Vector 
Laboratories, Burlingame, CA) for another hour. Sections were then incubated in blocking buffer 
with Streptavidin, Alexa Fluor 546 conjugate (S-11225, 1:1000; Life Technologies, Grand 
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Island, NY) and Alexa Fluor-conjugated antibodies for visualizing astrocytes (GFAP) and 
neurons (β-tubulin). Sections were rinsed 3 times with PBS, mounted on gelatin-coated slides 
and coverslipped with 4,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) Fluoromount-G 
(0100–20, Southern Biotech, Birmingham, AL, USA). For Kir6.2/glutamine synthetase (GS) co-
localization experiments, the same protocol was used for Kir6.2, however instead of a conjugated 
GS antibody, GS was incubated overnight in blocking buffer and followed by a 1-h incubation 
with Goat anti-Mouse Alexa Fluor 488 secondary antibody at room temperature (A-11029, 
1:1000, Life Technologies, Grand Island, NY). 
Brain sections from the human AD and aged-matched control groups were batch-
processed immunohistochemically to determine the expression of Kir6.2 and GFAP, using the 
same ABC/DAB staining protocol as described above for the mouse brain sections. Co-
localization of Kir6.2 and GFAP was examined in the human hippocampus using confocal 
double immunofluorescence and the human brain sections were processed with the same 
protocol as used for the mouse tissues, with the exception that an additional treatment in 0.5% 
Sudan black (10–20 s) was performed prior to mounting with an anti-fade medium. These 
experiments were ran by our collaborators in China.  
 
Table 2.5: Primary Antibodies used for Immunohistochemistry 
Antibody Source Dilution 
Rabbit GFAP  Cell Signaling Technology, Danvers, MA 1:2000 
Mouse GFAP  Sigma-Aldrich, St. Louis, MO 1:2000 
GFAP Alexa Fluor 488  Molecular Probes, Eugene, OR 1:1000 
β-tubulin Alexa Fluor 647 BD Pharmingen, San Jose, CA 1:1000 
 82 
 
Glutamine Synthetase BD Biosciences, San Jose, CA 1:100 
Kir6.1 Santa Cruz, Dallas, Texas 1:100 
Kir6.2 Santa Cruz, Dallas, Texas 1:100 
Kir6.2 Alomone Labs, Jerusalem, Israel 1:100 
 
 
Image Acquisition and Analysis 
All mouse brain sections (immunoperoxidase or immunofluorescence) were analyzed by light 
microscopy using a Zeiss Axioimager. Control and experimental images from each set of 
experiments were taken with the same exposure. For imaging of immunofluorescence, image 
planes were sampled with structured illumination at 1-μm intervals with each fluorophore 
imaged independently (200X, Zeiss AxioImager equipped with an Apotome). For quantification 
purposes images were collected from 4 evenly spaced sections between bregma −1.34 and −2.70 
per mouse. These images were taken within CA1 since this region preferentially exhibits β-
amyloid plaques and hyper-phosphorylated tau in the hippocampus of 3xTg-AD mice (Cai et al. 
2012; Yan et al. 2012b). From each section in the AD study, a total of 3 non-overlapping images 
of hippocampal region CA1 were taken spanning from the border of the subiculum to CA3. For 
the LPS study 1 image per section was taken directly above the hilus of the dentate gyrus. 
Images were taken with the cell body layer at either the bottom of the frame or the top of the 
frame in order to capture SO or stratum SR respectively. Maximum projections consisting of five 
consecutive images for the AD study and ten consecutive images for the LPS study were then 
produced using Image J (National Institutes of Health, Bethesda, MD, USA). For all images 
shown below, pictures were imported into Photoshop, composite images were made from 
overlapping images when needed, and the same linear enhancements were made to matching 
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pairs of images. Z-stacks of the immunofluorescent images were imported into Volocity 
(Version 4.3; Improvision) where they were pseudocolored. Composite images (SR, SO and 
ALV) were created from overlapping images using the stitch option in Volocity. For the AD 
study the total number of GFAP-immunoreactive (IR) astrocytes and the number of GFAP-IR 
astrocytes exhibiting Kir6.2-IR were counted in an area 300 μm × 1390 μm in both the SO and 
ALV and 550 μm × 1390 μm in the SR from each of the three pictures taken for all four sections 
per animal. Contrast enhancement was done separately for each image and only astrocytes with 
both cytoplasmic and nuclear components visible within the stack were counted. The total 
number of astrocytes within a region (SR, SO, or ALV) from each section per animal was added 
together to get the total number of astrocytes and the number of Kir6.2-IR astrocytes in each 
region. The total number of astrocytes and the number of Kir6.2-IR/GFAP-IR astrocytes were 
statistically compared using a two-tailed Mann–Whitney U test where a p < 0.05 was considered 
significant. For the LPS study, matching contrast enhancement was used for all sections and the 
immunoreactivity of GFAP, Kir6.2 and their total co-localization was calculated using the 
intersect tool in Volocity. These experiments were done with both blind manual adjustments and 
automatic settings (not shown) from the program. Co-localization was calculated in a region of 
1360 μm x 650 μm in SO and 1360 μm x 350 μm in SR. Values are expressed as the average 
immunoreactivity from each group in a region. A non-paired Student’s T-test was used to 
statistically compare these values where a p < 0.05 was used to determine significance. 
Human brain sections were examined on an Olympus (BX51) fluorescent microscope 
equipped with a digital camera and imaging system (CellSens Standard, Olympus), as well as on 
a confocal microscope (Nikon, Digital Eclipse C1 plus). For counting of the Kir6.2- and GFAP-
labeled cells, four equally spaced sections were selected from each brain, with five non-
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overlapping images of the CA1 regions SR, SO or ALV captured with the 10× objective lens in 
each section. The labeled cells were then counted in each image, and summed for each brain. 
The mean density of the cells for each brain was calculated according to the total area of the 
images. Numerical densities were compared for the AD and aged groups using a two-tailed 
Mann–Whitney U test. Significance was determined by a p < 0.05. (Prism GraphPad 4.1, San 
Diego, CA). 
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RESULTS 
Characterization of 3xTg-AD mice: selecting age groups 
3xTg-AD mice have been thoroughly characterized in previous studies, however, there is 
conflicting data over the timing of the development of pathology and cognitive decline in this 
model. Originally, these mice were reported to express extracellular Aβ at 6 months and 
neurofibrillary tangles by 12 months (Oddo et al., 2003). Other studies report plaque formation 
around 14 months of age with neurofibrillary tangles and cognitive decline appearing around 18 
months of age (Cai et al., 2012; Mastrangelo and Bowers, 2008). For this study time points were 
selected based on previous work using our 3xTg-AD mice that examined neuoropathology using 
IHC for Aβ and pTau and used the MWM to evaluate learning and memory. Additionally, one of 
the goals of this study was to determine if alterations in peripheral metabolism are associated 
with alterations in CNS insulin signaling since previous work has shown that 3xTg-AD mice 
have impaired glucose tolerance and decreased insulin levels. Thus, previous work performed by 
others in the lab examining these parameters is presented briefly below in Figures 3.1-3.3. 
In general, IHC shows that while at 1-2 months of age, 3xTg-AD mice show 
intraneuronal 6E10 staining in pyramidal neurons in cortical layer V, the subiculum, and 
hippocampal region CA1 (Figure 3.1), extracellular 6E10 or Aβ1-42 immunoreactivity were not 
observed until 14 months of age when 3xTg-AD mice exhibited extracellular plaques. Labeled 
plaques were increased, particularly in the subiculum, in 18-month old 3xTg-AD mice. In 
addition, very little p-Tau immunoreactivity was seen in the somata or processes of pyramidal 
neurons in hippocampal region CA1 at 1-2 months but increased with age. By 18 months of age 
p-Tau immunoreactivity was highly visible in the principal neurons of the subiculum and CA1. 
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 Data from the MWM (Fig 3.2), demonstrate that at 6-10 months 3xTg-AD mice and wild 
type controls exhibited comparable reductions in the latency with no statistically significant 
differences found between 3xTg-AD mice and controls in the number of platform location 
crossings or the latency to the first platform location crossing in the probe trial. By 14-16 months 
3xTg-AD mice exhibited a slower rate of learning compared to controls during the five days of 
MWM training, but had a comparable reduction in latency by day five. Probe testing at this time 
point revealed no statistically significant differences between groups in the number of platform 
crossings or the latency to the first platform crossing indicating that memory retention is 
preserved in 14-16 month old 3xTg-AD mice. In mice ≥ 18 months of age both groups exhibited 
a reduction in the latency to the hidden platform during the five days of training, but 3xTg-AD 
mice were not as efficient in finding the platform on the last two days and had significantly 
fewer platform location crosses and a significantly longer latency to the first platform location 
cross during the probe trial demonstrating that 3xTg-AD mice ≥ 18 months of age display 
cognitive deficits. 
As has been previously discussed, humans and mouse models of AD display differences 
in peripheral glucose metabolism and insulin levels. Thus, after establishing the time course of 
pathogenesis and cognitive decline, the relationship between peripheral metabolism and these 
changes were examined in our 3xTg-AD mice by testing glucose tolerance using an ipGTT with 
insulin levels assessed before and 15 min. post-glucose bolus levels using a commercially 
available insulin ELISA kit. 3xTg-AD mice as early as 1-3 months exhibited impaired glucose 
tolerance after an i.p. bolus of glucose and had a significantly greater area under the curve 
measurement (AUC) as calculated from the GTTs relative to wild type controls. A similar 
disruption in glucose tolerance following a glucose challenge was found in 3xTg-AD mice at 
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both 8-10 months and 17-18 months of age. Further, the calculated AUC was greater in 3xTg-
AD mice than in wild type controls at both time points. Additionally, both pre and post-glucose 
bolus insulin levels were decreased in 3xTg-AD mice, compared to wild type controls, at all ages 
examined suggesting that plasma insulin levels are decreased in 3xTg-AD mice and that insulin 
secretion appears diminished. Taken together, these data reveal that glucose tolerance is 
consistently impaired in 3xTg-AD mice relative to wild type controls at all ages examined, thus 
demonstrating a lifelong dysfunction in glucose regulation in 3xTg-AD mice. In particular, 
glucose tolerance is impaired in 3xTg-AD mice at 1-3 months of age, well prior to β-amyloid 
plaque deposition, hyperphosphorylated tau accumulation or cognitive decline. 
Based on these data we selected: 1) a time point where glucose tolerance and insulin 
secretion are impaired, but no pathological or behavioral changes are seen (6-8 months); 2) a 
time point in which peripheral metabolism is altered and pathological changes are seen but 
memory is intact (16-18 months); and 3) a time point in which cognitive decline occurs along 
with impaired peripheral metabolism and neuropathology (18-20 months). Insulin signaling was 
examined at each of these time points to determine if alterations among these pathways was 
associated with alterations in peripheral glucose and insulin levels or if it occurred later.  
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Figure 3.1: Human amyloid precursor protein (APP), β-amyloid peptide 1-42 (Aβ) and human 
hyper-phosphorylated tau (p-Tau) immunoreactivities in the forebrain of 3xTg-AD mice at 1-2, 
4-6, 8-10, 14 and 18 months of age. In wild type control mice, no immunoreactivity for any of 
these epitopes was detected at any age group examined (data not shown). In comparison, 3xTg-
AD mice exhibited intraneuronal 6E10 and p-Tau staining in pyramidal neurons in the 
subiculum, and hippocampal region CA1 in 1-2 month old mice (A, C) that further increased 
with age. However, extracellular 6E10 or Aβ 1-42 immunoreactivity was not observed until 14 
months of age (J, K). By 18 months of age 3xTg-AD mice exhibited extracellular plaques with 
6E10 and Aβ 1-42 immunohistochemistry (M, N). P-tau immunoreactivity was also highly 
visible in the principal neurons of the subiculum and CA1 (O). Scale bar in “A” applies to all 
other images. Insets in “J” and “K” show plaques at higher magnification. Abbreviations:  Ctx = 
neocortex; DG = dentate gyrus; Sub = subiculum; Th = thalamus. 
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Figure 3.2: Morris water maze data from 6-10 (A), 14-16 (B), and ≥ 18 month old (C) 3xTg-AD 
and wild type control mice. Left -- Latency to find the hidden platform platform over the 5 day 
training period. No difference was observed in 6-10 month old 3xTg-AD mice compared to 
controls. By 14-16 months of age a difference in the rate of learning was noted, although by the 
5th day of training similar latencies to the hidden platform was observed in both groups. In 
contrast, the latency to the hidden platform was significantly increased on days 4 and 5 in 3xTg-
AD mice ≥ 18 months of age. Right -- Probe data revealed a significant decrease in the number 
of probe crosses and an increased latency to the first probe crossing in 3xTg-AD mice at ≥ 18 
months of age compared to controls, but not earlier. *p < 0.05; **p < 0.01 versus wild type 
values. 
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Figure 3.3: 3xTg-AD mice exhibited impaired glucose regulation following an ip bolus of 
glucose at all ages examined:  A. 1-3 months old; B. 8-10 months old; C. 17-18 months old. For 
each age group the GTT time course is shown on the left and the integrated area under the curve 
(AUC) results are shown on the right. *p < 0.05, **p < 0.01, ***p < 0.001 versus control. See 
text for details of the statistical analysis. 
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Specific Aim I: Assess CNS insulin signaling in a mouse model of AD known to exhibit 
peripheral and CNS inflammation and determine how these changes temporally correlate 
with peripheral metabolic dysfunction and AD-like neuropathology. 
 
MAPK/ERK Signaling in 3xTg-AD mice 
To begin to determine if CNS insulin signaling is altered in 3xTg-AD mice, the 
MAPK/ERK pathway was assessed using western blotting. Total levels of the MAPK/ERK p42 
and p44 subunits along with their phosphorylated versions (threonine 202 and tyrosine 204 
respectively) were examined in the hippocampus of 3xTg-AD mice at time points prior to (6-8 
months) and following the development of neuropathology and cognitive decline (18-20). 
Neither young (Fig. 3.4A) nor old (Fig. 3.4B) 3xTg-AD mice exhibit a significant change in 
either basal or activated MAPK/ERK subunits compared to wild type controls suggesting that 
MAPK/ERK signaling was not altered in 3xTg-AD mice. 
 
Figure 3.4: Hippocampal MAPK/ERK signaling was not altered in 3xTg-AD mice. (A) 
Representative immunoblot and normalized densitometric quantification of p42 and p44 subunits 
of MAPK along with their phosphorylated versions at Thr202 and Tyr204 from 6-8 month and 
(B) 18-20 month old wild type and 3xTg-AD mice. Compared to wild type controls there was no 
significant difference in any of the components of the MAPK/ERK pathway in 6-8 or 18-20 
month old 3xTg-AD mice.   
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PI3K/AKT Signaling in 3xTg-AD mice 
CNS insulin signaling was further assessed in the 3xTg-AD mouse model by examining 
the PI3K/AKT pathway using western blots to look at IRS1, phosphorylated IRS1 (ser307), 
AKT, and phosphorylated AKT (ser473) in the hippocampus of 6-8, 16-18,  and 18-20 month old 
wild type and 3xTg-AD mice. No significant changes were detected in either basal levels or 
phosphorylated versions of IRS1 or AKT in 6-8 month 3xTg-AD mice (Fig. 3.5A). However, in 
18-20 month old 3xTg-AD there was a significant decrease in the phosphorylation of IRS1 and 
AKT (Fig. 3.5C). To determine if this change correlated with Aβ plaque formation, an additional 
time point, 16-18 months was examined. There were no significant changes at this time point 
suggesting that this change correlated with the onset of cognitive impairment. Thus, the decrease 
in hippocampal PI3K/AKT signaling in 3xTg-AD mice appears to correlate with the first 
detection of cognitive impairment, but not with the appearance of either peripheral metabolic 
compromise or classical neuropathological hallmarks of AD. This suggests that changes in the 
periphery and Aβ plaque formation do not directly translate into impaired CNS insulin signaling.  
 
GSK3 and p-Tau in 3xTg-AD mice 
To begin to examine changes in downstream targets of PI3K/AKT signaling western 
blots were used to assess hippocampal levels of total GSK3α and β and their phosphorylation at 
ser21 and 9, respectively, in wild type controls and 3xTg-AD mice at 6-8, 16-18, and 18-20 
months of age. Neither basal levels nor their phosphorylated states were altered in 6-8 (Fig. 
3.6A) or 16-18 (Fig. 3.6B) month old 3xTg-AD mice compared to wild type controls. Similarly, 
there was no difference in total levels or pGSK3α in 18-20 month old 3xTg-AD mice, but 
GSK3β phosphorylation was significantly decreased (Fig. 3.6C). Since this decrease in GSK3β 
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phosphorylation was only observed at a time point when pAKT was also decreased, it suggests 
that this decrease in pGSK3β is likely the result of decreased AKT activation since AKT is a 
known regulator of GSK3 phosphorylation. Additionally, since GSK3 regulates tau 
phosphorylation we examined tau phosphorylation at sites known to contribute to the paired 
helical filament formation associated with neurofibrillary tangles, Ser396 and Ser202/Thr205. As 
expected due to transgene expression, tau phosphorylation was significantly increased in 3xTg-
AD mice compared to wild type controls at all ages examined (Fig. 3.6A, B, and C) although the 
accumulation of hyperphosphorylated tau was not observed until the 18-20 month time point. 
 
Glucose Transporters in 3xTg-AD mice 
Since PI3K/AKT signaling was decreased in old 3xTg-AD mice and insulin can regulate the 
translocation of glucose transporters to the neuronal membrane in a PI3K/AKT-dependent 
manner, GLUT3 and GLUT4 translocation was examined using western blots to look at crude 
plasma membrane and total levels of GLUT3 and GLUT4 in 6-8, 16-18, and 18-20 month old 
3xTg-AD and wild type control mice to determine if decreased PI3K/AKT signaling leads to 
decreased GLUT translocation in the hippocampus of 3xTg-AD mice. In all age groups there 
was no significant difference in total levels of GLUT3 or GLUT4 nor was there any significant 
changes in the plasma membrane levels of GLUT3 or GLUT4 in 6-8 (Fig. 3.7A) or 16-18 month 
old 3xTg-AD mice (Fig. 3.7B). Additionally, plasma membrane GLUT4 was not changed in 18-
20 month old transgenic mice. However, GLUT3 was significantly reduced in the crude plasma 
membrane of 18-20 month old 3xTg-AD mice compared to their age matched WT controls (Fig 
3.7C). suggesting that the translocation of GLUT3 is decreased. Since this change was only 
observed in the oldest age group when AKT/PI3K pathway signaling is also decreased, it is 
reasonable to conclude that this is likely the result of decreased hippocampal insulin signaling.  
 94 
 
 
 
Figure 3.5: PI3K/AKT signaling was significantly decreased in the 18-20 month old 3xTg-AD 
mouse hippocampus. Representative immunoblot and normalized densitometric quantification 
(values in Table 3.1-3.3) of IRS1, pIRS1 (ser307), AKT and pAKT (ser473) in the hippocampus 
of (A) 6-8 month, (B) 16-18 month and (C) 18-20 month old wild type and 3xTg-AD mice. No 
significant change was seen in 6-8 or 16-18 3xTg-AD mice compared to controls at either the 
total or phosphorylated levels.  In contrast, old 3xTg-AD displayed a significant decrease in 
phosphorylation of both IRS1 and AKT compared to controls, although total IRS1 and AKT 
levels were not different.  * = p < 0.05, **** = p < 0.0001. 
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Figure 3.6: 18-20 month old 3xTg-AD mice have decreased hippocampal levels of pGSK3β. 
Tau phosphorylation was increased in 3xTg-AD mice at 6-8, 16-18, and 18-20 months of age. 
Representative immunoblot and normalized densitometric quantification (values in Table 3.1-
3.3) of GSK3, GSK3, pGSK3 (Ser21), pGSK3 (Ser9), pTau (Ser396), pTau 
(Ser202/Thr205) in the hippocampus of (A) 6-8, (B) 16-18, and (C) 18-20 month old 3xTg-AD 
mice compared to wild type controls. These results demonstrate that there was no significant 
difference in GSK3α/β or pGSK3α/β in the hippocampus of young 3xTg-AD mice compared to 
controls. However, in the hippocampus of old 3xTg-AD mice there was a significant decrease in 
pGSK3β but GSK3α/β and pGSK3α were not changed. Both pTau (Ser 396) and 
(Ser202/Thr205) were significantly increased in the hippocampus of 3xTg-AD mice at all ages 
examined. * = p < 0.05, *** = p < 0.001. 
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Figure 3.7: GLUT3 translocation was significantly reduced in 18-20 month 3xTg-AD mice. 
Representative immunoblot and normalized densitometric quantification (values in Table 3.1-
3.3) from (A) 6-8, (B) 16-18, and (C) 18-20 month old 3xTg-AD mice compared to wild type 
controls. GLUT3 and GLUT4 total levels were not altered at 6-8, 16-18, or 18-20 months in the 
hippocampus of 3xTg-AD mice. Additionally, there was no significant difference in plasma 
membrane levels of GLUT3 or GLUT4 in 6-8 or 16-18 month old 3xTg-AD mice. In contrast 
plasma membrane GLUT3 was significantly reduced in the plasma membrane in the 
hippocampus of 18-20 month old 3xTg-AD mice compared to WT controls, though no 
differences was seen in plasma membrane GLUT4 at this age. These results suggest that 
translocation of GLUT3 was decreased in old 3xTg-AD mice. **** = p < 0.0001.  
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Table 3.1: 6-8 month insulin signaling western blot values. Wild type values are normalized to 1 
and all values are expressed as the mean ± SEM. p-values were obtained using a nonpaired 
student’s T-test to compare wild types to 3xTg-AD mice 
 
Protein 
Wild-type NOD 
(mean  ±  SE) 
3xTg-AD NOD 
(mean  ±  SE) 
p-value 
MAPK 1 ± 0.02; n = 9 1.08 ± 0.06; n = 8 p = 0.15 
MAPK 1 ± 0.04; n = 9 1.12 ± 0.07; n = 8 p = 0.13 
pMAPK 1 ± 0.04; n = 9 0.88 ± 0.08; n = 8 p = 0.41 
pMAPK 1 ± 0.06; n = 9 1.07 ± 0.05; n = 8 p = 0.32 
IRS1 1 ± 0.07; n = 9 0.95 ± 0.17; n = 8 p = 0.77 
pIRS1 (ser612) 1 ± 0.13; n = 9 1.10 ± 0.15; n = 8 p = 0.63 
AKT 1 ± 0.09; n = 9 0.95 ± 0.08; n = 8 p = 0.71 
pAKT (ser473) 1 ± 0.06; n = 8 1.28 ± 0.34; n = 8 p = 0.44 
GSK3a 1 ± 0.02; n = 8 0.96 ± 0.05; n = 8 p = 0.53 
GSK3b 1 ± 0.02; n = 8 1.01 ± 0.04; n = 8 p = 0.90 
pGSK3a 1 ± 0.08; n = 9 0.92 ± 0.06; n = 8 p = 0.43 
pGSK3b 1 ± 0.08; n = 9 1.00 ± 0.06; n = 8 p = 1.00 
pTau 1 ± 0.04; n = 5 1.81 ± 0.23; n = 6 p ≤ 0.05 
pTau (Ser396) 1 ± 0.11; n = 5 3.06 ± 0.35; n = 6 p ≤ 0.001 
GLUT3 TM 1 ± 0.05; n = 6 1.03 ± 0.09; n = 6 p = 0.15 
GLUT3 PM 1 ± 0.04; n = 6 1.11 ± 0.12; n = 6 p = 0.13 
GLUT4 TM 1 ± 0.13; n = 6 1.05 ± 0.07; n = 6 p = 0.32 
GLUT4 PM 1 ± 0.04; n = 6 0.94 ± 0.05; n = 6 p = 0.32 
 
 
Table 3.2: 14-16 month insulin signaling western blot values Wild type values were normalized 
to 1 and all values are expressed as the mean ± SEM. p-values were obtained using a nonpaired 
student’s T-test to compare wild types to 3xTg-AD mice. 
 
Protein 
Wild-type NOD 
(mean  ±  SE) 
3xTg-AD NOD 
(mean  ±  SE) 
p-value 
IRS1 1 ± 0.07; n = 9 0.95 ± 0.17; n = 8 p = 0.77 
pIRS1 (ser612) 1 ± 0.13; n = 9 1.10 ± 0.15; n = 8 p = 0.63 
AKT 1 ± 0.09; n = 9 0.95 ± 0.08; n = 8 p = 0.71 
pAKT (ser473) 1 ± 0.06; n = 8 1.28 ± 0.34; n = 8 p = 0.44 
GSK3a 1 ± 0.02; n = 8 0.96 ± 0.05; n = 8 p = 0.53 
GSK3b 1 ± 0.02; n = 8 1.01 ± 0.04; n = 8 p = 0.90 
pGSK3a 1 ± 0.08; n = 9 0.92 ± 0.06; n = 8 p = 0.43 
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pGSK3b 1 ± 0.08; n = 9 1.00 ± 0.06; n = 8 p = 1.00 
pTau 1 ± 0.04; n = 5 1.81 ± 0.23; n = 6 p ≤ 0.05 
pTau (Ser396) 1 ± 0.11; n = 5 3.06 ± 0.35; n = 6 p ≤ 0.001 
GLUT3 TM 1 ± 0.27; n = 7 1.50 ± 0.16; n = 7 p = 0.15 
GLUT3 PM 1 ± 0.17; n = 7 1.01 ± 0.13; n = 7 p = 0.13 
GLUT4 TM 1 ± 0.06; n = 7 1.39 ± 0.18; n = 7 p = 0.32 
GLUT4 PM 1 ± 0.16; n = 7 0.75 ± 0.08; n = 7 p = 0.32 
 
 
Table 3.3: 18-20 month insulin signaling western blot values. Wild type values were normalized 
to 1 and all values are expressed as the mean ± SEM. p-values were obtained using a nonpaired 
student’s T-test to compare wild types to 3xTg-AD mice. 
  
Protein 
Wild-type NOD 
(mean  ±  SE) 
3xTg-AD NOD 
(mean  ±  SE) 
p-value 
MAPK 1 ± 0.02; n = 8 1.12 ± 0.07; n = 9 p = 0.14 
MAPK 1 ± 0.05; n = 8 0.99 ± 0.07; n = 9 p = 0.88 
pMAPK 1 ± 0.04; n = 8 0.89 ± 0.05; n = 9 p = 0.11 
pMAPK 1 ± 0.04; n = 8 0.90 ± 0.04; n = 9 p = 0.08 
IRS1 1 ± 0.12; n = 8 0.82 ± 0.21; n = 9 p = 0.49 
pIRS1 (ser612) 1 ± 0.15; n = 8 0.50 ± 0.10; n = 8 p ≤ 0.05 
AKT 1 ± 0.11; n = 8 0.97 ± 0.06; n = 8 p = 0.77 
pAKT (ser473) 1 ± 0.01; n = 7 0.50 ± 0.07; n = 8 p ≤ 0.0001 
GSK3a 1 ± 0.03; n = 8 0.95 ± 0.02; n = 8 p = 0.19 
GSK3b 1 ± 0.01; n = 7 0.96 ± 0.03; n = 9 p = 0.35 
pGSK3a 1 ± 0.07; n = 8 0.82 ± 0.13; n = 9 p = 0.25 
pGSK3b 1 ± 0.06; n = 8 0.62 ± 0.06; n = 8 p ≤ 0.001 
pTau 1 ± 0.02; n = 5 1.57 ± 0.50; n = 6 p ≤ 0.05 
pTau (Ser396) 1 ± 0.09; n = 5 2.74 ± 0.23; n = 6 p ≤ 0.0001 
GLUT3 TM 1 ± 0.06; n = 13 1.02 ± 0.12; n = 14 p = 0.15 
GLUT3 PM 1 ± 0.11; n = 13 0.49 ± 0.08; n = 13 p = 0.13 
GLUT4 TM 1 ± 0.08; n = 14 1.04 ± 0.05; n = 14 p = 0.32 
GLUT4 PM 1 ± 0.07; n = 14 1.16 ± 0.12; n = 13 p = 0.32 
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Specific Aim II: Determine whether the expression of Kir6.2, a downstream target of 
insulin is altered in AD and epilepsy.  
 
Reactive astrogliosis in 3xTg-AD mice 
Since Alzheimer’s disease is associated with neuroinflammation, astrogliosis was assessed in the 
hippocampus of 3xTg-AD mice at a time point when neuropathological changes and cognitive 
decline were present (18-20 MOA) by determining the level of GFAP using immunoblotting. 
IHC was also used to confirm the western blot experiments and further assess hippocampal 
region CA1 since CA1 is preferentially affected in AD. Immunoblotting revealed a significant 
increase in the level of GFAP protein in 3xTg-AD mice compared to controls (Fig. 3.8A). Next 
the morphology of GFAP-IR astrocytes was examined in hippocampal region CA1 of 3xTg-AD 
and wild-type mice (n = 4 per group). GFAP-IR was dramatically increased throughout CA1 in 
3xTg-AD (Fig. 3.8C) mice compared to controls (Fig. 3.8B). At higher magnification, increased 
GFAP staining was seen in astrocytes in the SR in 3xTg-AD mice (Fig. 3.8F) compared to 
control (Fig. 3.8D) as well as in astrocytes in the ALV (Fig. 3.8G, E) and SO (not shown). This 
suggests that both astrocytes in the gray and white matter (i.e. protoplasmic and fibrous 
astrocytes respectively) become reactive in AD.  
 
Kir6.1 in 3xTg-AD mice 
KATP channels have been shown to be a potential therapeutic target of AD, however their 
expression in AD has not been examined. Further, KATP channels have been shown to be 
insulin sensitive and link together cellular activity and metabolism. AD is characterized, in part, 
by hippocampal hypometabolism and in aim 1 we demonstrated that 3xTg-AD mice exhibit 
impaired CNS insulin signaling. Subsequently, we examined whether the expression and or 
distribution of the Kir6.1 and Kir6.2 subunits of KATP channels is altered in 3xTg-AD mice at 
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18-20 months of age, a time point when CNS insulin is impaired. To begin to assess these 
channels in 3xTg-AD mice, total and crude plasma membrane levels of one of the pore-forming 
subunits, Kir6.1, were examined using immunoblotting. As demonstrated in Fig. 3.6A, neither 
total nor plasma membrane Kir6.1 was altered in 3xTg-AD compared to wild-type controls. 
Next, IHC was performed for Kir6.1 (n = 4 per group) to assess regional and cell type-specific 
differences. As previously described, Kir6.1-IR was seen in the neuronal somata in SP, in 
presumptive interneurons in SR and SO, and in the neuropil in CA1 which was previously 
suggested to be intra-astrocytic based on EM studies (Zhou et al., 1999, Fig. 11; Thomzig et al., 
2001, Fig. 3.9A; Thomzig et al., 2005). Additionally, some astrocytic cell body labeling was also 
seen in the ALV (Fig. B). Consistent with western blot data, wild-type (Fig. 3.9B) and 3xTg-AD 
(Fig. 3.9C) mice displayed no stark differences in staining patterns or intensity in hippocampal 
region CA1. 
 
Kir6.2 in 3xTg-AD mice 
Following examination of Kir6.1, similar experiments were ran for the other pore-forming 
subunit, Kir6.2. As shown in Fig. 3.10A, a significant increase in crude plasma membrane Kir6.2 
was found in 3xTg-AD mice though no change was noted in Kir6.2 in the total protein sample. 
To further evaluate this change, regional and cell type-specific changes were assessed using IHC 
(n = 4 per group). Kir6.2-IR appeared to have a similar staining pattern in wild type control mice 
to what has been previously reported with somatic and dendritic processes labeled in SP neurons 
and interneuron cell bodies in SR and SO, with very little astrocytic staining (Thomzig et al., 
2001, Fig. 3.10B; Thomzig et al., 2005, Fig. 3H; Zhou et al., 2002, Fig. 3.10B). Similar to wild 
types, 3xTg-AD sections displayed Kir6.2-IR in pyramidal cells and interneurons with no 
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detectable change in its relative distribution though a slight reduction in Kir6.2-IR was seen in 
SP in some sections. Most surprisingly however, was a dramatic increase in Kir6.2-IR in 
presumptive reactive astrocytes throughout SR, SO and the ALV in 3xTg-AD mice compared to 
WT controls (Fig. 3.10C). This staining appeared to be primarily localized to the somata and 
primary processes of presumptive reactive astrocytes and higher magnification revealed an 
increase in Kir6.2-IR in 3xTg-AD mice in cells with a morphology characteristic of reactive 
astrocytes in SR (Fig. 3.10F), SO (not shown), and the ALV (Fig. 3.10G) suggesting that both 
protoplasmic and fibrous astrocytes exhibit increased Kir6.2. To ensure that our antibody was 
specific and astrocytic-like cell staining was real, both wild type and 3xTg-AD samples were ran 
with an additional Kir6.2 antibody (rabbit polyclonal anti-Kir6.2, sc-20809, 1:100; Santa Cruz, 
Dallas, TX). As shown in Fig. 3.10 similar results were obtained. 
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Fig. 3.8: Astrogliosis in 3xTg-AD mice. (A) Representative immunoblot and normalized 
densitometric quantification (values in Table 3.4) of GFAP in the hippocampus of wild type and 
3xTg-AD mice. GFAP was significantly increased in 3xTg-AD mice compared to wild-type 
controls (∗ = p < 0.05). GFAP-IR in hippocampal region CA1 of (B) a wild-type mouse and (C) 
a 3xTg-AD mouse. Rectangular boxes denote protoplasmic astrocytes of SR and fibrous 
astrocytes of the ALV for the wild-type and 3xTg-AD mice and images shown at higher 
magnification in (D-G). 3xTg-AD mice displayed extensive astrogliosis in hippocampal region 
CA1 compared to controls. This increased GFAP-IR was observed throughout all hippocampal 
lamella. GFAP-IR was increased in fibrous astrocytes within the alveus and in protoplasmic 
astrocytes in the SO, SP and SR. Circles on the figure denote areas of astrocytic overlap 
suggesting that their domain structure may be somewhat altered. Figure published in Griffith et 
al., 2017.  
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Fig. 3.9: Kir6.1 was not altered in 3xTg-AD compared to wild-type controls. (A) Sample 
immunoblot and normalized densitometric quantification (values in Table 3.4) of plasma 
membrane and total Kir6.1 in wild-type and 3xTg-AD mice revealed no significant difference in 
3xTg-AD mice compared to controls. Kir6.1-IR in hippocampal region CA1 of (B) a wild-type 
mouse and (C) a 3xTg-AD mouse. Kir6.1-IR was seen in neuronal somata in SP and in 
presumptive interneurons in the SR and SO. There was no visible difference in Kir6.1-IR 
between groups. Figure published in Griffith et al., 2017.  
 104 
 
 
 
Figure 3.10: Plasma membrane Kir6.2 was significantly increased in 3xTg-AD mice compared 
to wild-type controls. (A) Sample immunoblot and normalized densitometric quantification 
(values in Table 3.4) of Kir6.2 revealed that while total Kir6.2 was not altered, plasma 
membrane Kir6.2 was significantly increased in 3xTg-AD mice compared to controls. Kir6.2-IR 
in hippocampal region CA1 of (B) a wild-type mouse and (C) a 3xTg-AD mouse shows an 
increase in Kir6.2-IR in SO, SR and the ALV in cells with an astrocytic morphology along with 
an apparent decrease in Kir6.2 in SP neurons in the 3xTg-AD mouse. Boxed regions in (B and 
C) display higher magnification images of presumptive protoplasmic astrocytes in the SR in (D) 
wild type and (F) 3xTg-AD mice and presumptive fibrous astrocytes in the alveus of (E) a wild-
type mouse and (G) a 3xTg-AD mouse. * = p < 0.025. Figure published in Griffith et al., 2017.  
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Table 3.4: KATP channel western blot values. Wild type values were normalized to 1 and all 
values are expressed as the mean ± SEM. p-values were obtained using a nonpaired student’s T-
test to compare wild types to 3xTg-AD mice.  
 
Protein 
Wild-type NOD 
(mean  ±  SE) 
3xTg-AD NOD 
(mean  ±  SE) 
p-value 
GFAP 1 ± 0.05; n = 12 1.17 ± 0.05; n = 12 p < 0.05 
PM Kir6.1 1 ± 0.04; n = 11 1.10 ± 0.12; n=11 p = 0.45 
Total Kir6.1 1 ± 0.04; n = 11 1.19 ± 0.09; n =11 p = 0.06 
PM Kir6.2 1 ± 0.06; n = 12 1.60 ± 0.24; n = 11 p = 0.02 
Total Kir6.2 1 ± 0.07; n = 12 1.21 ± 0.14; n = 12 p = 0.16 
 
 
 
 
Figure 3.11: The Santa Cruz antibody reveals a similar staining pattern for Kir6.2 to that of the 
Alomone labs antibody. As seen in the wild type a similar staining pattern for Kir6.2 was 
observed with this additional antibody. Further, presumptive astrocytes were also seen to be 
labeled with this Kir6.2 antibody in the 3xTg-AD mouse.  
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Kir6.2 in reactive astrocytes in 3xTg-AD mice 
To determine if Kir6.2-IR cells with an astrocytic morphology in the CA1 of 3xTg-AD 
hippocampi were indeed reactive astrocytes, triple immunofluorescence in conjunction with the 
nuclear stain 4',6-diamidino-2-phenylindole (DAPI) was used in sections from 18-20 month old 
wild type and 3xTg-AD mice (n = 4 per group). DAPI was used to assess cellular lamination 
while antibodies for β-tubulin and GFAP were used to label neurons and astrocytes respectively 
(Fig. 3.12). DAPI exhibited dense staining in SP and ALV and had more dispersed labeling in 
SR and SO. DAPI staining patterns between 3xTg-AD and control mice were similar suggesting 
that hippocampal lamination was retained. The intensity of DAPI staining was however 
somewhat decreased in 3xTg-AD mice suggesting that either some cell loss of altered lamination 
may occur. The somata and apical dendritic processes of the pyramidal neurons in SP along with 
interneurons in the SR and SO were strongly labeled with β-tubulin. Oddly, β-tubulin-IR in SR 
and SO appeared to be somewhat increased in 3xTg-AD mice relative to wild-type controls (B2 
compared to A2). GFAP clearly labeled cells with an astrocytic appearance in both groups but, 
3xTg-AD mice displayed an increase in GFAP-IR in SR, SO and the ALV (B3) as was 
previously seen with DAB-IHC. However, there were some differences between GFAP staining 
with immunofluorescence versus immunoperoxidase in SP. Specifically, DAB-IHC revealed 
clearly labeled astrocytic somata and processes in SP. A similar specific staining pattern was 
seen in SP with immunofluorescence, although there was additional non-specific staining that 
exhibited both intra and inter-group variability. This is presumably the result of an age-related 
increase in autofluorescense with neuronal-like fluorophores (e.g., lipofuscin, ceroid) and the 
light wavelength used to activate Alexa Fluor-488 for GFAP identification. Indeed, control 
experiments using a different Alexa Fluor (647) reduced this non-specific staining in the SP. 
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Kir6.2-IR was observed in the neuropil of SR and SO and in the pyramidal cell body layer in 
both groups. Pyramidal cell labeling did appear to be decreased in some 3xTg-AD sections (B4 
versus A4). However, this difference was not consistent throughout sections. The most striking 
difference between groups was the increase in Kir6.2-IR in cells with an astrocytic morphology 
in SR, SO and the ALV in 3xTg-AD sections. Co-localization confirmed that the observed 
increase in Kir6.2-IR was present in these GFAP-IR labeled cells. Upon higher magnification 
some sections from wild-type mice were seen to also display faint Kir6.2-IR in GFAP-IR cells, 
although this appeared to be primarily restricted to the somata with very little staining in their 
processes. In contrast, a clear increase in the co-localization of Kir6.2-IR and GFAP-IR was seen 
in 3xTg-AD mice in SR, SO and ALV and appeared to be localized to the processes of GFAP-
labeled astrocytes (4F). Additionally, both protoplasmic (SR and SO) and fibrous astrocytes 
(ALV) displayed an increase in co-localization of GFAP and Kir6.2 (Fig. C1–F3; SO not 
shown). These results suggest that this change occurs throughout the hippocampus rather than 
only in the vicinity of plaques since plaques primarily occur in gray matter. 
To get a more quantitative assessment of astrocytic Kir6.2, GFAP-IR astrocytes in SR, SO and 
the ALV and the number of GFAP-IR cells that exhibited Kir6.2-IR were counted and a Mann–
Whitney U test was used to determine significance where the degree of freedom was 6 and a p-
value of <0.05 was considered significant. This revealed that the number of Kir6.2-IR and 
GFAP-IR co-labeled cells in CA1 of 3xTg-AD mice was significantly increased in SO and ALV 
but not in SR compared to wild-type controls. Interestingly, the total number of GFAP-IR cells 
was not significantly different in SR or SO but was significantly increased in the ALV of 3xTg-
AD sections, compared to wild-type controls.  
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Figure 3.12: Kir6.2-IR was increased in GFAP labeled cells. Triple immunofluorescent labeling 
with DAPI in hippocampal region CA1 of (A) a wild-type mouse and (B) a 3xTg-AD mouse. 
Single channel images of (1) DAPI, (2) β-tubulin, (3) GFAP, and (4) Kir6.2 are shown along 
with (5) a merged image of all 4 channels. Higher magnification images of boxes in A5 and B5 
are shown in the lower panels displaying astrocytes in the SR (C, D) and the alveus (E, F) of 
wild-type and  3xTg-AD mice respectively. For each series the single channel image for (1) 
GFAP, (2) Kir6.2, and (3) the merged image are shown. While there does appear to be astrocytic 
Kir6.2 in the wild-type sections (C, E), there was an increase in Kir6.2-IR present in the reactive 
astrocytes from the 3xTg-AD sections (D, F). Figure published in Griffith et al., 2017.  
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Table 3.5: Kir6.2 and GFAP cell counts in SR, SO and ALV of 3xTg-AD mice. There was no 
significant difference in the number of astrocytes observed in either the SR, or SO in 3xTg-AD 
mice compared to controls, although there was a significant increase in the alveus. In contrast, 
the percentage of reactive astrocytes in the 3xTg-AD mice that exhibited Kir6.2-IR was 
significantly greater than that observed in controls in the stratum oriens and alveus but not in the 
stratum radiatum. Table published in Griffith et al., 2017.  
 
 
Stratum Radiatum Stratum Oriens  Alveus 
 # GFAP-
IF cells 
# Cells 
GFAP and 
Kir6.2-IF 
% co-
labeled 
# GFAP-
IF cells 
# Cells 
GFAP and 
Kir6.2-IF 
% co-
labeled 
# GFAP-
IF cells 
# Cells 
GFAP and 
Kir6.2-IF 
% co- 
labeled 
Wild Type    
1 148 49 33.1% 128 50 39.1% 118 37 31.4% 
2 130 48 36.9% 108 47 44.5% 72 14 19.4% 
3 165 66 40.0% 96 44 45.8% 87 27 31.0% 
4 180 110 61.1% 136 74 54.4% 123 47 38.2% 
Mean 155.75 68.25  117 53.75  100 31.25  
SEM 10.79 14.52  6.86 9.15  12.27 7.05  
3xTg-AD    
1 107 92 86.0% 135 104 77.0% 145 119 82.1% 
2 159 154 96.9% 147 132 89.8% 156 143 91.7% 
3 172 126 73.3% 132 108 81.8% 146 125 85.6% 
4 138 129 93.5% 127 112 88.2% 138 119 86.2% 
Mean 144 125.25  135.25 114  146.25 126.5  
SEM 14.18 12.74  6.22 4.25  3.71 5.68  
p - 
value 
0.6857 0.0571  0.3429 0.0286  0.0286 0.0294 
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Glutamine synthetase in Kir6.2 positive cells  
GFAP only labels approximately 80% of astrocytes in hippocampal region CA1 (Olabarria et al. 
2010) and has also been shown to label glial and neuronal progenitor cells in other hippocampal 
regions (Weiss et al. 1996; Doetsch et al. 1999; Laywell et al. 2000). Thus, an additional 
astrocytic marker, GS, was used to verify that the GFAP-IR cells were indeed reactive 
astrocytes. First, to confirm overlap of GFAP and GS, we looked at dual IF of GFAP and GS 
(Fig. 3.13), which demonstrated that the same cells contained both proteins. Upon examination 
of GS, a decrease in GS-IR was noted in the sections from old 3xTg-AD mice, relative to 
controls (Fig. 3.14A1, B1) similar to what has been reported in human tissue (Le Prince et al., 
1995; Robinson, 2001) and in 3xTg-AD mice (Olabarria et al. 2010). Despite this phenotypic 
difference in GS-IR, merged images clearly showed increased co-localization of GS-IR and 
Kir6.2-IR in reactive astrocytes throughout SR, SO and the ALV of CA1 in 3xTg-AD sections 
compared to control. Examination at higher magnification (Fig. 3.14C1-F3) clearly revealed GS-
IR and Kir6.2-IR co-localization in SR, ALV and SO (not shown) in sections from 3xTg-AD 
mice with very little co-localization seen in wild-type control sections. 
 
Figure 3.13: GFAP positive cells displayed co-localization with GS. Astrocytes labeled with 
GFAP are shown in red and glutamine synthetase is in green.  
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Figure 3.14: Kir6.2-IR was increased in GS labeled cells. Triple immunofluorescent labeling 
with DAPI in hippocampal region CA1 of (A) a wild-type mouse and (B) a 3xTg-AD mouse. 
Single channel images of (1) DAPI, (2) β-tubulin, (3) GS, and (4) Kir6.2 are shown along with 
(5) a merged image of all 4 channels. Higher magnification images of boxes in A5 and B5 are 
shown in the lower panels displaying astrocytes in the SR (C, D) and the ALV of (E, F) of wild-
type and  3xTg-AD mice respectively. For each series the single channel image for (1) GS, (2) 
Kir6.2, and (3) the merged image are shown. This further demonstrates that Kir6.2 -IR cells were 
indeed astrocytes and that Kir6.2 was increased in reactive astrocytes in 3xTg-AD mice. Figure 
published in Griffith et al., 2017.  
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Kir6.2 in human AD-tissue 
To confirm the presence of aberrant Kir6.2 expression in reactive astrocytes in human 
AD, GFAP and Kir6.2 were examined in hippocampi from human AD and non-AD cases post-
mortem. Overall, GFAP-IR was increased in CA1 in AD cases compared to non-AD cases (Fig. 
3.15). The labeled cells were mostly located in SO and the ALV, and displayed a typical 
astrocytic morphology as shown at higher magnification (B, C, E, F). In non-AD cases, Kir6.2 
labeling was predominantly in SP, localizing to the pyramidal neurons (G, I). The labeling in the 
pyramidal neurons appeared to be similar between AD and non-AD controls (J, L), but there was 
an increase in Kir6.2 labeling in SO and the ALV in the AD cases compared to non-AD cases 
(G, H, J, K). Examination at higher magnification revealed that these cells appeared to have an 
astrocytic morphology (K). The numerical density of GFAP-IR cells in SO and ALV was 
significantly increased in the AD group (76.3 ± 6.5 cells/mm2) relative to the non-AD group 
(19.9 ± 2.7 cells/mm2) (p = 0.0002) (Fig. 3.15M). Quantification of Kir6.2-labeled cells in SO 
and the ALV were also significantly increased in the AD group (165.5 ± 9.0 cells/mm2) 
compared to controls (31.9 ± 16.3 cells/mm2) (p = 0.0002) (O). In contrast, Kir6.2-labeled cells 
in the SP was comparable between the two groups, suggesting that there was no change in Kir6.2 
in human pyramidal neurons in AD, (AD vs. control, 172.1 ± 11.6 vs. 166.6 ± 13.2 cells/mm2).  
To confirm that Kir6.2 IR was indeed in GFAP-IR reactive astrocytes in the human 
hippocampi, dual immunofluorescence was done (Fig. 3.16). In general, Kir6.2 and GFAP co-
localization could be seen in both aged and AD cases, with only a few Kir6.2/GFAP labeled cells 
present in SO and ALV in controls (A–D) that exhibited an astrocytic morphology (E–H). In 
comparison, the number of Kir6.2 and GFAP double-labeled cells that exhibited an astrocytic-
like morphology in SO and the ALV in the AD group (I–P) was dramatically increased. 
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Figure 3.15: GFAP and Kir6.2 DAB-IHC in human tissue. (A–C) GFAP-IR in CA1 of a non-
AD hippocampus. (D–F) GFAP-IR in CA1 of a hippocampal section from an AD case. (G) 
Kir6.2-IR in CA1 of the non-AD hippocampus. Higher magnifications of the ALV and SP 
(boxes marked in (G)) are shown in (H) and (I) respectively. (J) Kir6.2-IR in CA1 of an AD 
hippocampus. Higher magnifications of the ALV and SP (boxes marked in (J)) are shown in (K) 
and (L) respectively. (M) Relative density of GFAP in SO/ALV in human AD versus age-
matched control tissue. (N, O) Relative density of Kir6.2-IR in SP and SO/ALV respectively in 
control versus AD tissue. Quantitative analysis revealed a significant increase in Kir6.2-IR 
preferentially in the SO/ALV region that is primarily devoid of principal neurons yet abundant in 
astrocytes. No change in Kir6.2-IR was observed in SP. Scale bar = 200 μm in (A), (D), (G), and 
(J); equivalent to 80 μm for the middle column panels and 20 μm for the right column panels. * = 
p < 0.05. Figure published in Griffith et al., 2017.  
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Figure 3.16: Kir6.2-IR was increased in GFAP labeled cells in human AD tissue. Dual 
immunofluorescent staining with DAPI in CA1 of a control (A–D) and AD (I-L) hippocampus. 
Single channel images of DAPI (A, I), Kir6.2 (B, J), and GFAP (C, K) are shown along with a 
merged image of the 3 channels (D, L). Higher magnification images of the same channels 
demarcated by the box in D and L are shown in (E-H) and (M-P) respectively. Scale 
bar = 100 μm in (A), to (B–D), and (I–L), scale bar equals 50 μm for the remaining panels. These 
data reveal that Kir6.2 and GFAP co-localization was increased in human AD-hippocampus 
compared to controls.  
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Pilocarpine Mouse Model of TLE: Confirmation of Epilepsy 
Since AD and TLE share numerous characteristics (e.g. hippocampal hypometabolism, 
neuroinflammation, decreased hippocampal dependent learning and memory, and an increased 
susceptibility for eleptiform activity), KATP channels were also examined in the pilocarpine 
mouse model of TLE. To verify that the mice treated with pilocarpine underwent a sufficient 
insult to trigger epileptogenesis, mice were first behaviorally assessed during pilocarpine-
induced status epilepticus since ≥3 -4 convulsive seizures induces epilepsy in nearly all mice 
treated. All but 1 mouse developed this phenotype. A portion of these mice were sacrificed 24 
hours following the initial bout of SE while a second group was allowed to survive and were 
assessed over the next 3 months for spontaneous recurrent seizures. All of the mice in this group 
exhibited at least one spontaneous generalized seizure prior to sacrifice.  
 In addition to behavioral confirmation of epilepsy, histological examination was done by 
looking at cresyl violet staining to verify cell loss in the hippocampus and dentate MF sprouting 
(Fig 3.17) since these are hallmark features of temporal lobe epilepsy (Buckmaster & Dudek 
1997; Curia et al. 2008; Tang & Loke 2010). No obvious cell loss was observed in the 
hippocampal formation in mice 24-48 hours after pilocarpine-induced status epilepticus (B). 
However, epileptic mice exhibited dramatic cell loss in the hilus, CA1 and CA3 (C). 
Additionally, the cross-sectional area of the hippocampal formation appeared to be dramatically 
decreased in epileptic groups compared to controls (i.e. was sclerotic).  
As noted mossy fiber sprouting was also examined using BACE1 IHC since BACE1 
immunolabeling is present in normal and sprouted mossy fibers in pilocarpine-induced epileptic 
mice (Yan et al. 2012b). BACE1 immunolabeling in saline-treated controls and mice 24–48 h 
after pilocarpine induced status epilepticus was observed in the mossy fibers in the hilus and 
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CA3 (Fig. 3.17). Slightly increased BACE1-IR was observed in these locations in pilocarpine-
induced epileptic mice (E, F). Further, epileptic mice also exhibited a clear band of BACE1 
labeling in the inner molecular layer of the dentate gyrus consistent with mossy fiber sprouting 
(F). 
 
 
Figure 3.17: Histological verification of hippocampal cell loss and mossy fiber sprouting in 
pilocarpine-induced epileptic mice. Hippocampal cell loss was visualized using cresyl violet. 
Cresyl violet staining in saline controls (A), mice that were sacrificed 24-48 hours following 
status epilepticus (B) and pilo-induced epileptic mice (C). Additionally, mossy fiber sprouting 
was examined using Bace1 IHC in these same groups (D, E, F).  
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GFAP in Epileptic Mice 
To confirm that our epileptic mice display reactive astrogliosis and thus 
neuroinflammation, GFAP-IR was examined using DAB-IHC in the hippocampus of saline-
treated, post-status, and epileptic mice (Fig. 3.18). GFAP-IR was increased throughout the 
hippocampus following status epilepticus (B) compared to controls (A) and continued to increase 
in the epileptic mice (C). This change was further demonstrated at higher magnification in both 
the CA1 (D-F) and the DG (G-I). Further, higher magnification images really displayed the 
hypertrophy of these cells (J-O). In general, these GFAP-IR cells had the classical morphology 
of reactive astrocytes (CA1 & dentate molecular layer). However, there also did appear to be 
some GFAP-IR cells that did not exhibit classical astrocytic morphology in the subgranular zone 
(SGZ) of the dentate gyrus which could potentially be GFAP labeled neuroprogenitor cells or 
newly generated granule cells (K, M, O) are seen in the DG of epileptic mice and is consistent 
with prior data reporting dentate granule cell proliferation following status epilepticus (Parent et 
al. 1997; Danzer 2012). 
 
Kir6.2 in Epileptic Mice 
Kir6.2 IHC was performed to examine the distribution and levels of Kir6.2 in short-term 
vs. long-term pilocarpine-treated mice (i.e. post-status vs. epileptic) as well as in controls (Fig. 
3.19). Kir6.2-IR appeared to be similar throughout the hippocampus in control and post-status 
mice. However, in epileptic mice an increase in Kir6.2-IR was present in cells with a 
morphology typical or reactive astrocytes appearance throughout the hippocampus. In addition, 
to this finding cells that did not display an astrocytic-morphology but were labeled with GFAP in 
the subgranular zone of the dentate gyrus also exhibited Kir6.2-IR. Based on their appearance, 
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these cells could be neuroprogenitor cells or newly generated granule cells suggesting that not 
only reactive astrocytes and have an increase in Kir6.2 in epileptic mice. Identification of these 
cells would require the use of additional markers for progenitors or newly generated neurons and 
were outside the scope of the current project.   
 
 
Figure 3.18: GFAP-IR was increased in pilocarpine-treated mice. (A-C) GFAP-IR in the 
hippocampus of saline-treated, post-status and epileptic mice. Higher magnification of the boxes 
demarcated in A-C show GFAP-IR in CA1 (D-E) and the DG (F-H) respectively. Astrocytic 
morphology and hypertrophy are displayed in the higher magnification images of (D-I) in (J-O). 
(K, M, O) GFAP-IR cells that do not have a classical morphology of reactive astrocytes were 
also seen in the subgranular region of the dentate gyrus. Based on their appearance and location 
they are likely to be neural progenitor cells or newly generated granule cells. Overall epileptic 
mice display a stark increase in GFAP-IR compared to both other groups suggesting reactive 
astrogliosis in epileptic mice.  
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Figure 3.19: Kir6.2-IR was increased in astrocytic-like cells in pilocarpine-induced epileptic 
mice. (A-C) Kir6.2-IR in saline-treated, post-status and epileptic mice in the hippocampus. 
Higher magnification of the boxes demarcated in A-C show Kir6.2-IR in CA1 (D-E) and the DG 
(F-H). The morphology of Kir6.2-IR cells are seen at higher magnification in the images in (D-I) 
and (J-O). (K, M, O) Cells without a typical astrocytic appearance also showed Kir6.2-IR in 
sections from pilocarpin-induced epileptic mice. Overall, Kir6.2 was increased throughout the 
entire epileptic hippocampus in cells that appear to have an astrocytic-like appearance.  
 
Kir6.2 in Reactive Astrocytes in Epileptic Mice 
To determine if the Kir6.2-IR cells with an astrocytic morphology in hippocampal region CA1 of 
epileptic mice were indeed reactive astrocytes, double immunofluorescence (GFAP and Kir6.2) 
with DAPI was used in saline-treated control and pilocarpine-treated post-status and epileptic 
mice (Fig. 3.20). DAPI was used to assess cellular lamination revealing that while post-status 
and controls exhibit a similar hippocampal lamination pattern, this was completely lost in 
epileptic mice with extensive loss of the CA1 pyramidal cell layer. GFAP was used as an 
astrocytic marker and it clearly labeled cells with an astrocytic-like appearance in all three 
 120 
 
groups. GFAP-IR was increased in post-status mice compared to saline-treated controls and was 
further increased in epileptic animals throughout hippocampal region CA1 (C) as was previously 
noted with DAB-IHC. A similar distribution and intensity of Kir6.2-IR was observed between 
controls and post-status animals in SR, SO, and SP. In contrast, in epileptic mice, where CA1 
lamination was severely perturbed due to neuronal loss, there was a tremendous increase in 
Kir6.2-IR in the region where SP typically is in controls. Co-localization of Kir6.2 and GFAP-IR 
confirmed that these Kir6.2-IR cells were also GFAP-IR suggesting reactive astrogliosis 
following neuronal loss in this region as has been previously described. These GFAP-IR cells 
appear to form a glial scar in the area where CA1 is lost. Upon higher magnification one can 
observe that while there was no to very little overlap between GFAP and Kir6.2 in saline and 
post-status animals, GFAP-IR was highly co-labeled with Kir6.2-IR in astrocytic-like cells in the 
epileptic animals 
In addition to CA1, the DG was also assessed in these animals (Fig. 3.21). Unlike CA1, 
lamination was retained in the DG of epileptic mice and is displayed using the DAPI staining 
although hilar neuron loss was seen. Similar to what was seen in CA1, an increase in GFAP-IR 
was noted in the post-status DG that was further increased in the DG of epileptic mice. Kir6.2-IR 
did not appear to differ in the granule cell layer of the DG in the 3 groups, although there does 
appear to be a substantial increase in Kir6.2-IR in cell layers with an astrocytic morphology in 
the ML and hilus of the DG in sections from epileptic mice. Again co-localization studies reveal 
that these cells do display GFAP-IR suggesting they are indeed reactive astrocytes. Higher 
magnification images further display this change and show that while there is very little overlap 
of Kir6.2-IR and GFAP-IR in post-status and saline-treated mice, epileptic mice show a large 
degree of co-localization.  
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Figure 3.20: Kir6.2-IR was increased in GFAP-IR cells in CA1 of epileptic mice. Triple 
immunofluorescent labeling with DAPI in the CA1 of (A) a wild-type mouse (B) a mouse post-
status and (C) an epileptic mouse. Single channel images of (1) DAPI, (2) GFAP, and (3) Kir6.2 
are shown along with (4) a merged image of all 4 channels. Higher magnification images of 
boxes in A4-C4 are shown in the lower panels displaying co-localization of Kir6.2 and GFAP in 
(D) saline (E) post-status and (F) epileptic mice. For each series the single channel image for (1) 
GFAP, (2) Kir6.2, and (3) the merged image are shown. Scale bar = 50 μm in (A), applying to 
top panels, and equal to 20 μm for the remaining panels. These data demonstrate that 
Kir6.2/GFAP co-localization is increased in CA1 in epileptic mice. 
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Figure 3.21: Kir6.2-IR is increased in GFAP-IR cells in DG of epileptic mice. Triple 
immunofluorescent labeling with DAPI theDG of (A) a wild-type mouse (B) a mouse post-status 
and (C) an epileptic mouse. Single channel images of (1) DAPI, (2) GFAP, and (3) Kir6.2 are 
shown along with (4) a merged image of all 4 channels. Higher magnification images of boxes in 
A4-C4 are shown in the lower panels and display co-localization of Kir6.2 and GFAP in (D) 
saline (E) post-status and (F) epileptic mice. For each series the single channel image for (1) 
GFAP, (2) Kir6.2, and (3) the merged image are shown. Scale bar = 50 μm in (A), and also 
applies to the rest of the top panel, and equals 20 μm for the remaining panels. These data 
demonstrate that Kir6.2/GFAP co-localization was increased in the DG in epileptic mice. 
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Aim 3: Determine if chronic vs. acute inflammation by itself can induce astrogliosis and 
altered Kir6.2 expression. 
 
Peripheral Inflammation causes reactive gliosis and increased Kir6.2-IR in GFAP-IR cells 
 
Since both AD and epilepsy are characterized by inflammation and CNS inflammation 
leads to astrogliosis, we assessed Kir6.2 and GFAP in an LPS model of peripheral inflammation. 
These experiments were done using both an acute model group that entails only 1 dose of LPS 
and a chronic model group that entails treatment for 3 days. While both in vivo (Gatti et al. 1993; 
Ban 1994; De Simoni et al. 1995; Cai et al. 2000) and in vitro studies (Chao et al. 1992b; Lee et 
al. 1994) have demonstrated that an LPS challenge induces alterations in the expression of many 
genes, especially those encoding inflammatory cytokines and inducible nitric oxide synthase in 
the CNS and neuroglial cells whether an acute dose of i.p. LPS can induce astogliosis is unclear 
since there are studies that report that a single dose of LPS can induce increased GFAP 
(Zamanian et al. 2012a) and others suggest that a single dose of LPS up to 5mg/kg does not 
induce astrogliosis although it can increase the expression of proinflammatory cytokines and 
chemokines (O’Callaghan et al. 2014). Thus, in our current experiment, GFAP levels were 
assessed in hippocampus using western blots of both acute and chronic LPS mice and their 
respective controls. These western blot data demonstrated that there was no significant increase 
in GFAP in the hippocampus (Fig. 3.22) following a single dose of LPS. In contrast, in the 
chronic group there was a significant increase in GFAP within the hippocampus. To determine if 
inflammation led to an increase in Kir6.2 in reactive astrocytes, dual immunohistochemistry with 
GFAP and Kir6.2 was performed using immunofluorescense in both the acute (Fig. 3.23) and 
chronic (Fig. 3.24) groups. These experiments further demonstrated that there was no significant 
increase in GFAP in the acute inflammation group in either SO or SR. In contrast, GFAP 
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appeared to be significantly increased in the chronic group in both regions. Interestingly, these 
experiments also revealed that while there was no significant difference in Kir6.2 levels in either 
LPS group compared to controls, there was a significant increase in co-localization of GFAP and 
Kir6.2 in the chronic but not acute group. This suggests that chronic, but not acute, peripheral 
inflammation can induce astrogliosis in mice and that these reactive astrocytes do display 
increased Kir6.2 suggesting that inflammation by itself can drive this phenotypic change in 
reactive astrocytes.      
 
 
Figure 3.22: Astrogliosis occurred in mice treated with LPS for 3 days. Representative 
immunoblot and normalized densitometric quantification of GFAP in the hippocampus of wild 
type and LPS-treated mice(1-day treatment – acute; 3-day treatment – chronic). GFAP was 
significantly increased in the chronic, but not the acute, LPS group compared to saline-treated 
controls (∗ = p ≤ 0.001). 
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Figure 3.23: (A) Dual immunohistochemistry for GFAP, Kir6.2 and their merged image in 
hippocampal region CA1 from mice treated for 1 day with either saline or LPS. (B) Higher 
magnification of GFAP and Kir6.2 in SR of saline and LPS treated mice. Scale bars = 100 μm 
and 20 μm respectively. (C) Quantification of Kir6.2, GFAP and their co-localization in SO and 
SR of saline vs. LPS-treated mice revealed no significant change in acute LPS-treated mice. 
Saline treated mice were normalized to 1 and a non-paired student’s T-test was used to determine 
significance. 
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Figure 3.24: (A) Dual immunohistochemistry for GFAP and Kir6.2 in hippocampal region CA1 
from mice treated for 3 days with either saline or LPS. (B) Higher magnification of GFAP and 
Kir6.2 in the boxed region of SR in saline and LPS treated mice. Scale bars = 100 μm and 20 μm 
respectively. Arrows indicate points of co-localization. (C) Quantification of Kir6.2, GFAP and 
their co-localization in SO and SR of saline and LPS-treated mice. LPS-treated mice showed a 
significant increase in GFAP and co-localization of GFAP with Kir6.2. Saline treated mice were 
normalized to 1 and a non-paired student’s T-test was used to determine significance. * = p < 
0.05. 
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DISCUSSION 
Alzheimer’s disease is a neurodegenerative disease characterized by pathological 
hallmarks (β-amyloid plaques, neurofibrillary tangles, neuron/synapse loss), CNS 
hypometabolism, and cognitive decline. In addition to these hallmarks, several epidemiological 
studies have shown that patients with AD often show alterations in peripheral metabolism and 
that metabolic disease increases the risk of developing AD (Meneilly & Hill 1993; Yoshitake et 
al. 1995; Leibson et al. 1997; Ott et al. 1999; Arvanitakis et al. 2004; Yaffe et al. 2004; Biessels 
& Reagan 2015b). Our lab has shown that the triple transgenic mouse model of AD (3xTg-AD 
mice) that expresses mutated human PS1, APP and tau, shows peripheral glucose intolerance and 
low insulin levels as early as 1-3 months of age and that this continues throughout their lifespan 
(Fig. 3.3). Since the primary source of CNS insulin is from the periphery we hypothesized that a 
decrease in peripheral insulin would lead to decreased CNS insulin signaling as has been 
reported in post-mortem human AD brain tissue (Bomfim et al., 2012; Jolivalt et al., 2010; Liu et 
al., 2011; Moloney et al., 2010; Steen et al., 2005). Thus, we examined CNS insulin signaling in 
6-8, 14-16 and 18-20 month old 3xTg-AD mice and wild type controls. These studies revealed 
that PI3K/AKT signaling and several of its downstream targets (e.g. pGSK3β and GLUT3 
translocation) were altered in old mice (18-20 months) but not in the younger groups examined. 
These results suggest that metabolic proteins are altered in AD and that another factor may be 
involved in disrupting CNS insulin signaling in AD in addition to peripheral insulin 
levels/responsiveness.  
Indeed, peripheral glucose levels have been linked to increased amyloid production 
(Chen et al. 2015; Macauley et al. 2015; Yang et al. 2015). As beta amyloid increases insoluble 
plaques form and drive inflammation. Inflammation in the CNS is characterized by a process 
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known as reactive gliosis in which glial cells (microglia and astrocytes) become proliferative and 
hypertrophic. Reactive glia in turn further increase cytokine release (Sofroniew 2013). Certain 
cytokines such as TNF, IL-2, and IL-6 have been shown to increase serine phosphorylation of 
IRs and IRS1 thus inducing or contributing to insulin resistance (Bloch-Damti & Bashan 2005). 
Additionally, Aβ itself and changes in tau phosphorylation (both characteristics of AD 
pathogenesis) can also affect CNS insulin signaling.   
Further, reactive astrocytes have been shown to exhibit a differential expression of genes 
compared to non-reactive astrocytes with the changes observed depending on the degree and 
type of insult (Zamanian et al. 2012b). Thus, in addition to changes in CNS insulin signaling 
affecting metabolic proteins, inflammatory conditions within the CNS may also contribute to 
changes in the expression of metabolic proteins, such as KATP channels. KATP channels link 
neuronal metabolism and activity and both are altered in AD and other neuropathological 
conditions, such as TLE. Recent studies have shown that chronic treatment with the KATP 
channel opener diazoxide decreases AD-like pathogenesis in 3xTg-AD mice (Liu et al. 2010). 
KATP channel openers have been shown to decrease inflammation suggesting that these 
channels may further link together inflammation and insulin signaling in AD. To first determine 
whether this protein was altered in 3xTg-AD mice we examined the pore-forming subunits, 
Kir6.1 and Kir6.2 and showed that Kir6.2 but not Kir6.1 was increased in reactive astrocytes in 
old 3xTg-AD mice (18-20 months). Since a common problem in AD research is that treatments 
can work in AD models but not human clinical trials, presumably due to differences in models 
vs. the human disease, Kir6.2 was also examined in post-mortem human AD tissue. As was seen 
in 3xTg-AD mice, human AD tissue showed increased Kir6.2 within reactive astrocytes 
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demonstrating that this is not just an occurrence in an animal models but rather a characteristic of 
AD.  
Like AD, several other neurodegenerative diseases are characterized by metabolic 
disturbances and reactive gliosis, such as TLE. To examine whether a similar change in KATP 
channels was seen in TLE, another neuropathological condition that displays similar changes to 
those seen in AD, Kir6.2 was examined in the pilocarpine mouse model of TLE. These studies 
showed that reactive astrocytes also occur in TLE as has been previously reported and that they 
also express increased Kir6.2 levels suggesting that there is another common link between these 
two pathological conditions. Since both conditions exhibit CNS inflammation we next 
hypothesized that chronic inflammation itself was the driving force behind the aberrant 
expression of Kir6.2. To test this hypothesis, wild type mice were treated with LPS for either 1 
or 3 days to induce peripheral inflammation (acute vs. chronic). These experiments revealed that 
increased colocalization of Kir6.2 and GFAP occurred in hippocampal reactive astrocytes 
following chronic peripheral and presumably CNS inflammation by itself. 
In summary, the primary findings of these studies were: 1) reduced activation of the 
PI3K/AKT, but not MAPK/ERK signaling pathway, was seen in 3xTg-AD mice concurrent with 
the detection of cognitive decline (i.e., impaired memory retention at18-20 months), although 
neuropathological and peripheral metabolic changes were detected earlier (i.e., 14 and 1-3 
months of age respectively); 2) the downstream target of PI3K/AKT, pGSK3β, was decreased in 
18-20 month 3xTg-AD mice, although tau phosphorylation was increased very early on; 3) 
GLUT3, but not GLUT4, translocation was decreased in 18-20 month 3xTg-AD mice, but not at 
earlier time points, and coincided with the decrease in PI3K/AKT signaling; 4) Kir6.2 is 
aberrantly expressed in reactive astrocytes in old 3xTg-AD mice and in post-mortem human AD 
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hippocampal tissue; 5) Epileptic mice also exhibited increased Kir6.2 in reactive astrocytes; and 
6) Chronic, but not acute, peripheral inflammation induced by LPS can by itself lead to increased 
Kir6.2 levels in reactive astrocytes.  
 
Alterations in CNS Insulin Signaling in 3xTg-AD Mice 
Previous results from our laboratory have shown that glucose tolerance is altered as early 
as 1 month of age in both 3xTg and APP/PS1 mouse models of AD (Fig. 3.3). This alteration 
occurs prior to the detection of Aβ plaques, neurofibrillary tangles (but did see 
hyperphosphorylated tau in 3xTg-AD mice) (Fig. 3.1) and cognitive decline (Fig. 3.2) and 
persists throughout their lifespan. The 3xTg-AD mouse model showed impaired glucose 
tolerance associated with a reduction in plasma insulin both at baseline and 15 minutes post-
glucose challenge compared to wild-type controls, while APP/PS1 mice showed glucose 
intolerance concomitant with slightly elevated insulin levels and some degree of insulin 
resistance during an insulin tolerance test (Macklin et al. 2017). In both models this change in 
glucose tolerance was seen at the 1 month time point prior to any significant pathology (although 
hyperphosphorylated tau was detected in 3xTg-AD mice) suggesting that a decrease in plasma 
insulin or a change in insulin sensitivity could contribute to AD pathogenesis due to a decrease in 
peripheral and presumably CNS insulin signaling. Although most data suggest that Type II 
diabetes is the most prevalent form associated with AD (Ott et al. 1996; Leibson et al. 1997), 
whether insulin concentrations are decreased or are elevated with a decreased receptor 
sensitivity, the end result is that a decrease in insulin signaling could occur in the CNS since the 
primary source of CNS insulin is the periphery (Banks 2004). Specifically, peripheral 
hyperinsulinemia can cause a down-regulation of insulin transporter at the BBB and thus 
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decrease brain insulin levels (Kaiyala et al. 2000). Peripheral hypoinsulinemia can also result in 
decreased CNS insulin signaling due to the reduce amount of peripheral insulin. In this study we 
subsequently tested the hypothesis that the decrease in peripheral insulin seen in the 3xTg-AD 
mouse would translate into decreased CNS insulin signaling.  
Insulin, as well as several other signaling molecules, stimulates the MAPK/ERK and 
PI3K/AKT pathways (Boucher et al. 2014). Both pathways have been linked with learning and 
memory and thus, it is plausible that disruptions in either one, or both of these pathways could 
contribute to AD-related cognitive decline. To begin to assess whether the lifelong change in 
peripheral insulin level/secretion results in impaired CNS insulin signaling, western blots were 
used to assess the activation of the MAPK/ERK pathway. In our current study no difference in 
the MAPK/ERK signaling pathway was observed in 3xTg-AD mice at either time point 
examined (6-8, and 20-24 months of age). While this was somewhat surprising given the lifelong 
change in peripheral insulin levels and a proposed role of the MAPK/ERK pathway in cognitive 
function, the MAPK/ERK pathway can be regulated (i.e. activated) by pro-inflammatory 
cytokines (e.g., tumor necrosis factor (TNF)-α and interleukin (IL)-1β) or cellular stress (Kim & 
Choi 2010) and 3xTg-AD mice exhibit increased inflammatory markers including TNF and 
reactive astrogliosis (Janelsins et al. 2005, 2008; Olabarria et al. 2010). Thus MAPK/ERK 
signaling could be maintained in 3xTg-AD mice due to increased oxidative stress even if plasma 
and CNS insulin levels were reduced. Additionally, while some studies have shown that Aβ can 
inhibit ERK1/2 (Townsend et al. 2007), others have suggested that Aβ has no effect on MAPK 
signaling (Savage et al. 2002) or can even increase ERK1/2 (Ghasemi et al. 2014). However, Aβ 
can also regulate inflammation and these studies did not assess levels of inflammation. 
Regardless, these published data help demonstrate the dynamic interplay between AB, 
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inflammation and MAPK signaling. Thus, despite data linking MAPK/ERK with normal 
cognitive function, it is unlikely that a disruption of this pathway is a primary regulator of insulin 
related AD pathology and cognitive decline in 3xTg-AD mice. 
 In contrast, PI3K/AKT pathway activity has been shown to be altered in post-mortem 
human AD brain tissue (Steen et al. 2005; Liu et al. 2011), and recent studies suggest that 
alterations in this pathway also occur in mouse models of AD (Chen et al. 2013a; Velazquez et 
al. 2017). Thus, in our current study, we examined hippocampal insulin signaling and PI3K/AKT 
activity in 3xTg-AD mice prior to and after the detection of neuropathology and cognitive 
decline (6-8 and 18-20 months of age respectively). A 16-18 month time point was also 
examined since neuropathology is detected at this time but cognition, at least spatial learning and 
memory, appears to be intact. These experiments revealed no significant difference in insulin 
signaling via the PI3K/AKT pathway at 6-8 and 16-18 months of age, but at 18-20 months there 
was a significant reduction in the phosphorylation of AKT at serine 473 and IRS1 at serine 307. 
No changes in basal AKT or IRS1 levels were however observed. Thus, our results demonstrate 
that impaired glucose tolerance and neuropathology are seen prior to alterations in hippocampal 
insulin signaling. Additionally, decreased hippocampal insulin signaling appears to correlate 
with detection of behavioral deficits in these mice with the Morris water maze, suggesting that 
decreased insulin signaling may contribute cognitive decline in AD. Interestingly, these results 
are contradictory to a previously published study suggesting that altered insulin signaling 
occurred prior to a change in peripheral glucose tolerance. Specifically, Velazquez and collegues 
(2017) showed a decrease in IRS-1 and the phosphorylation of IRS-1 at ser612 at 10 months of 
age although no change in the GTT was seen until later. Further, they reported an increase in 
pAKT at both serine 308 and 473 at 16 months of age when impaired glucose tolerance was 
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observed. These results are somewhat surprising given the data from human AD suggesting that 
impaired peripheral metabolism is a risk factor for developing AD and numerous groups have 
shown a decrease in AKT activation in the human AD brain post-mortem. The reason for the 
difference between studies is unknown but could result from gender differences (female vs. male 
mice) and the lack of attention to the stage of estrus in their female mice since hormonal 
fluctuation can dramatically affect insulin signaling (Bailey & Matty 2009). Further, their study 
used a cortex hippocampus homogenate while ours used solely hippocampal tissue. This 
hippocampal/cortex homogenate could produce a dilution effect or contamination since not all 
cortical regions are uniformly affected in AD and it is unclear what cortical regions were used in 
their study.  
 AKT is a primary regulator of insulin’s metabolic effects. In the presence of insulin, AKT 
becomes phosphorylated at ser308 by PI3K and then by mTORC2 at serine 473 to become fully 
activated. In the current study we have shown that serine 473 phosphorylation is decreased but 
only at the latest time point examined (18- 20 MOA). In addition, the decrease we observed was 
at serine 473. While phosphorylation at this residue inuces full activation and only occurs after 
phosphorylation of serine 308, it is the result of mTORC2 activity and thus a decrease in Serine 
473 phosphorylation could also reflect mTORC2 dysfunction in AD. Indeed, several studies have 
suggested that mTORC1 signaling can be increased by Aβ and is increased in AD (Griffin et al. 
2005; Caccamo et al. 2010; Ma et al. 2010; Spilman et al. 2010) but wheterh mTORC2 I altered 
is unclear. Additionally, the mTOR inhibitor rapamycin has been reported to improve cognitive 
function in AD (Spilman et al. 2010), but since mTORC2 is insensitive to rapamycin (Loewith et 
al. 2002) it suggests that these effects are due to mTORC1. Thus, it is clear that further work is 
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needed to assess the specific functions of mTORC1 and mTORC2 in human AD and 3xTg-AD 
mice. 
Regarding IRS1, when insulin is present IRS1 becomes phosphorylated at tyrosine 
residues to cause its activation. In contrast, IRS1 serine phosphorylation inhibits its activity. 
Serine phosphorylation is increased by inflammasomes such as TNF and has been suggested to 
be linked to insulin resistance (Kanety et al. 1995; Hotamisligil et al. 1996; Rui et al. 2001). 
Indeed, several studies have reported increased serine phosphorylation of IRS1 in human AD 
tissue and mouse models (Bomfim et al. 2012; Talbot et al. 2012; Chen et al. 2013b). Thus, in 
our current study it is surprising to see a decrease in IRS1 serine phosphorylation based on 
previous studies and the reported increase in neuroinflammation in old 3xTg-AD mice (Janelsins 
et al. 2005, 2008; Olabarria et al. 2010). However, IRS1 serine 307 phosphorylation has also 
been shown to occur via AKT in a negative feedback mechanism. Specifically, an increase in 
insulin induced serine 307 phosphorylation of IRS1 can be blocked by the PI3K inhibitor 
LY290042 (Rui et al. 2001). Thus, since our current study also revealed a decrease in AKT 
phosphorylation, it is plausible that the decrease in IRS1 serine 307 phosphorylation is a result of 
impaired AKT signaling. Further experiments are required to figure out this complex interplay in 
the context of AD, however.  
What is fascinating is that the observed decrease in insulin signaling in 3xTg-AD mice 
appeared to correlate with the onset of cognitive decline despite the earlier appearance of 
neuropathological findings. In this regard, intranasal insulin has been shown to improve 
cognition in patients with mild-moderate AD, patients with mild cognitive impairment, as well as 
in normal patients (Reger et al. 2008; Craft et al. 2012). Further, it has also been shown to 
improve spatial memory in 3xTg-AD mice along with increasing AKT activation (Chen et al. 
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2014). Taken together these results suggest that decreased AKT phosphorylation could 
contribute to the cognitive decline seen in 3xTg-AD mice and humans with AD, especially given 
the apparent role of insulin-AKT signaling in normal cognitive function (Kelly & Lynch 2000; 
Raymond & Redman 2002; Mizuno et al. 2003; Chen et al. 2005; Karpova et al. 2006). Further, 
it can explain why supplying insulin directly to the brain via intranasal delivery can improve 
cognitive function in AD. Specifically, such direct administration of insulin could restore 
signaling along the PI3K/AKT pathway without having to deal with a compromised BBB. 
Additionally, while peripheral insulin levels were decreased in 3xTg-AD relative to wild type 
controls as early as 1 month of age and the periphery is the primary source of CNS insulin, no 
change in hippocampal insulin signaling was observed until after neuropathology was detected. 
This delay in CNS insulin signaling following the decrease in peripheral insulin suggests that 
another factor is likely to contribute to the decrease in insulin signaling seen in old 3xTg-AD 
mice. In this regard, it is interesting to note that Aβ, in addition to inflammatory compounds, can 
reduce responsiveness to insulin in presynaptic terminals (Heras-Sandoval et al. 2012) and 
Amyloid beta-derived diffusible ligands (ADDLs) can cause a loss of neuronal surface IRs (Zhao 
et al. 2008). Thus, one parsimonious explanation for the delayed reduction in CNS insulin 
signaling in 3xTg-AD mice is that a combination of factors may be required to produce this 
result. Specifically, it is possible that a decreased supply of peripheral insulin coupled with an 
increase in Aβ production and neuroinflammation may be required to perturb hippocampal 
insulin signaling. As noted above, an increase in inflammation could also block insulin signaling, 
redistribute cellular components, alter mitochondrial activity, and decrease GLUT translocation. 
Further, insulin levels are decreased with normal aging. Thus, it is possible that the decrease in 
peripheral insulin levels seen early on in the 3xTg-AD mice is sufficient to maintain insulin 
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transporter saturation at the BBB in young mice, the additional decrease in peripheral insulin 
seen with aging can lead to a decreased concentration that is below what is required for 
transporter saturation in aged mice. 
 
pGSK3β is Decreased in Old 3xTg-AD Mice 
Glycogen synthase kinase-3 (GSK3α/β) is a constitutively active, ubiquitous 
serine/threonine kinase (Woodgett 1990), that is critical for neuronal function (Hoeflich et al. 
2000; Ougolkov et al. 2007; Takeda et al. 2011).  Aberrant over-expression of GSK3 has been 
linked with cell death (Pap & Cooper 1998; Tong et al. 2001; Carmichael et al. 2002; Maggirwar 
et al. 2002; Jin et al. 2005) and a reduction in cell proliferation (Sato et al. 2004; Tseng et al. 
2006). Since we have shown that AKT activation is decreased in 18-20 month old 3xTg-AD 
mice and GSK3 inhibition is primarily mediated by PI3K/AKT via serine phosphorylation 
(Downward 1998), we also examined GSK3 levels and its phosphorylation. The current results 
revealed that phosphorylation of GSK3β at serine 21 is decreased in 3xTg-AD mice at 18-20 
months but not at earlier time points suggesting that this is likely to occur subsequent to the 
decrease in pAKT. This decrease in GSK3β phosphorylation could lead to GSK3 hyperactivation 
and GSK3 has been implicated in AD since it can increase Aβ production and toxicity (Bayatti et 
al. 2003; Ryder et al. 2003; Su et al. 2004; Akiyama et al. 2005), neuroinflammation (Jope et al. 
2007; Lipton 2007) and tau phosphorylation (Takashima et al. 1993; Hong et al. 1997). Thus, 
this decrease in GSK3 phosphorylation could further contribute to AD neuropathogenesis and 
cognitive decline and further impair CNS insulin signaling. Despite the role of GSK3 in tau 
phosphorylation, it is not really surprising that tau phosphorylation was observed in 3xTg-AD 
mice prior to the change in pGSK3β since the human transgene that was expressed in 3xTg-AD 
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mice produces hyperphosphorylated tau. What is interesting however, is that the apparent 
deposition of hyperphosphorylated tau only occurred at about the same time as the observed 
change in AKT activation and GSK3β inhibition. Moreover, several studies demonstrate a link 
between tau levels and insulin sensitivity. Specifically, tau knockout mice and neurons 
containing hyperphosphorylated tau have impaired insulin responsivity (Marciniak et al., 2017; 
Rodriguez-Rodriguez et al., 2017). In addition, tau has also been linked to insulin-sensitive LTD 
and cognitive performance. For example, tau transgenic mice display impaired LTD that can be 
rescued by GSK3B inhibitors (Ahmed et al. 2015) and tau knockouts have impaired MWM 
performance and synapse loss which can be corrected by DHA which can decrease inflammation 
and also increases GSK3 phosphorylation (Ma et al. 2014). While further experiments are 
required to directly test this cause and effect relationship, it is clear to see that many variables 
can contribute to the change in CNS insulin signaling seen in 3xTg-AD mice and human AD 
brain tissue post-mortem. 
 
GLUT3 Translocation is decreased in the hippocampus of old 3xTg-AD mice 
Insulin’s effects on learning and memory have been suggested to be largely independent 
of glucose utilization. Whether this assertion is valid however is unclear since recent studies 
have shown that: 1) insulin can stimulate neural glucose uptake in medial temporal lobe 
structures involved in learning and memory (Doyle et al. 1995; Bingham et al. 2002); 2) subjects 
with insulin resistance exhibit a regional reduction in glucose metabolism (Baker et al. 2011) 
that can be improved with exogenous insulin administration  (Hirvonen et al. 2011); 3) 
conditional IR knock out mice (NIRKO) exhibit decreased glucose uptake in their brain (Fisher 
et al. 2005); 4) the expression or translocation of several of the facilitated glucose transporters 
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(i.e., GLUT1, GLUT3 and GLUT4) can be affected by insulin/IGF1 signaling or insulin 
sensitizing drugs (Uemura & Greenlee 2006; Grillo et al. 2009; Fernandez et al. 2017), and 5) 
Gold and colleagues have shown that a subject’s performance on hippocampal-dependent 
cognitive tasks is dependent on glucose uptake and that increasing hippocampal glucose supply 
can enhance memory performance (McNay et al. 2000; McNay & Gold 2001; Gold 2005). 
Taken together, these studies suggest that insulin may actually affect neuronal/network glucose 
utilization and subsequently learning and memory.  
The majority of glucose uptake in peripheral tissues is under the control of insulin via the 
insulin-sensitive glucose transporter, GLUT4 (Simpson & Cushman 1986). Recently it has been 
suggested that a similar mechanism may occur in the hippocampus since: 1) GLUT4 is found 
there (Vannucci et al. 1998; Apelt et al. 1999; Choeiri et al. 2002; El Messari et al. 2002) and 
the hippocampus also contains high levels of the IR (Havrankova 1978; Heidenreich et al. 1983; 
Marks et al. 1990; Unger et al. 1991) 2) ICV administration of insulin can induce GLUT4 
translocation in rats via a PI3K/AKT dependent manner (Grillo et al. 2009), 3) GLUT4 mediates 
glucose uptake in an activity dependent manner in hippocampal pyramidal cells (Fernando et al. 
2008) 4) Aβ1-42 oligomers can impair spontaneous alternation behavior, prevent the dip in 
extracellular glucose normally associated with performing such tasks and decrease the plasma 
membrane translocation of the GLUT4 subsequent to impaired AKT phosphorylation (Pearson-
Leary & McNay 2012) and 5) animal models of type II diabetes exhibit impaired hippocampal 
GLUT4 translocation as well as synaptic plasticity and insulin signaling (Winocur et al. 2005). 
Taken together these studies suggest that GLUT4 may play a similar mechanism in the CNS to 
what it does in the periphery. However, surprisingly no change in GLUT4 translocation was 
observed in 3xTg-AD mice in this study despite the decrease in PI3K/AKT activation. While the 
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reason for this is unclear, data suggest that multiple factors other than insulin can affect GLUT4 
translocation (Fernando et al. 2008) including PKC (Imamura et al. 2003), tumor necrosis factor-
α (Roher et al. 2008), AMP kinase (Burcelin et al. 2003), and endothelin (Lawrence & Birnbaum 
2001). Further, insulin appears to increase GLUT4 translocation in an activity dependent 
manner. Thus, a decrease in GLUT4 translocation may only be detected in 3xTg-AD mice if 
exogenous insulin were administered concurrent with a decrease in PI3K/AKT signaling. 
Additional experiments would however be required to directly test this hypothesis.  
As for the primary neuronal glucose transporter GLUT3, recent data demonstrate that 
insulin is also involved in its translocation to the plasma membrane through a PI3K/AKT 
dependent mechanism although neuronal depolarization is also required (Uemura & Greenlee 
2006). This observation has in turn lead to the suggestion that upon metabolically challenging 
tasks (i.e., cognitive task) GLUT3 translocation could occur in the hippocampus to accommodate 
the increased demand for glucose. Interestingly, in post-mortem tissue from AD patients GLUT3 
protein levels are decreased (Simpson et al. 1994) and GLUT3 levels are also decreased in 
patients with Type 2 diabetes (Liu et al. 2009). Finally, Aβ can also decrease glucose uptake by 
inhibiting GLUT3 fusion with the membrane suggesting that a decrease in translocation rather 
than GLUT3 expression may be critical for overall GLUT3 function (Prapong et al. 2002). Our 
current studies demonstrate that decreased GLUT3 translocation correlated with reduced AKT 
activation in 3xTg-AD mice suggesting that this may be a downstream effect of impaired CNS 
insulin signaling. This decrease in GLUT3 translocation corresponded with the first detection of 
cognitive impairment and was not observed at earlier time points. This timing could reflect a 
potential cause and effect relationship between decreased GLUT3 translocation and cognitive 
decline and is consistent with other studies that have reported an increase in glucose uptake 
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during cognitive tasks and an increase in neuronal glucose requirement would be accomplished 
by increasing GLUT3 expression (Vannucci 1994). Whether this decrease in GLUT3 
translocation also underlies AD-related hippocampal hypometabolism is unclear however, 
although intranasal insulin administration has been shown to improve both cognitive 
performance and CNS metabolism (Craft et al. 2012). 
 
Alterations in KATP channels in 3xTg-AD mice 
An additional insulin sensitive target that has been linked to cognition and AD is the 
KATP channel. Insulin has been shown to activate KATP channels in glucose responsive 
neurons of Zucker rats (Spanswick et al. 2000) and exogenous insulin can hyperpolarize 
pancreatic β-cells in a KATP dependent manner (Khan et al. 2001). Modulation of these 
channels has also been shown to affect normal cognition (Ghelardini et al. 1998; Betourne et al. 
2009) and alter AD pathogenesis/phenotype (Liu et al. 2010; Macauley et al. 2015). Thus, we 
began to examine these channels in the context of AD. Despite being found in both neurons and 
glia, the cognitive effects of KATP channel modulators have been primarily suggested to be due 
to neuronal KATP channels. Surprisingly, however, we found that the major change seen in 
3xTg-AD mice was that the pore-forming channel protein Kir6.2, was increased in reactive 
astrocytes at a time point when Aβ plaques and tau pathology (Oddo, 2003; Fig. 3.1), memory 
deficits (Billings et al., 2005; Fig. 3.2), and CNS hypometabolism (Nicholson et al. 2010) are 
present. Further, this change in Kir6.2 subunit expression was not just an AD-model related 
epiphenomenon since complementary experiments performed on human AD and age-matched 
non-AD hippocampal tissue obtained from the Chinese brain bank revealed that similar changes 
occurred in human AD.  
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Since our studies revealed a change in Kir6.2 expression in reactive astrocytes in 3xTg-
AD mice we examined reactive astrogliosis in more detail. Prior studies indicate that reactive 
astrogliosis is a graded response that can range from astrocytic hypertrophy to more severe 
changes entailing both hypertrophy and proliferation (i.e., scar formation) (Sofroniew & Vinters 
2010; Pekny et al. 2014). Reactive astrogliosis is associated with cytoskeletal changes (e.g., 
increased GFAP and vimentin), as well as a change in the expression of numerous genes 
dependending on the severity or trigger of the astrogliosis (Zamanian et al. 2012a). AD studies 
using post-mortem human tissue have reported that reactive astrogliosis is characterized by 
hypertrophy, but does not appear to involve astrocytic proliferation (Orre et al. 2014b; 
Rodríguez-Arellano et al. 2015). Further, studies in the 3xTg-AD mouse model suggest that 
reactive astrogliosis in AD could vary depending on the stage of AD pathogenesis. Specifically, 
astrocytic atrophy may occur early during AD pathogenesis and eventually evolve into astrocytic 
hypertrophy, primarily in the vicinity of β-amyloid plaques (Olabarria et al. 2010; Verkhratsky et 
al. 2010; Yeh et al. 2011; Rodríguez-Arellano et al. 2015). Indeed, several groups have reported 
hypertrophic astrocytes in the hippocampus of 3xTg-AD mice at later stages (Mastrangelo & 
Bowers 2008; Chen et al. 2013a). While, examination of our results (not shown) did not reveal a 
significant difference in GFAP-IR in 6-8 month old 3xTg-AD mice, our data found that both 
protoplasmic and fibrous astrocytes become hypertrophic in aged 3xTg-AD mice and in human 
AD tissue. Our data from the 3xTg-AD mice, demonstrated an increase in GFAP protein level in 
the hippocampi of aged 3xTg-AD mice with immunoblotting, and IHC revealed increased 
GFAP-IR in SR, SO and the ALV. However, GFAP-IF cell number was only significantly 
different between groups in the ALV and may be the result of a decrease in white matter volume 
that occurs with AD and thus be a compensatory change. In human AD tissue there was also a 
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dramatic increase in GFAP-IR observed in the SO/ALV, compared to age-matched control. 
Thus, it appears that the increased levels of GFAP seen in aged 3xTg-AD mice is primarily a 
reflection of hypertrophic astrocytes in both the grey and white matter which is consistent with 
the available data on human AD tissue (Brun and Englund, 1986; Beach et al., 1989; Osborn et 
al., 2016). This suggests that both protoplasmic and fibrous astrocytes become reactive. Since 
reactive fibrous astrocytes are localized to the white matter and plaque deposition in AD is 
generally considered to be a neocortical and allocortical grey matter phenomenon, it appears that 
Aβ is unlikely to be the only trigger for reactive gliosis in AD as has been previously suggested 
(Olabarria et al., 2010; Wisniewski and Wegiel, 1991). While the underlying cause of reactive 
astrogliosis in AD is unclear, based on our current data it is likely that both Aβ (Olabarria et al., 
2010; Wisniewski and Weigel, 1991; Pike et al., 1994) and inflammation (Mrak et al. 1995) are 
involved. Indeed, neuroinflammation is a known trigger for reative astrogliosis.  
 Western blots and IHC data suggested that there was no significant difference in either 
the protein level or distribution of Kir6.1 in the hippocampus of aged 3xTg-AD mice compared 
to age-matched wild type controls. This result was somewhat of a surprise given the extent of 
reactive astrogliosis found in the aged 3xTg-AD hippocampus and available data suggesting that 
Kir6.1 is preferentially seen in astrocytes ((Thomzig et al. 2001, 2005). While these results 
provide evidence that Kir6.1 is not altered in AD, these results do not rule out the possibility that 
the effects of KATP channel modulation on AD phenotype/pathogenesis could be working via 
Kir6.1-containing KATP channels since our study focused on a later time point when pathology 
is already present and Kir6.1 channels were still abundant in the hippocampus of aged 3xTg-AD 
mice. Since no dramatic obvious change in Kir6.1 was noted, no additional experiments were 
performed on Kir6.1. 
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In contrast to Kir6.1, our results show that Kir6.2 is increased in hippocampal region 
CA1 in AD and that this increase is primarily due to its aberrant expression in reactive 
astrocytes. First, Kir6.2 levels were increased in the crude plasma membrane fraction of 
hippocampal tissue from 3xTg-AD mice. This occurred concomitant with an increase in Kir6.2-
IR in the somata and proximal processes of reactive astrocytes as assessed by co-localization of 
Kir6.2 with GFAP or GS. A similar change was seen in human AD tissue where an increase in 
Kir6.2-IR was observed in the somata and proximal processes of reactive astrocytes in SO/ALV 
as examined by Kir6.2/GFAP co-localization. Thus, the most parsimonious explanation is that in 
AD, reactive astrocytes exhibit increased Kir6.2 expression for some unknown reason. Whether 
other changes in the cellular localization of Kir6.2 occurs in AD is however less clear. For 
example, while Kir6.2-IR appeared qualitatively lower in SP in some sections from 3xTg-AD 
mice (although this was highly variable between sections and animals), a preservation of Kir6.2 
density was seen in SP in human AD tissue compared to age-matched control tissue. As to 
whether a potential change in intracellular Kir6.2 could have occurred in either 3xTg-AD mice 
or human AD tissue, our methodology did not allow for the differentiation of Kir6.2-IR in the 
plasma membrane versus cytoplasmic or organelle related Kir6.2-IR. Thus, while additional 
experiments are required to assess for additional changes in Kir6.2 in AD, our current 
experiments on tissue from both human AD and the 3xTg-AD model of AD reveal an aberrant 
expression of Kir6.2 in the plasma membrane in reactive astrocytes. To the best of our 
knowledge, this is this first time that a dramatic change in Kir6.2 expression has been observed 
in reactive astrocytes in a neuropathological condition although a decrease in inwardly rectifying 
K+ currents in astrocytes has been reported in other neuropathologies such as traumatic brain 
injury, temporal lobe epilepsy and entorhinal cortex lesion (D’Ambrosio et al. 1999; Schröder et 
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al. 1999; Bordey & Spencer 2004). Whether this change in inwardly rectifying K+ currents in 
these conditions are due to changes in Kir6.2 or other K+ channels, such as Kir4.1, is however 
unclear 
 
Kir6.2 is increased in astrocytes in Temporal lobe epilepsy  
AD patients have an increased risk of developing seizures and epilepsy (Pandis & 
Scarmeas 2012). Further, AD and epilepsy share several common characteristics, including 
cell/synapse loss, decreased glutamine synthetase levels, hypometabolism, neuroinflammation 
(characterized by marked gliosis and increased inflammatory mediators) and cognitive decline 
(Spencer 1994; Kennedy et al. 1995; Robinson 2001; Mosconi et al. 2004; van der Hel et al. 
2005; Eid et al. 2008; Zarow et al. 2008). Thus, we also examined Kir6.2 in the hippocampus of 
a mouse model of TLE, the pilocarpine-treated mouse. Since our previous results have shown 
that Kir6.2 was increased in reactive astrocytes, we first examined GFAP-IR in the piolocarpine-
treated mice to ensure that our model of TLE had reactive astrocytes. Indeed, these studies 
revealed that GFAP-IR was increased throughout the hippocampus in pilocarpine-treated mice 
that developed epilpsy as has been previously reported in both human TLE and mouse models of 
this neuropathology (Bouilleret et al. 1999; Crespel et al. 2002; Griffin et al. 2002). As in AD, 
this increase in GFAP was apparent in both the gray and white matter and was characterized by 
hypertrophy, although cell counts were not performed to assess proliferation in the pilocarpine-
treated mice. In addition to labeling astrocytes, GFAP has also been shown to label neural 
progenitor cells and newly generated granule cells (Weiss et al. 1996; Doetsch et al. 1999; 
Laywell et al. 2000). In this regard, adult neurogenesis occurs in the subgranular zone of the 
dentate gyrus (SGZ) and in the subventricular zone (SVZ) (Jin et al. 2001) and several studies 
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have demonstrated that following prolonged seizure activity there is an increase in this 
proliferation (Jessberger & Parent 2015). Additionally, ablating neurogenesis prior to 
pilocarpine-induced epilepticus reduces the frequency of recurrent seizures suggesting that 
neurogenesis may play a role in the development of epilepsy (Cho et al. 2015). In this study, we 
saw an increase in GFAP-IR not only in reactive astrocyte but also in the SGZ that is likely to 
reflect an increase in progenitors or newly generated granule cells due to their location and 
morphology which is distinct from that of reactive astrocytes. (Jin et al. 2001) 
GFAP-IR was assessed in mice post pilocarpine-induced status as well as after behavioral 
confirmation of spontaneous convulsive seizure to assess for changes associated with the initial 
insult versus changes associated with epileptogenesis and the epileptic condition. While an 
increase in GFAP-IR was already seen in post-status tissue, this change was further exacerbated 
in epileptic mice suggesting that astrocytes become incredibly more reactive during the process 
of epileptogenesis, the development of a permanent epileptic state.  
This increase in GFAP-IR was associated with increased Kir6.2-IR co-localization 
suggesting that an increase in astrocytic Kir6.2 was not just a phenomenon associated with AD 
but rather may be a common phenotype of several neuropathological conditions. Like the change 
in GFAP-IR, there appeared to be a slight increase in Kir6.2 in GFAP positive cells in mice post-
status that was further increased in epileptic mice suggesting that the increase in Kir6.2 
correlates with the degree of astrocytic reactivity. This increase in Kir6.2 appeared throughout 
the hippocampus in the somata and proximal processes of astrocytes in both gray matter and 
white matter. While we did not perform western blotting of cellular fractions due to the vast 
amount of neuronal cell loss (which would likely mask any changes seen) it is likely that this 
change in Kir6.2 also occurred at the plasma membrane level in reactive astrocytes in TLE as is 
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seen in AD. As noted above, there also appeared to be an increase in Kir6.2-IR in the SGZ of the 
dentate gyrus that could be indicative of Kir6.2 in neuronal precursors or newly generated 
granule cells, although additional co-localization experiments with markers for progenitors cells 
or newly generated neurons such as doublecortin, Ki67, or nestin would need to be performed to 
confirm this postulation. In this regard, it is interesting to note, in the pathogenic brain reactive 
microglia and astrocytes release trophic factors that promote neurogenesis (Ribeiro Xavier et al. 
2015) and recent studies demonstrate that the KATP channel openers diazoxide and 
glibenclamide can enhance neurogenesis and decrease neurodegeneration (Ortega et al. 2013; 
Martínez-Moreno et al. 2016). While previous studies suggest that neuroblasts do not contain 
Kir6.2, these recent data suggest that this enhanced neurogenesis may be due, in part, to the 
expression of Kir6.2 in neural progenitor cells or newly generated neurons in neurodegenerative 
conditions. Since our results reveal that similar changes in Kir6.2 occur in both AD and TLE, 
this suggests that this difference may occur due to a common underlying trigger that occurs in 
both AD and TLE. One commonality between both diseases is neuroinflammation. 
Neuroinflammation is a major trigger for inducing glial reactivity. Thus, we subsequently 
examined whether chronic inflammation induced by 3 days of peripheral LPS treatment could 
similarly induce increased Kir6.2 expression in reactive astrocytes.  
 
Kir6.2 is increased in reactive astrocytes following chronic LPS treatment 
Bacterial lipopolysaccharides act as an extremely strong stimulator of innate immunity 
(Alexander & Rietschel 2001). Though, LPS and pro-inflammatory cytokines are large 
molecules that cannot easily penetrate the BBB, peripheral administration of LPS has been 
shown to induce neuroinflammation (Cai et al. 2000; Xaio et al. 2001; Lee et al. 2008). Thus, in 
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our current we study examined hippocampal GFAP-IR and Kir6.2-IR one day following either 
one dose or three daily doses of peripheral LPS in male C47/129 mice to model acute and 
chronic inflammation respectively. We first confirmed previous reports of increased GFAP-IR in 
LPS-treated mice using western blots. Interestingly, in the acute group no significant increase in 
GFAP was observed. In contrast, in the chronic treatment group, a significant increase in GFAP 
levels was seen suggesting that while one dose may not be a sufficient insult, 3 days of LPS 
treatment can induce reactive astrocytes. We next assessed Kir6.2-IR and GFAP-IR in 
hippocampal region CA1. These results confirmed our western blot results demonstrating a 
significant increase in GFAP-IR in the 3-day but not the 1-day LPS treatment group. These 
results also showed that Kir6.2/GFAP co-localization was significantly increased in the 3-day 
group but not in the 1-day group further establishing the relationship between chronic 
inflammation, reactive astrocytes and increased Kir6.2. Surprisingly, however, Kir6.2-IR itself 
was not significantly increased in either group. These results support a previous study reporting a 
lack of change in KCNJ11 gene expression in conditions characterized by reactive astrocytes and 
could reflect an increase in Kir6.2 in reactive astrocytes concurrent with a decrease in Kir6.2 in 
another cell type (Zamanian et al. 2012a). Thus, cell sorting or single cell qPCR would be 
needed to more directly demonstrate an increase in mRNA in reactive astrocytes and a decrease 
in other cell types. Another possibility is that Kir6.2 is increased preferentially at the plasma 
membrane. In our western blot experiments using 3xTg-AD tissue we showed that total Kir6.2 
wasn’t changed but that plasma membrane Kir6.2 was increased. Since almost all GFAP in 
astrocytes is cytoplasmic (part of the cytoskeleton) and major cytoskeletal elements are 
frequently found attached to or near the plasma membrane (Weihing 1979), it is possible that 
while total Kir6.2 is not increased, Kir6.2 is increased only at the plasma membrane and is more 
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able to associate with GFAP. The apparent localization of Kir6.2-IR in the plasma membrane of 
reactive astrocytes suggests that the endoplasmic reticulum retention signal motif (RKR) that is 
found on Kir6.2 and restricts its translocation into the plasma membrane is somehow masked. 
The interaction between Kir6.2 and SURx subunits normally results in a masking of the RKR 
motifs found on both Kir6.2 and SURx allowing for plasma membrane translocation and 
insertion (Papazian 1999). Thus, one parsimonious explanation is that aberrant Kir6.2 subunits 
attach to endogenous sulfonylurea (SURx) subunits in reactive astrocytes and preferentially 
target the membrane (Shi et al. 2005). Another possibility is that the RKR motif on aberrant 
Kir6.2 subunits is altered and thus leads to Kir6.2 plasma membrane translocation.  
 
Implications of elevated Kir6.2 in reactive astrocytes 
Our current experiments on the Kir6.2 pore-subunit of KATP channels reveal that Kir6.2 
is increased in reactive astrocytes in multiple conditions. An increase in Kir6.2 in the plasma 
membrane of reactive astrocytes could dramatically affect astrocytic physiology, although it is 
unclear whether these changes would be beneficial or detrimental overall. In general, reactive 
astrogliosis was historically believed to be detrimental in nature due to the negative 
consequences of scar formation on neuronal process outgrowth and repair. However, more recent 
data suggest that reactive astrogliosis can also be beneficial. For example, knocking down glial 
hypertrophy during scar formation has been shown to result in greater cell loss, greater 
neuroinflammation and greater blood-brain barrier disruption (Bush et al. 1999; Sofroniew & 
Vinters 2010). Regarding AD, whether reactive astrogliosis is beneficial or detrimental is 
unresolved with contradictory data available. For example, some studies have demonstrated that 
knocking down GFAP and vimentin (astrocytic cytoskeletal proteins associated with 
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hypertrophy) can result in an increase in plaque load (Kraft et al. 2013) while other studies 
suggest that reactive astrogliosis could contribute to Aβ production since reactive astrocytes 
express BACE1, the rate limiting enzyme in the cleavage of APP to produce Aβ1-42 (Rossner et 
al. 2005). Reactive gliosis is also a major characteristic of epilepsy. A recent study has also 
shown that conditionally deleted β1-integrin (Itgβ1) in radial glia, which results in chronic 
reactive astrogliosis in almost every region of the brain without causing gross brain 
abnormalities or pronounced inflammation (Robel et al. 2011), causes rats to develop neuronal 
hyperexcitability and spontaneous recurrent seizures (Robel et al. 2015). Additionally, mice 
lacking the Kir6.2 subunit of the channels were extremely susceptible to generalized seizures 
after brief hypoxia (Yamada et al. 2001).  
The increase in astrocytic Kir6.2 could dramatically affect astrocytic functions. 
Specifically, inwardly rectifying K+ channels are believed to primarily dictate astrocytic resting 
membrane potential. Thus, an increase in plasma membrane Kir6.2 could affect astrocytic 
membrane potential especially during changes in metabolic supply and both AD and epilepsy are 
characterized by altered CNS metabolism (i.e., hypometabolic (Kennedy et al. 1995; Reiman et 
al. 1996; Mosconi et al. 2008; Nicholson et al. 2010). Further, experiments using primary 
astrocytic cultures have demonstrated that KATP channel openers (e.g., diazoxide and pinacidil) 
can increase glutamate uptake (Sun et al. 2008) which subsequently could impact neuronal 
excitotoxicity and glutamate-glutamine cycling (Mark et al. 2001; McKenna 2007) and both AD 
and epilepsy display decreased glutamate uptake. Thus, the increase in astrocytic Kir6.2 could be 
serving in a compensatory manner to increase extracellular glutamate uptake since there is loss 
of protein and functional levels of excitatory amino acid transporter 2 (EEAT2 or GLT-1 in 
rodents) in AD and epilepsy (Masliah et al. 1996).  
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KATP channel openers and blockers can also affect astrocytic gap junctions, with 
openers inhibiting gap junctions and blockers increasing gap junction permeability (Granda et al. 
1998; Velasco et al. 2000). Astrocytic gap junction permeability could in turn dramatically affect 
astrocytic function since they are involved with the propagation of astrocytic Ca2+ waves which 
can impact gliotransmitter release and extracellular K+ buffering and both could subsequently 
affect a variety of properties including neuronal excitability and neurovascular regulation. In 
addition, gap junctions are also found between astrocytes and oligodendrocytes (Nagy & Rash 
2000). These astrocyte-oligodendrocyte gap junctions are important in the formation of myelin in 
that mutations affecting astrocytic connexins cause demyelination (Paznekas et al. 2003). Thus, 
an alteration in KATP channels in fibrous astrocytes in the white matter could cause altered 
oligodendrocyte-astrocytic interactions. Interestingly, both AD and TLE are associated with 
changes in their white matter. However, further experiments entailing electrophysiological 
recordings from astrocytes, neurons and oligodendrocytes in hippocampal slices are required to 
begin to determine the exact physiological outcome of this increase in plasma membrane Kir6.2 
in reactive astrocytes.   
One possible reason for the increase in Kir6.2 in reactive astrocytes is that this is a 
compensatory mechanism subsequent to a decrease in Kir4.1 in reactive astrocytes in both AD 
and TLE. A large body of work demonstrates that glial Kir4.1 expression and function decreases 
following acute injury and is often associated with GFAP up-regulation and glial cell 
proliferation (Olsen et al. 2007). Additionally, glial hypertrophy and GFAP up-regulation are 
associated with diseases of chronic inflammation, such as epilepsy, amyotrophic lateral sclerosis, 
and AD and astrocytes from several animal models of these diseases show marked decreases in 
Kir channels and channel activity or function. Thus, it is conceivable that any insult to the CNS 
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that causes astrogliosis and potentially glial proliferation is associated with the loss of Kir4.1. 
Our current results suggest that there is also an increase in Kir6.2 following these insults. 
Subsequently, it is likely that an increase in Kir6.2 occurs concomitant to a loss of Kir4.1. This 
could be somewhat of a compensatory mechanism in an attempt to maintain astrocytic 
membrane potential, K+ homeostasis, and glutamate uptake, which may worsen the underlying 
condition. Additionally, Kir6.2 is present in what appears to be neural precursor cells and newly 
generated granule cells in the DG and thus may allow for increased cell proliferation. Indeed, 
during development, Kir6.2 is present in astrocytes and decreases with maturation, while Kir4.1 
is absent at first and appears later on (Brockhaus & Deitmer 2000; Kalsi et al. 2004; Moroni et 
al. 2015). This switch suggests that these channels may somehow be involved in regulating the 
expression of each other in astrocytes and also may be involved in regulating neurogenesis. 
Indeed, neurogenesis is altered in both epilepsy and AD and recently diazoxide has been shown 
to increase neurogenesis in the hippocampus. 
Another potential role for Kir6.2 in astrocytes is regulating inflammation. Several studies 
have demonstrated that KATP channels play a role in the inflammatory response of microglia. 
They have been shown to regulate the reactive state of microglia, control the release of 
inflammatory mediators such as nitric oxide, IL-6 and TNFa, and modify phagocytic activity 
(Zhou et al. 2008; Virgili et al. 2011; Ortega et al. 2013). Since astrocytes, in conjunction with 
microglia, are key players in inflammation it is likely that KATP channels may also affect their 
inflammatory functions. Indeed, our data suggest that inflammatory conditions can increase 
Kir6.2 expression in reactive astrocytes. This aberrant Kir6.2 may in part help mediate the 
inflammatory response in astrocytes. Similar to these results, activated microglia have been 
shown to express KATP channels (Ramonet et al. 2004; Ortega et al. 2013). Interestingly, no 
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changes in Kir6.2 mRNA were reported in the hippocampus in these studies. Again, this is likely 
due to the heterogeneity of cell types present in the hippocampus that may express different 
levels of KATP channels and subsequently could mask changes seen in only a select cell 
population. A potential role of Kir6.2 in regulating inflammation could also affect many 
metabolic functions including alterations in insulin signaling since inflammation can cause serine 
phosphorylation of the IR and decrease insulin activity. Thus, KATP channels may not only link 
metabolism and activity together, but may also link inflammation into this equation. 
The electrophysiological aspects of an alteration in Kir6.2 in astrocytes is currently 
unclear but could have many implications. One may assume that these channels may not have a 
large effect on astrocytes since electrophysiologically, astrocytes are characterized by a high K+ 
resting conductance and a hyperpolarized resting membrane potential. However, it has been 
shown that astrocytes are heterogenous and can have different resting membrane potentials and 
that even slight changes in the astrocytic membrane potential can have vast effects on the 
excitability of the cell (McKhann et al. 1997). Another possibility is that a change in 
extracellular potassium could result in a change in the osmolality of the cell and result in 
astrocytic swelling which has been shown to result in depolarization (Kimmelberg & O’Connor 
1988). Finally, the effects of potassium channel drugs have been suggested to be due to 
alterations in mitochondria (Liu et al. 2010). While our results suggest that the change is at the 
plasma membrane, we have not assessed mitochondrial levels in astrocytes directly and thus 
there could be a difference at the mitochondria which could alter the membrane characteristics 
and excitability of the cell.  
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Relevance to prior studies on KATP channel modulation and pathogenesis 
As mentioned earlier, previous studies have demonstrated that KATP channel modulation 
can affect AD pathogenesis in mouse models of AD. In the first study, 3xTg-AD mice treated 
chronically with diazoxide from 4 months of age onward and assessed at 13 months of age, 
exhibited less severe memory decline and a decrease in β-amyloid plaques and tau pathology 
(Liu et al., 2010). In a second study, elevating peripheral glucose levels in APP/PS1 mice prior 
to plaque formation induced an increase in interstitial β-amyloid in the hippocampus suggesting 
increased β-amyloid production. Further, they reported that direct application of the KATP 
channel opener, diazoxide, into the hippocampus could block this increase in interstitial β-
amyloid, while the KATP channel blocker, glibenclamide, increased interstitial β-amyloid levels 
(Macauley et al., 2015). Thus modulation of KATP channels can affect AD progression.  
The finding that diazoxide delays memory decline in 3xTg-AD mice is particularly 
interesting since diazoxide is an amnestic in normal mice (Betourne et al., 2009; Ghelardini et 
al., 1998). In contrast, glibenclamide, a KATP channel closer, has been shown to improve 
memory in normal mice (Stefani and Gold, 2001). In addition, several studies have shown that 
targeting KATP channels can provide neuroprotective effects for neurons and astrocytes against 
ischaemia, trauma and neuro-toxins (Busija et al., 2004; Hu et al., 2005; Yamada Inagaki 2005; 
Yang Y et al., 2006). Glibenclamide has also been found to be an effective treatment in various 
animal models of ischemic and hemorrhagic stroke, traumatic brain injury, spinal cord injury, 
neonatal encephalopathy of prematurity, and metastatic brain tumor (Kurland et al. 2013). It is 
likely that these beneficial properties occur as a result of a reduction in inflammation since 
glibenclamide has been shown to decrease the release of inflammatory mediators such as nitric 
oxide, IL-6 and TNFa, from microglia (Ortega et al. 2012). Indeed, glibenclamide has been 
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shown to improve memory function, reduce neuroinflammation, reduce brain edema, reduce 
contusion volume, minimize secondary hemorrhage, and reduce epileptic seizures after CNS 
injury (Simard et al. 2009; Patel et al. 2010; Zweckberger et al. 2014). Further, glibenclamide 
pre-treatment, but not post-treatment, protects against TBI induced hippocampal memory deficits 
and neuroinflammation (Stokum et al. 2017). 
Why the difference between these studies exists is unclear, however. It is compelling to 
speculate that these effects could in part be explained by altered KATP channel expression in 
certain neuropathological conditions. In this regard, our study shows a dramatic increase in the 
expression of Kir6.2 subunits in reactive astrocytes in both human AD and the 3xTg-AD model 
of AD at a time point when the AD phenotype is already established (i.e., memory decline, 
plaques and tangles are present), but not at an earlier time point (6-8 months). Moreover, the 
aforementioned studies never examined the effects of KATP channels modifiers in animals 
exhibiting the characteristics of AD but only examined earlier time points. Additionally, while 
diazoxide is well known to open mitochondrial KATP channels, its role at the plasma membrane 
is less clear with several studies suggesting that diazoxide is mitochondrial specific (Gonca & 
Bozdoğan 2010).  
As noted above, activated microglia have also been shown to express increased KATP 
channels in the hippocampus (Ramonet et al. 2004; Ortega et al. 2013). Additionally, LPS has 
been shown to up-regulate Kir6.1/SUR2B channel expression and enhance vascular KATP 
channel activity via NF-kappaB-dependent signaling (Shi 2009). These data suggest that 
inflammation may drive the change in Kir6.2 in reactive astrocytes and is consistent with our 
findings using chronic LPS treatment. It is possible that this entails an insulin dependent 
mechanism since insulin can regulate NF-kappaB activity through PI3K/AKT signaling.  
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KATP channels in the hypothalamus may also regulate peripheral metabolism and 
thereby affect certain neuropathological conditions. Specifically, KATP channels in the 
mediobasal hypothalamus lower blood glucose levels through inhibition of hepatic 
gluconeogenesis and infusion of a KATP blocker within the mediobasal hypothalamus, or the 
surgical resection of the hepatic branch of the vagus nerve, negates the effects of central insulin 
(Pocai et al. 2005). When POMC neurons are genetically modified to maintain open KATP 
channels, glucose tolerance is impaired (Parton et al. 2007). Additionally, POMC cell–restricted 
PTEN knockout (PPKO) mice exhibit hyperphagia and an obese phenotype. POMC neurons of 
PPKO mice were hyperpolarized and electrically silenced due to an increase in KATP 
conductance. Inhibition of both PI3K activity and KATP channels restored electrical activity of 
PPKO POMC neurons. Importantly, blocking KATP channels selectively in the central nervous 
system by ICV application of tolbutamide reversed hyperphagia in PPKO mice (Plum et al. 
2006). Thus, PI3K-dependent regulation of KATP channels in POMC neurons may play a 
central role in the regulation of energy homeostasis and peripheral glucose tolerance, which as 
discussed above can affect cognitive function. Interestingly, a single dose of glyburide, another 
KATP channel blocker, corrected deficiencies in novel object recognition and mitigated anxiety-
like behaviors in mice fed with HFD-diet for 3-weeks (Gainey et al. 2016). Wheterh changes in 
KATP channels occur in the hypothalamus in AD, TLE and following inflammation is however 
unknown.   
 156 
 
SUMMARY, CONCLUSION, RECOMMENDATION 
Several epidemiological studies have shown that patients with AD often show alterations 
in peripheral metabolism and that metabolic disease increases the risk of developing AD. 
Additionally, CNS hypometabolism and neuroinflammation are present in AD. Recent data has 
demonstrated the tight association between metabolism, inflammation and neuropathology. This 
work assessed metabolic and inflammatory associated proteins in 3xTg-AD mice and showed 
that activation of one of the primary insulin pathways was decreased in 3xTg-AD mice 
concurrent with the detection of cognitive decline and that downstream targets were also altered 
suggesting that insulin signaling is altered in old 3xTg-AD mice and might contribute to 
cognitive decline. Additionally, we assessed KATP channels, an inwardly rectifying potassium 
channel that links together metabolism and electrical activity. This revealed that Kir6.2 is 
aberrantly expressed in reactive astrocytes in old 3xTg-AD mice and in human AD tissue. 
Several other neuropathologies exhibit similar characteristics to AD such as TLE. Thus, we also 
examined epileptic mice and found a similar increase in Kir6.2 in reactive astrocytes in the 
hippocampus of pilocarpine-induce epileptic mice. Since both of these pathological conditions 
are associated with neuroinflammation, we induced acute or chronic peripheral inflammation in 
mice with LPS and showed that Kir6.2 was also increased in reactive astrocytes following 
chronic inflammation suggesting that this is property of reactive astrocytes and is likely to be 
highly coupled with neuroinflammation. Taken together, these data has show that insulin 
signaling and KATP channels may play major roles in neuropathological states and may serve as 
potential therapeutic targets.  
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Recommendation 
The current study found several altered metabolically-related proteins in AD that could 
act as potential therapeutic targets. In order to more fully assess these alterations a number of 
future experiments could be performed. A first step would be to further assess changes in 
PI3K/AKT signaling. Insulin has been shown to play a role in memory although the mechanism 
is not completely understood. Indeed data suggest that both the MAPK/ERK and PI3K/AKT 
pathways can be involved but their relative contribution is unclear. To begin to assess the 
mechanism of insulin in normal cognitive function and cognitive dysfunction we examined a 
model of cognitive decline, the 3xTg mouse model of AD.  In general, there is a great deal of 
cross talk between the molecular pathways activated by insulin and these pathways can also be 
activated by other compounds. Thus, by simply looking at only a few markers of each pathway 
we may be looking at changes that are not insulin dependent and can miss cross interactions 
between these two pathways. To follow up on our initial studies, other steps in the PI3K/AKT 
signaling pathway could be examined. For example PI3K and its phosphorylation as well as the 
IR itself could be examined. Additionally, while ser473 is commonly used as a marker for AKT 
activation since it is required for full activation, its phosphorylation is induced by mTORC1 so 
mTOR activity could be examined as could ser308 phosphorylation of AKT. Another way to 
assess these pathways is to use reverse phase protein assay (RPPA).  These chips allow one to 
look at many of the proteins and their phosphorylation states simultaneously using single 
samples. Thus, one can deduce the interplay between numerous signaling pathways at the same 
time in individual animals that were metabolically and behaviorally characterized. Further, using 
multiple animals at multiple time points could lend insight into the progressive changes in these 
signaling pathways.   
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Additionally, decreased CNS insulin signaling could also be due to decreased transport of 
insulin into the brain in 3xTg-AD mice. To investigate this radiolabeled insulin could be used to 
determine if old 3xTg-AD mice have a decrease in transport across the BBB compared to young 
3xTg-AD mice. To further assess the role of PI3K/AKT signaling in AD one could assess the 
PI3K/AKT signaling pathway in other AD models, such as the APP/PS1 mouse model, which 
shows glucose intolerance with insulin resistance compared to decreased peripheral insulin that 
was seen in 3xTg-AD mice and see if they express a similar change in CNS insulin signaling and 
if this change occurs at a similar time point in AD-pathogenesis (post-plaque pathology, but 
correlates with behavioral deficits). Additionally, to assess whether Aβ contributes to this change 
in insulin signaling, PI3K/AKT signaling could be assessed both in vitro and in vivo with acute 
vs. chronic Aβ treatment. However, based on our current results showing that 3xTg-AD mice 
have glucose intolerance and low insulin levels long before any changes in insulin signaling it is 
likely that a lifetime of altered peripheral insulin along with other factors (e.g. Aβ, tau, and 
inflammation) is actually driving this change in CNS insulin signaling. Thus, acute treatments 
with Aβ alone may not be enough. One-way to assess whether glucose intolerance and Aβ are 
working in conjunction could be to treat a model of diabetes with Aβ and assess PI3K/AKT 
signaling in the CNS. Since Aβ itself induces inflammatory changes, inflammation occurs 
around the same time as Aβ plaques, and inflammatory compounds can also block insulin 
signaling, it is possible that inflammation causes the reduction in PI3K/AKT signaling seen in 
3xTg-AD mice. To address the role of inflammation in changing insulin PI3K/AKT signaling in 
vivo and in vitro preparations can be used to see how LPS affects insulin signaling and the 
specific inflammatory modulators involved. Further, specific inhibitors of insulin signaling such 
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as LY294002, an inhibitor of PI3K, or rapamycin, an mTOR inhibitor, could be used to 
determine if an Aβ induced change could be reversed.  
Our study also investigated whether insulin sensitive proteins were also altered in 
epilepsy. Epilepsy displays many of the same characteristics as AD, including inflammation and 
hypometabolism, yet to my knowledge insulin signaling has not been examined in epilepsy. 
Since chronic inflammation could affect CNS insulin signaling in TLE, examining insulin 
signaling in TLE is another future direction. Additionally, IRs are found on both astrocytes and 
neurons. Thus, any change in CNS insulin signaling could be cell type specific and could differ 
in specific neuropathological conditions. Since these cells display many differences in their 
functions, specific differences in insulin signaling in principal neurons, interneurons, or 
astrocytes could affect function differentially. This is seen in other neuropathological conditions. 
For example, altered α-synuclein occurs in both Parkinson’s and multiple systems atrophy, but 
different cell types are affected (neurons vs glia respectively) and different phenotypes occur. In 
order to determine if this change is occurring in one cell type over another 
immunohistochemistry with co-labeling for IR and cell type markers such as β-tubulin for 
neurons, GFAP for astrocytes, and NeuN for interneurons could be used. Further, cell sorting of 
these different cell populations could be performed to get a more detailed molecular 
characterization of a specific population. 
Another future direction is to follow up on our experiments examining GLUT 
translocation. PI3K/AKT signaling has been shown to induce GLUT3 and GLUT4 translocation 
in the hippocampus and increased GLUT translocation may provide a mechanism through which 
neurons can increase their glucose uptake during metabolically challenging tasks such as 
learning and memory. Thus, in this study we assessed GLUT3 and GLUT4 translocation in the 
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hippocampus of 3xTg mice and noted a decrease in GLUT3 translocation compared to controls. 
We have also assessed GLUT3/4 translocation at earlier time points and noted that GLUT3, but 
not GLUT4, was decreased only in old 3xTg-AD mice. This suggests that a decrease in GLUT3 
translocation correlated with a decrease in PI3K/AKT signaling and the detection of cognitive 
decline. One limitation of our study was that while we observed a change in GLUT3 
translocation we didn’t see a change in GLUT4 despite the decrease in PI3K/AKT activation. 
Based on most available literature we expected that a decrease in insulin signaling would result 
in less GLUT4 translocation. While the reason for this is unclear Fernando et al. (2008) reported 
that while GLUT4 translocation does increase glucose uptake in hippocampal neurons, insulin 
did not affect this suggesting that another mechanism must be responsible for GLUT4 
translocation. Indeed, it has been shown that PKC can cause GLUT4 translocation (Imamura et 
al. 2003) and we do not know if PKC is affected in mouse models of AD. Thus, another future 
direction could be to examine this pathway in models of AD as well as human AD.  
Further, in our current study, we only assessed basal levels of insulin signaling. GLUT4 
translocation may be altered exclusively following administration of insulin. Thus, acute insulin 
administration could improve cognition through increased GLUT 3 and 4 translocation providing 
a mechanism through which glucose uptake can be increased during metabolic challenge.  Since 
we have shown that PI3K/AKT activation and GLUT3 translocation were decreased in the 3xTg-
AD model of AD at an age where cognitive decline occurs, we could hypothesize that in normal 
mice exogenous insulin can stimulate this pathway leading to increased GLUT 3 and 4 
translocation and thus cause improved cognition.  To test this mice could be given 
intrahippocampal insulin, insulin + a PI3K inhibitor (LY290042), or saline.  In the presence of 
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these compounds mice could then be tested through contextual fear conditioning or novel object 
recognition to assess alterations in behavioral performance.   
Another potential direction is to assess how insulin affects synaptic efficacy and 
plasticity. As noted, insulin has been shown to decrease the threshold for LTP, change synaptic 
input/output characteristics (Van Der Heide et al. 2005), and improve deficits in LTP in 
pathological conditions (Izumi et al., 2003).  Thus, we predict that exposing hippocampal slices 
from normal mice to insulin for a couple hours prior to electrophysiological recordings could 
induce a shift in the input/output curve, cause changes in paired pulse inhibition and facilitation, 
and increase LTP. Indeed, prior work form the laboratory has shown that synaptic efficacy is 
preferentially compromised in hippocampal slices from aged rodents during hypoglycemia 
(Jones et al., 2015) and that insulin can restore synaptic efficacy in aged slices to adult levels.  
What is unclear however is how the 2 main insulin-signaling pathways (MAPK/ERK and 
PI3K/AKT) contribute to these changes in synaptic efficacy/plasticity. Thus, we could 
additionally examine the effect of insulin in the presence of a MEK inhibitor (PD98059) or a 
PI3K inhibitor (LY290042) to pharmacologically tease apart the contribution of both pathways.  
This could enable us to assess whether these pathways work additively or synergistically. 
Further, we would hypothesize that blockade of PI3K/AKT signaling should inhibit insulin’s 
effect on synaptic efficacy/plasticity by blocking GLUT translocation.  To assess this hypothesis, 
slices could subsequently be collected and used for western blot analysis to examine changes in 
phosphorylation of AKT and translocation of GLUT3 and GLUT4.   
These results will show how insulin, through the PI3K/AKT and MAPK/ERK pathways 
can affect synaptic efficacy and plasticity and potentially lend insight into what happens in 
neuropathological conditions. We predict that insulin will improve synaptic efficacy and that 
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blocking the PI3K/AKT or MAPK/ERK pathway will interfere with this effect. The important 
question to now ask is whether these effects are additive or potentially synergistic. Further, based 
on our current studies we predict that a change in synaptic efficacy/plasticity will occur via the 
PI3K/AKT pathway and will be associated with an increase in GLUT3 translocation.  
The question of what aberrant Kir6.2 expression does to the function of reactive 
astrocytes is also a completely unknown field. Our study demonstrated that the expression of 
Kir6.2 is altered in reactive astrocytes but did not assess astrocytic function. Thus, there are 
many potential future directions. First, while our study revealed that Kir6.2 was significantly 
increased in reactive astrocytes we did not quantify Kir6.2 in neurons. While neuronal Kir6.2-IR 
was not quantified due to several limitations, it did appear that there might be a decrease in 
neuronal Kir6.2 in AD, epilepsy, and LPS tissue. This could explain the lack of a total difference 
seen with western blots. Since these channels have been suggested to be neuroprotective during 
hypometabolism, a loss of Kir6.2 could make the neurons more susceptible to damage under 
hypometabolic conditions such as those seen in AD and epilepsy. With regards to epilepsy, 
KATP channels in the dentate granule cells have been suggested to help confer the normal gating 
function of the DG, which is believed to control hyperexcitability in the rest of the hippocampus 
and is compromised in TLE (Patrylo & Dudek 1998). Thus, it is possible that a decrease in 
KATP channels could occur in dentate granule cells in TLE and thereby contribute to the 
enhanced susceptibility of the hippocampus for epileptiform activity. While it did appear that 
Kir6.2 was decreased, this could be due to neuronal cell loss occurring in these 
neuropathological conditions. Though most literature suggests that 3xTg-AD mice do not exhibit 
cell loss, cell loss is prominent in the hippocampus in AD and epilepsy and LPS treated co-
cultures display stark neuronal cell death (Kim et al. 2002). Further, KATP channels are also 
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expressed in mitochondria and mitochondrial KATP channels could play a major role in the 
metabolic properties of these cells. Alterations at the mitochondrial level could result in very 
different affects versus changes in the plasma membrane Kir6.2. Thus, one could use a stronger 
differential centrifugation method and separate out mitochondria to examine whether Kir6.2 is 
altered in the mitochondrial fraction. While several studies have shown that there was no 
difference in the levels of mRNA for KATP channels in the hippocampus in AD or other 
neuropathologies, these studies examined whole tissue. In order to see if there is a change at a 
more specific level (i.e. in reactive astrocytes) one would need to do either cell sorting or single 
cell qPCR. Moreover, identifying the specific SUR subunit composition of these aberrant KATP 
channels is critical since they can dramatically change the functionality of these channels (e.g., 
current amplitude and kinetics, and sensitivity to agonists and antagonists) and thus their 
capacity to regulate, cellular excitability and protective mechanisms (Isomoto et al., 1996; Seino 
and Miki, 2003; Shi et al., 2005). Thus, knowledge of the type of SUR subunits associated with 
the aberrant Kir6.2 in reactive astrocytes in AD is essential for understanding how the aberrant 
Kir6.2 expression affects astrocytic function and why/how antagonists can affect pathogenesis.  
Pancreatic Kir6.2 has been well studied and is known to regulate insulin release. While 
several metabolic conditions are associated with altered insulin release accompanied by changes 
in KATP channels nothing is known about whether KATP channels are altered in the pancreas in 
AD. As has been noted throughout this document, alterations in peripheral metabolism exist in 
AD. These alterations could be due to alterations in pancreatic release of either glucagon or 
insulin. Since KATP channels are responsible for their release a future study could include 
looking at KATP channels in pancreatic β-cells in the context of AD. Specifically, an 
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examination of Kir6.2 in the pancreas of 3xTg-AD mice could reveal a reason for the decrease in 
insulin secretion following a glucose challenge.  
Finally, one of the biggest future directions would be to examine the function of Kir6.2 in 
reactive astrocytes. This could entail many different routes and many different experiments. First 
one could set out to determine if these channels are functional by using patch clamp 
electrophysiology to examine the inwardly rectifying K+ currents in reactive astrocytes that 
express Kir6.2 vs. normal astrocytes with and without specific KATP channel agonists and 
antagonists. Additionally, Kir6.2 knockout mice have been produced and it could be interesting 
to assess what happens during an inflammatory event in these mice. However, to study the 
function of these channels in just reactive astrocytes a more selective Kir6.2 knock in or 
knockout mouse, or RNA interference would be necessary. For example, recombinant AAV-
mediated gene delivery of KCNJ10 selectively to astrocytes via an astrocyte specific promotor 
such as GFAP could be used. However, although GFAP is widely used as an astrocyte-specific 
promotor, GFAP is not entirely astrocyte specific as our data from pilocarpine-induced epileptic 
mice show and thus another promotor such as GS, S100B or Aldh11 may be better. The function 
of this aberrant expression of Kir6.2 in astrocytes could then be assessed in normal mice as well 
as animal models of AD or TLE in vivo. Additionally, Kir4.1 knockouts could be used to assess 
whether the increase in Kir6.2 is compensatory as we suggested above, by assessing whether 
Kir6.2 is increased in Kir4.1 knockout mice. However, it should be noted that the knockout of 
Kir4.1 could lead to an array of other problems, likely inducing inflammation and reactive gliosis 
and thus an increase in Kir6.2 could not be directly attributed to the deletion of Kir4.1. As has 
been previously mentioned, KATP channels have also been linked to inflammation and KATP 
channels have been shown to reduce inflammation in microglia. Another potential direction 
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could be to examine these properties in astrocytes. A simple start would be using co-cultured 
hippocampal neurons and astrocytes, pretreating with glibenclamide and inducing inflammation 
with LPS. One could then determine if glibenclamide inhibited glial reactivity by examining 
GFAP levels and levels of inflammatory compounds such as TNFa, and interleukins in the media 
and astocytes. Additionally, we could determine if the increase in astrocytic Kir6.2 is blocked. If 
inflammation is indeed decreased in cultures, these experiments could be followed up in vivo 
where behavioral consequences could then be examined in intact animals. Specifically, one could 
pre-treat mice with glibenclamide prior to pilocarpine to see if a decrease in reactive 
astrocytes/Kir6.2 expression could decrease seizure susceptibility.  
Thus, there are numerous future directions that our initial findings could trigger and their 
priority would depend on successful future funding for the proposed experiments.  
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APPENDIX A 
 
ABBREVIATIONS 
 
AD-Alzheimer’s disease 
CNS-Central nervous system 
GSK3-glycogen synthase kinase 3 
GLUT-glucose transporter 
KATP-ATP-dependent potassium channel 
IHC-immunohistochemistry 
TBI-traumatic brain injury 
HK-hexokinase 
GK-glucokinase 
GLP-1-glucogon-like peptide-1 
GIP-gastric inhibitory polypeptide 
POMC-proopiomelanocortin 
NPY-neuropeptide Y 
AgRp-agouti-related protin 
BBB-blood brain barrier 
mGluR-metabotropic glutamate receptor 
EETs-epoxyeicosatrienoic acids 
20-HETE-20-hydroxeicosatraenoic acid 
FDG-fluorodeoxyglucose  
PET-positron emission tomography  
ANLS-astrocyte-neuron lactate shuttle  
LDHA-lactate dehydrogenase A  
LDHB-lactate dehydrogenase B  
TCA-tricarboxylic acid  
PPP-pentose phosphate pathway  
ROS-reactive oxygen species  
GLT-1-glutamate transporter  
GLAST-glutamate aspartate transporter  
GS-glutamine synthetase  
CMRglu-cerebral metabolic rate of glucose 
PS1-presenilin 1 
APP-amyloid precursor protein 
MCI-mild cognitive impairment 
NFT-neurofibrillary tangles 
BACE1-β-secretase  
Aβ- beta-amyloid  
MAPT-microtubule-associated protein tau 
PP2A-proteinn phosphatase 2A 
LTP-long-term potentiation  
DG-dentate gyrus 
EC-entorhinal cortex 
PP-perforant pathway 
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SL-stratum lucidum 
ALV-alveus 
SO-stratum oriens 
SP-stratum pyramidale 
SR-stratum radiatum 
SLM-stratum lacunosum moleculare 
GCL-granule cell layer 
CA1-cornus amonus 1 
CA3-cornus amonus 3 
MF-mossy fibers 
SC-schafer collaterals 
SUB-subiculum 
FAD-familial AD 
LOAD-late-onset AD 
AGE-advanced glycation endproducts 
HFD-high fat diet 
PUFA-polyunsaturated fat 
STZ-streptozotocin 
LPS-lipopolysacharide 
ICV-intracerebroventricular 
SHC-Src homology 2 domain-containing 
GFB2-growth factory receptor bount protein-2 
SOS-son of sevenless protein 
GEF-guanine nucleotide exchange factors 
MAPK-mitogen-activated protein kinase 
IRS1-insulin receptor substrate-1 
PI3K-phosphoinositide 3-kinase 
PIP2-phosphatidylinositol 4,5-bisphosphate 
PIP3-phosphatidylinositol (3,4,5)-trisphosphate 
mTORC2-mammalin target of rapamyocin complex 2  
AMPA-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
PH-pleckstrin homology 
PKB-protein kinase B 
PDK1-pyruvate dehydrogenase kinase 1 
LTD-long-term depression 
GABA-gamma-aminobutyric acid 
IDE-insulin-degrading enzyme 
NDM-neonatal diabetes mellitus 
SUR-sulfonyl urea 
SNr-substantia nigra 
ACh-acetylcholine 
GFAP-glial fibrillary acidic protein 
DHA-docosahexanoic acid 
TNF-tumor-necrosis factor 
IL-interleukin 
TGFβ-Transforming growth factor-β 
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NO-nitric oxide 
NGF-nerve growth factor 
BDNF-brain-derived neurotrophic factor 
GDNV-glial cell line-derived neurotrophic factor 
IGF-insulin-like growth factor 
PKC-protein kinase C 
ASD-antiseizure drug 
TLE-temporal lobe epilepsy 
Tsc1-tuberous sclerosis complex type 1 
PPKO-PTEN knockout 
NIRKO-IR knockout mice 
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